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Abstract 
A series of new azaxanthone chromophores has been established as sensitisers of 
europium and terbium emission in aerated aqueous media. Chromophores incorporating 
either a pyridyl or pyrazoyl moiety have been devised with large molar extinction 
coefficients and long excitation wavelengths. 
The pyridyl and pyrazoyl-1-azaxanthones have been incorporated into an array of 
functionalised macrocycles, to yield a series of emissive europium and terbium 
complexes, including examples suitable for conjugation. The complexes possess high 
emissive quantum yields (Otu = 25 %, Orb = 64 %) and long emissive lifetimes (up to 2.3 
ms for Tb) in aqueous media. These properties arise from exclusion of coordinated water 
molecules, as a result of bidentate chelation of the heterocyclic chromophores. 
Quenching studies of the lanthanide excited states indicate that non-covalent protein 
association shields the complexes from quenching by endogenous electron rich species, 
such as urate and ascorbate. Under simulated cellular conditions, (0.4 mM serum 
albumin, 0.13 mM urate) the emissive lifetimes remain within 10 % of that observed in 
water, indicating protein binding does not quench the lanthanide excited states. 
Cellular uptake experiments have been performed with CHO and N1H-3T3 cell lines. 
Examination using fluorescence microscopy reveals cellular uptake, with complexes 
exhibiting a time-dependent localisation profile partitioning between mitochondrial and 
lysosomal regions. 
Following establishment of an efficient and reproducible method of conjugation, 
complexes have been covalently attached to benzyl guanine vectors to examine their 
performance as components in homogeneous time resolved fluorescence (HTRF) assays. 
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Introduction 
Chapter One: Introduction 
Chapter One: Introduction 
1.1 Overview of Fluorescent Probes 
Living organisms fianction by a complex array of cellular processes, utilising their 
intracellular network of interacting biopolymers, ions and metabolites. Our understanding 
of in cellulo phenomena, including intracellular signalling and recognition processes is of 
utmost importance for disciplines in biochemistry, drug design and medical 
diagnostics.' '^  At present, the biological characteristics of many biomolecules cannot be 
examined in their purified, isolated forms, increasing the impetus to monitor biological 
processes inside living cells.' Our ability to visualise, probe and sense intracellular 
analytes, including characterising their movement, interactions and chemical 
microenviroment is crucial in developing a detailed vinderstanding of their function.^ '* 
Recent decades have seen advances in the field of fluorescence microscopy,^ 
ultimately seeking a better understanding of cellular activity. Fluorescence microscopy 
provides a non-invasive procedure^ that is of particular use in examining and imaging 
living cells.' The technique monitors emitted photons from fluorescent moieties, and has 
been shown to be capable of analysing subcellular events.* The challenging objective for 
scientists is to devise responsive optical probes which,can either quantitatively signal 
information of the nature of their local environment, or be targeted to selective 
organelles.^ To date, probes for live cell imaging have been most frequently based on 
either recombinant proteins or heterocyclic organic fluorophores. 
Recombinant proteins 
Since the initial molecular cloning'" and genetic engineering" of green fluorescent 
protein (GFP), continued mutagenesis has led to a new generation of fluorescent 
proteins.'*''^''^ These proteins have variable excitation (> 350 nm) and emission 
wavelengths within the visible region of the spectra,'"''^ making them well suited for 
microscopic applications. The primary advantage of fluorescent protein probes over 
conventional organic dyes is their ability to be chemically manipulated (e.g. conjugation 
to signalling peptides), without compromising their photophysical characteristics.'^ Other 
benefits include reduced photodynamic toxicity and compatibility in protein recognition 
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studies, notably when used as components of fluorescence resonance energy transfer 
(FRET) s tudies . In addition to FRET applications, advanced microscopic techniques 
like time-lapsing imaging and fluorescence recovery after photobleaching have made it 
possible to extract spatial and dynamic information about fluorescent fusion proteins in 
live cells under physiological conditions.^ These techniques have been instrumental in 
improving our understanding of how proteins assemble in large protein complexes and 
ftmction in cellular processes, regulating the maintenance, growth, division, 
differentiation, and death of cells. However, despite being employed efficiently in 
biological applications, fluorescent proteins still have limitations. These are primarily 
related to their sub-optimal photophysical properties, high molecular weight and 
relatively time-consuming labelling processes.^  
Heterocyclic fluorophores 
Low molecular weight organic fluorophores based on fluorescein (A) and rhodamine (B) 
(Figure L I ) have provided luminescent probes that offer an effective alternative to the 
use of recombinant proteins.'^ '^ These condensed heterocyclic aromatics are highly 
emissive, possessing large molar absorption coefficients. Unfortunately, their short lived 
excited states (a few nanoseconds), do not easily allow distinction between their 
fluorescence and autofluorescence. Furthermore, these moieties exhibit broad absorption 
and emission bands, with small Stokes' shifts. For these reasons, a large proportion of 
research has focussed on modifying these dyes. The series of optical probes based on 
Alexa Fluor® and BOPIPY® structures provide attractive alternatives.-^"'^ ' These dyes 
prove more resistant to photobleaching, exhibit a pH-independent fluorescence and 
possess high extinction coefficients with emission quantum yields that are typically > 
0.5.^ ^ 
Chapter One: /nfroducf/on 
C O 2 H 
HQ- • '"O - "-O 
Fluorescein 
BODIPY 
H2N 
-O3S ) CO2H 
^X V ^ ' ' \ 
y H2N 
Rhodamine AlexaFluor 46a 
Figure 1.1: The structure of common commercial organic fluorescent dyes 
and emissive tags 
While the number of commercially available fluorescent probes continues to increase, 
the limitations of such compounds, namely their susceptibility tow^ards interference from 
light scattering in biological media or natural fluorescence from certain biomolecules, has 
led to research into possible alternatives. 
Over the past decade, attention has grown into the development of biocompatible 
semi-conductor quantum dots. At present their primary application is as replacements 
for fluorescent proteins in labelling cellular proteins,^^ as their lack of responsiveness to 
the local environment renders them applicable only as fluorescent tags. The primary 
drawbacks surrounding the use of quantum dots in biological applications, is their large 
molecular volume and poor cell permeability.'^ '*"^ '^^ ^ Strategies such as attaching 
appropriate surface vectors (e.g. amphiphilic polymer coatings) are used to enhance 
solubility and improve their biocompatibility.^' 
Significant progress has been made in recent years towards the development of highly 
emissive lanthanide ion complexes in aqueous solution, seeking to exploit their unique 
excited state properties.^^ This trend has led to the publication of various reviews, during 
recent years.^ ^ '^ *'^ '^^ '' Compared to other optical probes, lanthanide complexes possess 
sharp emission bands, large Stokes' shifts (separaUon between absorption and emission 
wavelengths) and are relatively insensitive towards dissolved 02and photobleaching.^' A 
more beneficial property is their long emissive luminescence lifetimes, which allow time-
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resolved spectroscopy and microscopy to be employed."'^  For europium (Eu) and terbium 
(Tb), the radiative lifetimes are typically milliseconds in duration. Thus, time-gated 
acquisitions can afford excellent discrimination between probe emission and background 
fluorescence or light scattering. 
In this thesis, the emerging use of lanthanide coordination complexes as cellular 
probes is explored. In particular, their application either as components of time-resolved 
luminescence assays or as probes to target organelles selectively in cellulo is addressed. 
A discussion of the properties of lanthanide complexes which make them suitable as 
luminescent probes follows. 
1.2 Luminescence Properties of the Lanthanide Ions 
With the exceptions of Ce'*^  and Eu^^, the most stable and predominant oxidation state of 
the lanthanide ions in solution is + 3 . Consequently, it is the result of the partial filling of 
the 4 / orbitals (except for lanthanum and lutetium) that determines their absorption and 
emission spectra properties. The energy levels of the 4 / orbitals are not degenerate. 
Electronic repulsion between electrons ' l if ts ' degeneracy to yield spectroscopic terms 
with separations between neighbouring terms of the order of 5,000 - 10,000 cm''. The J 
levels within each manifold are further separated by about 1000 cm"'.^^ 
The 4/orbitals in the Ln^^ ions are highly contracted, so that there is only a very weak 
interaction between the/orbitals and the ligands in a Ln complex. The shielded nature of 
the 4/electrons has profound effects on the optical spectra of lanthanides. Small ligand-
field splittings (typically 100 cm ") are associated with the Laporte forbidden f-f 
transitions.'^'' These effects are, to a first approximation, independent of environment.^^ 
However, changes in the fine structure and the relative intensity of emission bands can be 
very informative. This is particularly true for Eu^ "^ , for which subsequent alterations in 
the spectral form allow ratiometric analysis {See section 1.5). The forbidden nature of the 
f-f transitions means that the lowest energy excited states of lanthanides possess long 
natural lifetimes. The most studied emissive lanthanide ions are europium and terbium. 
They, and analogous gadolinium systems, are the only lanthanide complexes studied in 
this thesis. 
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1.3 Sensitised Emission 
The low extinction coefficients (0.5 - 3 dm^ mof' cm"')^^ of lanthanide ions mean that 
efficient population of excited energy states cannot be achieved by traditional sources of 
irradiation, e.g. flash-lamps. It is therefore necessary to adopt alternative approaches to 
ensure efficient population of the excited states. One option is the use of laser radiation. 
Eu and Tb are just two lanthanides that can be excited in this manner; using a rhodamine 
1 1 0 dye laser at 580 nm (matching the ^FQ ^ ^Do transition of Eu) or an argon ion laser at 
488 nm (^F(, -> for Tb).^^ Laser excitation is currently not a practical method for 
microscopy applications. Instead, efficient excitation can be achieved by incorporating an 
organic chromophore into a lanthanide-binding ligand, allowing indirect population of 
the lanthanide excited state by intramolecular energy transfer.^ '^^ ^ 
Exciiaiion 
Antenna 
Energyiransfer 
Figure 1.2: Schematic illustrating energy transfer from chromophore to lanthanide metal 
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The process of sensitised emission and indirect population of the lanthanide excited state 
(via the chromophore triplet state) is best summarised in a Jablonski digram (Figure 1.3). 
Absoqition 
So 
ISC 
Sensitiser 
Ftuorescence 
Energy 
Transfer 
Sensixiser 
Phosphorescence 
^ £m(ss/ve 
Lanth3ni<te 
Luminescence 
Ground 
State 
Sensitiser 
Figure 1.3: Jablonski diagram showing the energy transfer processes 
during sensitised emission 
Prior to excitation, the antenna chromophore is in the ground state SQ. Upon 
absorption of a photon, it is raised to a vibrationally excited singlet state (Sn where n = 
2,3....). The higher vibrationally and electronically excited state undergoes non-radiative 
relaxation (internal conversion IC) to a high vibrational energy level of the first excited 
state (Si) manifold in a process that occurs rapidly in comparison to the competing 
radiative decay process (i.e. S2 ^ So). The excess energy of the Si excited state is then 
lost by vibrational relaxation to the lowest level of the manifold. The sensitiser can now 
either undergo radiative decay by fluorescence, or undergo a change in spin multiplicity 
(AS 0 ) in the formally forbidden non-radiative process of intersystem crossing (ISC). 
This populates the triplet state, T i . Finally, reverse intersystem crossing to Si and 
sensitiser phosphorescence compete with energy transfer to the lanthanide excited state. 
The excited Ln^^ ion then relaxes to its ground state electronic configuration, resulting in 
luminescence. 
1.4 Energy Transfer Mechanisms 
The energy transfer step between the sensitiser triplet state and the lanthanide (III) ion 
can proceed via either a Forster or Dexter m e c h a n i s m . T h e Forster mechanism is a 
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through-space, dipole-dipole interaction which is strongly dependent on the donor / 
acceptor spectral overlap between the emission spectrum of the donor and the absorption 
spectrum of the acceptor. The rate of energy transfer ICET is a sensitive function of the 
mean separation (r) between the donor and acceptor, varying as r"^ . 
In the Dexter mechanism, a shorter range electron-exchange energy transfer process is 
involved. This mechanism requires orbital overlap between the donor and the acceptor. 
HOMO - # - LUMO 
Ground 
State 
HOMO 
Acceptor Donor 
Figure 1.4: Schematic diagram showing electron exchange between donor and acceptor 
The process can be regarded as a simultaneous exchange of electrons from the excited 
sensitiser to the lanthanide ion and vice versa."' The rate of energy transfer for the Dexter 
mechanism varies as e'^ '^  (where P is a constant). A sufficiently long-lived donor excited 
state is required for the energy transfer process to compete effectively with potential 
deactivation pathways. 
1.5 Eu (III) and Tb (III) Luminescence Characteristics 
Absorption of light can promote lanthanide (III) ions to any energetically accessible state, 
but rapid internal conversion to the lowest-lying J state of the first excited spectroscopic 
term ensures that emission occurs almost exclusively from this state. For Eu and Tb, 
these excited states are ^Do (17,200 cm"') and ^D4 (20,400 cm'') respectively. By 
examining the partial energy diagram for these ions, it is understandable why emission 
from these states may occur to several of the various J states of the ground manifold, 
resulting in a series of well defined, sharp, narrow bands. For Eu in particular, 
examination of the fine structure and intensity rafio of these bands (Figure 1.5) can 
provide valuable information regarding the coordination environment of the metal ion. 
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22 
21 
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c 
^ 6 
-So, 
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5D, 
F^4 
•5D4 
Euf///) rb(///i 
Figure 1.5: Partial energy diagrams of Eu(IIl) and Th(III) 
With Eu, the dominant emission bands arise at 590 nm (^DQ ^ ' F | , AJ = 1) and 612 
nm (^DO ^F2, A J = 2). The AJ = 1 transition is magnetic dipole allowed and its form is 
largely independent of the coordination sphere. The A J = 2 manifold is made up of 
electronic dipole allowed transitions. Each is extremely sensitive to the symmetry of the 
coordination sphere.^ ^ In a centrosymmetric environment, the AJ = 1 dominates, whereas 
the intensity of the AJ = 2 transition is enhanced as the distortion of symmetry around the 
ion increases. Since the ''FQ and ^Do states are non-degenerate, the number of A J = 0 
bands in the emission spectrum is related to the number of chemically distinct 
environments of the Eu^^ ion. 
In the case of Tb^ "^ , the hypersensitive ^D4 ^ F^s ( A J = 1) emission band at 545 nm is 
the most intense transition, but it is not as sensitive to the environment as the AJ = 2 
bands of Eu. The unique sensitivity of the exiropium emission spectral form has driven 
the development of 'responsive' lanthanide complexes, in which changes in the emission 
profile have been used to signal variations in the local environment, e.g. modulation of 
pH, pOj, pX and pM. ^' Examples include the pH responsive Eu(III) complex E U L ' 
which incorporates an azathioxanthone sensitiser and pendant pH sensitive 
alkylsulfonamide arm.'*^ This complex has been shown to be applicable for pH 
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determination in cellulo, over the pH range 6 to 8. Further examples of responsive 
lanthanide complexes are described in section 1.6. 
*Na-0 
o o P o 
O H b ^„ / 6 
s ^ 
*Na O *Na O 
Figure 1.6: Reversible protonation of pH dependent E U L ' 
1.6 Lanthanide Lunninescence Deactivation Processes 
The photochemical pathway that defines the kinetic profile of sensitised luminescence 
reveals that there are three excited states which can be perturbed: (i) the sensitiser singlet 
excited state; (ii) the sensitiser triplet excited state; (iii) the lanthanide emissive state.'^  
lanthartide 
ligand fluorescence luminescence 
43 
A 
If transfer 
Rem 
hv* energy 
s e n s — L n »-^sens—Ln sens Ln 
kq[02] kq"[XH] 
absorption 
keT 
y 
Figure 1.7: Deactivation pathways for sensitised lanthanide emission '^^ 
Deactivation of the sensitiser singlet excited state 
In addition to ligand fluorescence, electron or charge-transfer processes, which can be 
inter- or intramolecular in nature, can quench the singlet excited state of the sensitising 
chromophore. The most comprehensively studied examples are 'collisional' 
intermolecular interactions with halide ions,'''''*^ whilst examples of photoinduced 
electron intramolecular transfer from the excited S| of the chromophore to Ln(III) ion 
have also been published.'*^ The latter is more common with Eu"'^  complexes, owing to 
the ease of reduction of Eu(III) to Eu(II). 
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Deactivation of the sensitiser triplet excited state 
The energy of the aryl triplet state is arguably the most critical criterion in sensitised 
emission, as intramolecular energy transfer to the Ln(III) ion occurs from this state. For 
sensitisation of Tb(III) and Eu(III) luminescence, a singlet-triplet energy gap of less than 
7000 cm"' is desirable, with the Si state preferably lying less than about 29,000 cm"' 
above the ground state. 
I f the aryl triplet state and the accepting excited lanthanide state energy gap becomes 
less than 1,500 cm"' then the rate of thermally activated back energy transfer is greatly 
enhanced, leading to a re-population of the 'fragile' aryl state (i.e. deactivation of the 
lanthanide luminescent state)."*' However, i f the energy gap is too great, then the 
efficiency of the energy transfer step is diminished. Consequently, a compromise must be 
established whereby the aryl triplet state should lie between 1,700 and 3,000 cm ' above 
the lanthanide emissive state. 
A competing process to intramolecular energy transfer (^ sens to Ln) is collisional 
quenching of the triplet state by molecular oxygen. For complexes where kq[02] is 
competitive with RET , lanthanide emission intensity and lifetime become sensitive to 
oxygen concentration. Although appearing problematic, research groups have utilised this 
process to their advantage, designing oxygen sensitive luminescent lanthanide 
complexes. One example is the singlet oxygen dosimeter EuL^ (Figure 1.8),''* in which 
reaction of the anthroyl moiety leads to suppression of intramolecular triplet energy 
transfer between the terpyridyl moiety and the anthracene, switching 'on' Eu emission. 
The system has limited applicability however, due to a distinct absence of chemical 
reversibility at ambient temperature. 
Quenching 
No Quenching 
Figure 1.8: E u L ^ singlet oxygen sensitive phosphorescence 'probe , 48 
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Deactivation of the lanthanide excited state 
Lanthanide excited states may persist for several milliseconds, during which time they 
are prone to non-radiative quenching by one of three processes: 
1.) Vibrational energy transfer involving high frequency oscillators 
The 'Do and ^D4 excited states of Eu^^ / Tb''^ are prone to deactivation by vibrational 
energy transfer involving energy-matched X - H oscillators (X = O, C or N). In an 
aqueous medium, quenching by O - H oscillators is of particular significance. As 
expected due to the intrinsic r'^  dependence of this energy transfer step, directly 
coordinated water molecules have a more substantial quenching effect than closely 
diffusing waters."*^  Quenching by energy matched oscillators arises due to weak vibronic 
coupling between the f-electronic states of the lanthanide ion and the vibrational states of 
an O - H group, where the energy gap between the emissive excited state and the highest 
level of the ground manifold must be bridged by these vibrational states. The energy gaps 
for Eu^^ and Tb^^ are approximately 12,000 cm"' and 15,000 cm ", equating to the third 
and fourth vibrational overtones respectively. It is this lower overtone that makes 
europium more sensitive towards vibrafional quenching that terbium, as the Franck-
Condon overlap term is less favourable. 
X1000 cnr' 
25 J 
20 
1 6 J 
10 J 
5-^ 
xlOOOarr' 
U 30 
% • 
0-1 'fc 
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Y = 3 
r - 2 
Y = 1 
D,0 
= 7 
Hfi 
= 5 
= 4 
X' = 5 
V = 4 
V = 3 
V = 2 
y = 1 
V = 0 
U25 
L 20 
U l 5 
U 10 
\-5 
Figure 1.9: Energy level diagram for Eu, Tb, 0-H and O-D oscillators 
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Vibrational quenching in D 2 O is much less efficient than H2O, as the O - D oscillator 
possesses a lower stretching frequency. Thus, energy matching is only feasible by 
occupation of higher vibrational states (4"^  and 5"^  overtones).^ *^ By measuring the 
difference in rate constants k for the depopulafion of the lanthanide excited state in H 2 O 
and D 2 O respectively, it is possible to estimate a hydration state of a given complex. 
Displacement of bound water molecules by inter- or intramolecular anion binding 
directly to the Ln"'^ centre may lead to both emission intensity and lifetime increases, 
with the variation in the emission spectrum allowing ratiometric analyses. Numerous 
research groups have utilised this property, creating chemoselective sensors for citrate 
(EuL^), bicarbonate (EuL"*) and phosphate anions.^ '"^ '^^ ^ 
o 
E t 0 2 C ^ \ 
I 
I 
CO2" 
E U L ' EUL* 
Figure 1.10: Chemoselective citrate (EuL^) and bicarbonate (EuL') sensors 
2. ) Energy transfer to an acceptor of appropriate energy 
Quenching of the lanthanide excited state by energy transfer may occur to an energy-
matched acceptor, usually within a Forster radius of about 9 nm of the complex. This 
process is the principle behind fluorescence resonance energy transfer (FRET) and wil l 
be discussed in more detail in section 1.12. 
3.) Electron transfer involving the metal-centred excited state 
The Tb and Eu excited states lie at 244 and 206 kJ mol ' above their ground states. This 
free energy can be used to 'drive' various electron transfer processes, including 
coUisional encounters with electron rich anionic species. Species such as halide anions 
13 
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and the low molecular weight anti-oxidants urate and ascorbate are well known 
quenching species. Urate and ascorbate typically occur in between 0.1 and 2.0 mM levels 
in most cell types." '^^ '' Parker and co-workers have used this quenching pathway to their 
advantage. The dynamic quenching of a tetraazatriphenylene complex (EuL"'', Figure 
1.11) has been shown to provide a non-enzymatic luminescence assay for uric acid 
detection, in diluted urine samples. A systematic study of dynamic quenching of 
lanthanide complexes by selected reductants is discussed in Chapter 2. 
•02C 
-0-,C " H 0=' ^ " 2 ^ NH 
/ 
EuL^ 
Figure 1.11: Uric acid sensor EuL^ 
1.7 Summary - Essential Requirements for a Sensitising Moiety 
The choice of sensitiser in lanthanide complexes is determined primarily by the energy of 
the emissive excited state of the chosen lanthanide. The chromophore must possess an 
excited state from which there is efficient energy transfer to the lanthanide excited state. 
Ideally, this equates to a triplet energy of slightiy greater than 22,000 cm ' for Tb (^ D4 = 
20,400 cm"') and 19,000 cm'' for Eu (^ Do = 17,200 cm''). Other essential criteria for the 
sensitising moiety can be summarised as follows: 
o High extinction coefficient at an excitation wavelength for single photon 
excitation in the range of 340 - 420 nm. This is to avoid the need for quartz optics 
and prevent excitation of common biomolecules. Of particular interest are 
excitation wavelengths that correspond to readily available laser or LED lines 
(337, 355 or 405 nm). 
o Fast rate of intersystem crossing to ensure the aromatic triplet state is populated 
efficiently, minimising ligand fluorescence. 
14 
Chapter One: /ntroduct/on 
o Fast energy transfer step, leading to efficient population of lanthanide excited 
state. 
o A high reduction potential, minimising electron-transfer quenching involving 
electron rich species. 
1.8 Luminescent Lanthanide Complexes 
Like the sensitising antenna, the ligand surrounding the lanthanide ion plays a pivotal role 
in establishing emissive systems. The chromophore must be engineered into a ligand 
structure, thereby providing a kinetically and thermodynamically stable seven to nine 
coordinate complex.'^ The high charge density and low polarisability of Ln^ "^  ions means 
they exhibit 'hard acid' like behaviour. Consequently, lanthanide ions are best 
accommodated by ligands offering nitrogen or oxygen donors, typically coordinating via 
ionic interactions. 
Complexes derived from a 1,4,7,10-tetraazacyclododecane (cyclen) macrocycle often 
provide well-defined and highly stable complexes. An advantageous property of cyclen is 
the ease with which a diverse range of pendant arms can be introduced. Carboxylate, 
phosphinate and amide groups have all been used to synthesise stable, water soluble 
lanthanide complexes. Manipulation of these pendant arms allows control over the charge 
of the complex, while can minimise quenching of the lanthanide excited state by water 
molecules. The latter is most notably achieved by providing sterically bulky complexes 
with adequate donor atoms in order to complement the lanthanide's coordination number, 
preventing any directly bound water molecules. 
In addition to cyclen derivatives, other systems such as cryptates,^^" calixarenes, 
podands, helicate and bipyridyl-functionalised macrocycles have been employed as 
chelating agents for lanthanide complexes.^ ** The following examples highlight the 
diverse range of aromatic chromophores / chelating ligands which have been 
implemented successfully for sensitised lanthanide emission. 
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Acridones 
o Allow efficient Eu^^ sensitisafion. without direct coordination ^^-.^o 
o Excitation at wavelengths > 4 0 0 nm 
o Two inner sphere bound water molecules , X^^^Yu^^^^ 
o (D ( H 2 O ) = 0.05, E t O j C ^ K 
NH 
o Low <t> associated with large ligand fluorescence in polar media ^^co Et 
EuL 4 
Azaxanthones / Azathioxanthones 61 
o Allow sensitisafion of Eu'''^  and Tb^ "^  in aqueous media 
o Excitafion at 336 nm (azaxanthone) and 380 nm 
(azathioxanthone) respectively 
o ' Ln j N o One inner sphere boimd water molecule 
N N ^ 
o o <DEU ( H 2 O ) = 0.07, t = 0.57 ms; 
° 0 
X = O Azaxanthone 
S Thioazaxanthone 
LnL« 
a)Tb(H20) = 0 . 1 4 , 1 = 1.82 ms 
o A range of substituents can be incorporated in the 
benzenoid ring 
o Thioxanthones exhibit modest ligand fluorescence 
43 Tetraazatriphenylene 
o Ti = 24 ,000 cm"' enabling Eu''* and Tb^* sensitisation 
HN o Excitation at 348 nm 
o Serves as a bidentate ligand (no bound H 2 O ) 
N N-
o Possesses a fast rate of inter-system crossing. ° ^^ M^'"K 
N 
o High quantum yields in water; 
OEU (H2O) = 0.16, T = 0 .99 ms; 
N i N ' \ N 
° ' NH 
(DTb(H20) = 0 . 4 0 , 1 = 1.46 ms , ,7 
LnL 
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n . 1 o 62,63,64,65,66 
Pyrazoylpyndines 
H02C. r ^ ° 2 H O,C^)N \ # NCCOZH 
C02H 
LnL« 
LnL^ R = CH3o rC6H5 
o Both ligands allow Eu^^ / Tb^^ sensitisation (LnL* T, = 24,500 cm"', L n L ' T,= 
26,000 cm"') 
o Ligand has a high extinction coefficient 26,600 cm'', but a low excitation 
wavelength 306 - 310 nm. 
o These complexes are water soluble and coordinate to the Ln ion via the 
iminodiacetate groups. This results in a long Ln - chromophore distance and 
subsequent poor energy transfer, 
o Ligand L ' has a low excitation wavelength (294 nm). 
o Despite one bound water molecule, an efficient ligand to lanthanide energy-transfer 
process is observed. This results in a high quantum yield for Tb sensitisation. 
%b(H20) = 0.49 ,1= 1.85 ms 
2-Hydroxyisophthalamide ( lAM) ''^  
-N N 
H N 
NH 
/ o -
IN 
O O 
HO O O OH 
O NH H O 
HO OH 
O O 
NHMe MeHN 
10 
NHMe 
L ' 
Enantiopure, octadentate ligand L ' " incorporates repeating 2-hydroxyisophthalamide 
o 
units to chelate a Tb ion. 
o Excitation at 340 ran (s = 28,200 M"' cm"') 
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The absence of water (q = - 0.04) in the immediate proximity of the Tb(III) ion results 
in long luminescence lifetime (TH2O = 2.28 ms). 
o Forms very emissive Tb system in aqueous media, Opb (H2O) = 0.57. 
Substituted Bipyridyls / Terpyrdiyls 
HO2C 
N 
N 
N N ^ 
HO2C CO2H 
Numerous bipyridyl systems have been used in lanthanide sensitisation, including 
complexes E U L ' ^ and L O L ' * which will be discussed in section 1.12. 
Research in the design of new sensitising moieties is a continually evolving field, with 
recent publications citing emissive systems incorporating thiophene-derivatised Pybox'*', 
quinoxaline^' and 2-hydroxyisophthalate'^ chromophores. Although reporting large 
quantum yield measurements, these systems are rather limited in application, as emission 
is only observed in organic solvents (e.g. acetonitrile). 
In contrast to the intramolecular sensitiser complexes shown above, short peptides 
have been studied to promote intermolecular lanthanide sensitisation. One example is the 
synthesis and design of a cyclin fluorescent sensor using Tb^^ DOTA.'^ The macrocycle 
is covalently bound to a short cyclin binding protein. This protein has an appropriately 
poshioned Trp amino acid residue that can sensitise the lanthanide ion (at 280 nm) when 
in close proximity. Imperial! et al. have also used this principle to devise new Eu^^ and 
Tb^* sensitising binding tags.'"* By replacing tryptophan with unnatural amino acids, it 
has been shown that Eu sensitisation can be achieved with excitation at 337 nm or 390 
nm. This method of sensitisation is extremely fragile, with a detailed understanding of 
protein modelling and structure required. For efficient systems, the Ln ion and amino 
acid residue must be in close proximity to ensure efficient energy transfer. 
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1.9 Aim and Objectives 
As shown previously, numerous organic chromophores have been utilised as sensitisers 
for lanthanide emission. Very few of those reported possess a Si - T| energy gap in protic 
media that is sufficiently small to allow excitation in the range 338 to 410 nm, without 
depopulation of the sensitiser triplet excited state. This could involve either back energy 
transfer or competitive quenching by triplet oxygen. Furthermore, the high excited state 
energies of Eu and Tb reduces the number of compatible candidates. 
The objective of this thesis is to devise practicable routes to new highly emissive 
complexes of Eu and Tb that possess the following characteristics: 
a) can be excited in the range 337 (nitrogen laser) to 420 nm; 
b) possess an overall emission quantum yield in biological media in excess of 
10%; 
c) resist quenching of the intermediate sensitiser and lanthanide excited states; 
d) can be conjugated to appropriate vectors and bio-molecules, as required for 
their application in a variety of time-resolved luminescence assays, or for their 
direct application as probes in cellulo. 
1.10 Engineering Lanthanide Complexes for Biological Applications 
Emissive lanthanide complexes that are to be used either as 'responsive' systems or as 
luminescent 'tags' in bio-conjugates must funcfion in aqueous media. This ftinction must 
be maintained in the presence of significant concentrations of competing endogenous 
ligands or buffers (e.g. proteins, phosphorylated anions, citrate, ascorbate, urate and 
glutathione).^^ Complexes are therefore required to be water soluble, non-toxic and have 
both high kinetic and thermodynamic stabilities with respect to lanthanide ion 
dissociation, preferably over the pH range 4.5 - 8. The complex should also be stable 
with respect to photofading and oxidative degradation in air or aqueous solufion. 
Complexes must possess an excitation wavelength in excess of 337 nm, with a high 
overall emission quantum yield (> 10 % in aqueous medium) and large extinction 
coefficient at the excitafion wavelength. 
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1.11 Using Lanthanide Complexes for Imaging in ce//ulo' 
For a complex to be employed as a cellular probe it must exhibit cell permeability by 
either passive diffusion or an active transport mechanism. In addition to this, a distinct 
compartmentalisation profile (i.e. preference to localise in a given organelle) is desirable. 
The complex must convey information about its local environment (e.g. as a fionction of a 
given intracellular analyte) by either changes in its spectral emission profile or lifetime, 
while resisting competitive quenching from endogenous ions or biomolecules. 
Recently, lanthanide complexes have been reported that are taken up by live cells and 
can be observed by fluorescence microscopy. Examples include complexes E U L ' ^ and 
TbL'"', which have specific targeting vectors located on a pendant arm of the cyclen 
macrocycle. In the case of E U L ' ^ , the o-chlorophenylquinoline moiety reportedly targets 
benzodiazepine receptors that are over expressed in glioblastoma cells.^' Cellular uptake 
experiments suggest this complex localises in the outer mitochondrial membrane, 
following an endocytosis uptake mechanism. Excitation of the lanthanide is achieved at 
320 nm via an attached quinoxaline group. For TbL*'', the tetrapeptide tuftsin is known to 
be responsible for activation of macrophage cell lines and is internalised by 
macrophages.^ ^ Luminescence spectra of macrophages incubated with TbL' ' ' suggest the 
complex is internalised / bound within macrophage cells, but have not been confirmed by 
any cell localisation studies. The absence of a sensitising moiety in the complex could 
present poor sensitivity in vivo, with the complex liable to quenching. At present 
luminescence is only observed by direct excitation at 366 nm (corresponding to the ^F(, -> 
transition). 
1^ 
• V, V i ' N ' 
V. p N , '..o- ~ \ - -CO, -
1^  H O ' "o NH-Thr-Lys-Pro-Arg 
13 TbL^* 
Figure 1.12: Examples of lanthanide complexes used in cellular imaging 
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Diffusion enhanced fluorescence resonance energy transfer (DEFRET) studies of 
complex TbL'"* were used to determine its cellular localisation.^^ It has been suggested 
that this complex labels cells by inserting the two hydrophobic alkyl chains into the cell 
membrane, with the remainder of the complex in the extracellular medium. Complexes 
E U L ' ^ , TbL*"' and TbL*'* demonstrate the use of structural manipulation to provide 
certain criteria essential for their respective cellular applications. 
Azaxanthone and thiaazaxanthone containing complexes have also shown interesting 
cellular behaviour. The two heptadentate macrocyclic complexes, E U L ' ^ and EuL^ are 
just two complexes that include these chromophores, which warrant further investigation. 
1 
COaMe / 
' HN 
\ •A J 
HN N"' t\ r-N I N--^  \\ 
, . N - ^ X - - ' ^-N ^N-' ^ 
H2O o 
Figure 1.13: Azaxanthone complex E U L ' ^ and thiaazaxanthone complex EuL^ 
The localisation of these complexes has been examined by fluorescence microscopy in 
a range of cell lines.''*'''^ Within 5 minutes of incubation at 50 \iM, complex E U L ' ^ was 
found to localise in cell mitrochondria. This hypothesis was confirmed by co-staining 
with commercially available Mitotracker Green™. After longer incubation periods (> 
4 h), E U L ' ^ appears to migrate from the mitochondria to late endosomes/lysosomes 
(Figure 1.14).^ ^ This process has been attributed to the complex's ability to bind 
reversibly with a given carrier protein. This behaviour highlights the need for complexes 
to resist fast intracellular trafficking, and persist long enough in their desired locations to 
convey information about their surrounding environment. 
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(a) 
(b) 
T 
(c) 
V 
\ i 
Figure 1.14: Microscopy images for EuV^.showing a mitochondrial localisation profile 
and subsequent migration of the complex to the perinuclear endosomes/lysosomes. 
(a) Eu complex (50 fiM complex, 4 h incubation) 
(b) Mitotracker Green ™ 
(c) Merged image of (a) and (b) 
(d) Eu complex (50 ^M complex, 24 h incubation time) 
(e) Mitotracker Green ™ 
( f ) Merged image of (d) and (e) consistent with migration of the complex from the 
mitochondria to the perinuclear endosomes/lysosomes 
Protein association may also explain the affinity of complex EuL^ to cross the nuclear 
membrane and stain the nucleoli of mouse skin fibroblast, Chinese hamster ovarian and 
HeLa cells. At a 100 | i M concentration, EuL^, has been shown to co-localise with SYTO 
RNA-select,^^ a fluorescent stain that highlights the position of RNA (free or protein 
bound). 
Despite promising results, the design of single-component luminescent species for a 
specific cellular compartment remains extremely difficult to predict from structure alone. 
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This is exemplified by the constitutional isomeric complexes EuL"* and E u L ' * . Originally 
developed as H C O 3 " anion sensors, these two complexes have been shown to exhibit 
differing behaviour in mouse skin fibroblast (NIH 3T3) cells.^"'^° 
•02C 
HN 
•O2C H 
N N 
0 - — E " - OH2 
N N ^ 
NH 
C02-
E u L ' ' 
•02C ^ 
HN Q 
H2O N N 
0 
y N N 
-O2C U Q, 
Lysotracker Green Eu Complexes Merged Images 
NH 
CO2" 
16 EuL 
Figure 1.15: Fluorescence microscopic images of complexes EuL'' and EUL'^ 
As shown in Figure 1.15, isomer EuL'* distributes well in the cytosol, with 
fluorescence microscopy and co-staining with Brefeldin A suggesting localisation in the 
endoplasmic reticulum, hi contrast, complex E u L ' * shows a tendency for 
compartmentahsation in acidic lysosomal environments."' This work is part of an 
extensive study (> 60 complexes) within the Parker research group, seeking to rationalise 
the cellular behaviour of luminescent Ln complexes (e.g. uptake / compartmentalisation). 
Preliminary resuUs indicate it is the nature and linkage of the sensitising moiety that 
defines the extent of the complex's protein interaction. It is believed that this interaction 
is fundamental in defining the cellular uptake/egress rates and the compartmentalisation 
profile. The mechanisms of cellular uptake and cellular localisafion behaviour wil l be 
discussed in Chapter 5. 
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1.12 Using Lanthanide Complexes as Bioconjugate 'tags' 
If luminescent lanthanide complexes are to serve as emissive 'tags', they must possess a 
suitable reactive functional group to expedite conjugation e.g. pendant acid or primary 
amine group. The following section highlights some recent literature publications of 
bioconjugate lanthanide complexes and their respective applications. 
H T R F ® / F R E T 
Cisbio International, sponsors and collaborators for the duration of this thesis, have 
developed a technique knoun as homogeneous time-resolved fluorescence, HTRF®.^° 
This technique relies on fluorescence resonance energy transfer (FRET) principles, with 
the time-resolved measurement of fluorescence. FRET is based on the transfer of energy 
between two fluorophores, a donor and an acceptor, in a process which is distance 
dependent (r'^).^' For FRET to occur, the donor and acceptor must have certain 
compatible criteria. These include: 
o non-overlapping emission spectra in order to measure each component's 
fluorescence individually 
o the FRET quantum yield must be as high as possible 
o fluorescence emission must occur within a region of the spectrum remote from 
that naturally produced by proteins 
HTRF® allows molecular interactions between biomolecules to be assessed by 
coupling each respective component with a fluorescent label and detecting the level of 
energy transfer. To date, numerous assays have been devised, among them those which 
measure protein - protein interactions and kinase / protease enzyme activity. Leading on 
from the revolutionary work by Prof. J. M . Lehn, Cisbio International have developed 
long-lived luminescent donors such as Europium cryptate E U L ' ' and Lumi4-Tb^'^ (a Tb"'"^  
cryptate). 
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Figure 1.16: EUL'^ developed by Cisbio international 
These cage structures confer long-lived fluorescence, high emissive quantum yields 
(Xex 337 rmi) and stability towards photobleaching and ion dissociation. Commercial 
acceptors used in HTRF® include X L 6 6 5 , a 105 kDa cross-linked allophycocyanin 
protein. It presents a set of photophysical properties matching the TBP Eu^^ cryptate 
E U L ' ^ : a high molar absorptivity at the cryptate emission wavelength which allows a 
high transfer efficiency (Ro ~ 9.5 nm); emission in a spectral range where the cryptate 
signal is insignificant, high quantum yield (~ 70 %) not quenched in biological fluids.^ 
3 3 7 nrrK. 
^ 665 nm 
SA- Europium 
Cryptate 
XL665 lab«(ed 
anti-human antikwdy 
80 
Figure 1.17: Illustration of fluorescence resonance energy transfer (FRET) 
Following excitation, HTRF® emissions are measured at two different wavelengths, 
620 nm (donor) and 665 nm (acceptor). This allows ratiometric analysis, with emission at 
620 nm used as an internal reference, while emission at 665 nm is used to assess the 
biological reaction. 
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Bioconjugate Complexes 
Complex L n L ' * (Figure 1.17) has been cited in the literature to be employed in protein 
labelling and time-resolved luminescence imaging.^^ The complex consists of a glutamic 
acid framework, bis-functionalised with bipyridyl carboxylic acid sensitising moieties. 
These moieties have a triplet excited state of 22,100 cm"', enabling both europium and 
terbium sensitisation. The respective Eu and Tb complexes possess quantum yields of 
Oeu = 0.08, (Djb = 0.31 in aqueous solution. The extinction coefficient of the bipyridyl 
system lies in the range of 19,000 to 21,000 M ' ' cm"'. A terminal carboxylate function in 
the complex has been shown to be activated into the corresponding A^ -
hydroxysuccinimidyl ester using EDC.HCl and A^-hydroxysuccinimide in DMSO. It is 
this activated form that has been covalently linked to amino functions (e.g. on BSA) and 
implemented in time-resolved luminescence imaging. 
, o 
N O 
O O -
° H 2 P 
N. O / 
J 8 
Figure 1.17: N-Hydroxysuccinimidyl ester complex LnL 
Despite positive preliminary results, analogous systems have proved unstable when 
anionic species such as phosphates are present. For this reason, improvements may 
orientate around changing the chemical structure to provide an additional donor atom. 
This modification may help exclude the present bound water molecule and therefore 
increase the emissive quantum yields and lifetimes. 
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NH2 
OH HO. .. . 1 „ 
NHCH3 - j ^ I - NHCH3 " N 11 
NHCH3 NHCH3 i !^ 
Figure 1.18: Ligands a«c/ L^" 
Ligands L " and L^" (Figure 1.18) constitute two other systems cited as being 
applicable as bioconjugate complexes.^ ^" '^'" '^' The octadentate Hgand L " , incorporates 
repeating 2-hydroxyisophthalamide chelating units to coordinate to a lanthanide ion (Ln 
= Eu, Tb, Sm, Dy). The respective Tb complex possesses a X«xc 350 nm with an 
extinction coefficient of 26,800 M"' cm''. These attributes, in addition to an efficient 
ligand to lanthanide energy transfer process are responsible for a quantum yield of 0.59 in 
aqueous solution. This value is 30 times larger than the commercially used FRET 
component EuL*' . Unlike the latter, this system does not require external fluoride ions to 
prohibit direct water coordination. However, no emission lifetimes or pH / anion 
sensitivity experiments are evident in the literature, providing no indication as to how 
these systems might behave in biological media. It can be assumed that the coordinated 
water molecule wil l deacfivate the lanthanide excited state, providing an area of possible 
structural improvement. 
The dipicolinic acid derivative L^" has been identified as a possible assay component. 
The incorporation of a terminal amine group situated at the end of a polyoxyethylene 
linker enables potential vector conjugation. Despite proving efficient sensitisers of Eu"'"*^  
in aqueous media (C)eu = 0.29), these complexes have numerous limitafions. A low 
excitation wavelength of 279 nm is not optimal for biological applicafions, while the 
complexes show inconsistent stoichiometrics and are often racemic. I f complexes are to 
be used in biological situations, it is essential to have a detailed understanding of their 
confirmation and chirality. This is due to the fact that racemic complexes may interact 
with endogenous chiral species with differing affinities, making subsequent changes in 
behaviour difficult to distinguish. 
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Although ligands L " and L ^ " have been described as potential candidates for 
bioanalytical applications, neither has been covalently conjugated or used in biological 
media. This is extremely important to identify i f the respective complexes retain their 
structural and photophysical attributes that are observed in aqueous media. 
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As discussed in the previous chapter, ligands containing substituted 1-azaxanthone and 
azathioxanthones have been demonstrated to be efficient sensitisers of Eu^^ and Tb^^ in 
aqueous media. It was envisaged that by modifying the azaxanthone structure to 
incorporate an additional heterocyclic moiety, an additional donor atom to bind to the 
lanthanide (III) ion could be incorporated. This would also extend the conjugation length 
of the chromophore, shifting the lower energy absorption band of the ligand to a longer 
wavelength, increasing the molar extinction coefficient. The putative bidentate binding of 
the chromophore, when incorporated into a macrocyclic structure, creates a nonadentate 
environment for the Ln ion, excluding any bound water molecules. 
2.1 Chromophore Synthesis 
The versatile synthetic intermediate 6-/er/-butyl-2-chloro-9-oxa-l-aza-anthracen-10-one, 
6, was synthesised according to Scheme 2.1. The synthesis of 6-/er/-butyl-9-oxa-]-aza-
anthracen-lO-one, 2, was accomplished by a two-step process involving a nucleophilic 
aromatic substitution reaction between 2-chloronicotinic acid and 4-tert-h\xty\ phenol, 
followed by electrophilic cyclisation under acidic conditions. Methylation of azaxanthone 
2 with methyl triflate' and subsequent anion exchange chromatography yielded the water 
soluble azaxanthone 4 as its chloride salt. Oxidative hydrolysis using a literature 
protocol^ with [K3Fe(CN)6] and NaOH afforded the N-methylpyridone intermediate, 5, in 
74 % yield. The reaction was easily monitored by ' H NMR, with the loss of pyridine 
aromaticity accompanied by a proton shift from 7.99 to 6.54 ppm. Finally, chlorination 
(POCI3) of intermediate, 5, yielded the 2-chloro derivative, 6, in 50 % yield after 
chromatographic purification on silica. 
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CF3SO3CH3, Toluene 
o°c 
91 % 
NaOMe. MeOH 
By % 
DOWEX 1-X8(CI) Resin 
MeOH. H 2 O 
Me CI Me SO3CF3 
3 
POCb, C6H5N(CH3)2 
[K3Fe(CN)6], NaOH 
0°C 
74 % 
Scheme 2.1: Synthesis of intermediate 2-chloro-azaxanthone, 6. 
Initial attempts to synthesise the corresponding unsubstituted and C02Me derivatives 
of Cl-azaxanthone, 6, (i.e. replacing 'Bu by H or CO^Me) proved unsuccessful. The 
C02Me functional group was seen as a possible route for bioconjugation via an activated 
ester derivative. However, both compounds exhibited poor solubility in organic solvents, 
resulting in poor yields. Research studying the photophysical properties of an array of 
substituted azaxanthone derivatives has been reported in the literature"' (Table 2.1). It was 
shown that substituting a terl-bu\.y\ group (or methyl carboxylate) into the 7 position of 
the azaxanthone structure had no significant effect on the A^ iax or energy of the triplet 
excited state. For these reasons, a /er/-butyl group was introduced into the azaxanthone 
moiety in the knowledge that it would help enhance solubility, without compromising 
any photophysical attributes associated with azaxanthone moieties. 
Azaxanthone A.nia.x / nm (e; M"' cm"') ^ A.em / nm (r^'em) E t / cm"'" 
la 330 (6,900) 405 (1) 24,800 
lb 328 (5,270) 392 (1.3) 24,900 
Ic 336 (9,380) 409 (0.4) 24,600 
o 
1 a R = H 
lb R = C02Me 
1 c R = ' B u 
Table 2.1: Photophysical properties of 2-methyl-l -azaxanthone derivatives 
f MeOH. 295 K; " 77K in an Et20-isopentane-ethanol (EPA) frozen glass with typically a I OO^s decay) 
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The chloride functionality o f compound 6, provided a reactive group to utilise for the 
introduction o f heterocylic moieties. Any potential heterocyclic rings that were to be 
included into the azaxanthone scaffolding would have to possess the following 
requirements; 
o Extend the conjugation 
o Be suitably functionalised as to allow linkage to a cyclen framework 
o Be either commercially available or synthetically accessible from an appropriate 
precursor 
A 2-pyridyl and a 2-pyrazoyl group were deemed suitable for this purpose, as the 
corresponding bipyridyls and 2-pyrazoylpyridines constitute well-studied classes o f 
ligands in coordination chemistry"* and have been shown (Chapter 1) to be effective 
donors in Ln ' " complexes. 
2.1.1 2-Pyridyl -azaxanthone 
The Suzuki - Miyuara cross-coupling reaction is the most common way of introducing 
carbon - carbon bonds in heterocyclic chemistry.^ It is often preferred to alternative 
cross-coupling reactions because o f the non-toxic, mild, and air / water stability o f 
boronic acids.^'^ The most frequently used substrates are aryl bromides, iodides and 
triflates, with aryl chlorides often proving unreactive substrates. This poor reactivity is 
attributed to the reluctance o f aryl chlorides towards oxidative addition to Pd (0). 
However, recent publications have highlighted the successful coupling o f electron- rich 
aryl chlorides when using tri(dibenzylideneacetone)dipalladium (0) as a catalyst.^ '^ 
This literature precedent prompted us to explore the possibility o f coupling 6, with 
commercially available 6-methyl-2-pyridineboronic acid 7V-phenyldiethanolamine ester. 
6-/eA-/-Butyl-2-(6-methyl-pyridin-2-yl)-9-oxa-l-aza-anthracen-10-one, 8, was isolated in 
16 % yield, with reduction o f the starting material (CI -> H) constituting a significant by-
product. A potential solution was to employ an alternative nucleophilic substrate. 
Literature shows the Negishi cross-coupling reaction and arylzincs has been used to 
synthese bipyridyl s y s t e m s , " u s i n g functionalised pyridine chlorides. However, despite 
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using these literature conditions, attempts to couple 6-/e/-/-butyl-2-chloro-9-oxa-l-aza-
anthracen-lO-one, 6, with 6-methyl-2-pyridylzinc bromide proved unsuccessful. 
An alternative approach investigated was via a Stille-coupling reaction. The reaction 
o f 2-bromo-6-methyl-pyridine with w-BuLi, followed by /r/-n-butyl-tin chloride gave 6-
methyl-2-(tributylstannyl)pyridine, 7 (Scheme 2.2). 1 3 . 1 4 
n-BuLi SnBusCI 
N Br T H F , - 7 8 ° C N L i , N SnBu3 
7 
Scheme 2.2: Synthesis of 6-methyl-2-(trihutylstannyl)pyridine. 7. 
6-Methyl-2-(tributylstannyl)pyridine 7, was used directly in a Stille-coupling with 
azaxanthone 6, without any purification. Using Pd(PPh3)4 as a catalyst, 6-/e/-/-butyl-2-(6-
methyl-pyridin-2-yl)-9-oxa-l-aza-anthracen-10-one, 8 ( ' H N M R and X-ray crystal 
structure are shown in Figures 2.1 and 2.2), was isolated in 61 % yield following 
purification by trituration in diethyl ether (Scheme 2.3). 
(i)or(ii) 
CI N O 
6 
Conditions; Me 
N O 
(i) 6-Mettiyl-2-{tributylstannyl)pyridine, Pd(PPh3)4, toluene, 61 % 
(ii) 6-Methyl-2-pyridineboronic acid W-ptienyldiettianolamine ester. 
CS2CO3, Pd2(dba)3, P( 'Bu)3, dioxane, 16 % 
N B S , (C6H5CO)202 
CCI4 
N O N 0 
Br 
9 41 % 
Br Br 
10 3 3 % 
'Pr2NEt, (C2H50)2P(0)H 
7 9 % 
Scheme 2.3: Synthesis ofbromopyridyl-azaxanlhone, 9. 
Selective bromination o f the a-methyl substituent o f 8 was performed using radical 
bromination with 7V-bromosuccinimide and benzoyl peroxide in CCI4 . The reaction was 
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monitored by ' H N M R to provide ratiometric analysis o f the formation o f the desired 
mono-brominated derivative 9, and the competing di-brominated analogue 10. 
Purification by column chromatography on silica yielded 9 and 10 in 41 % and 33 % 
yields respectively. Reaction o f compound 10 with diethyl phosphite and DIPEA enabled 
conversion o f the di-brominated material to the corresponding mono-brominated 
analogue, fol lowing chromatographic purification. 
Figure 2.1: X-ray crystal structure of methylpyridyl-azaxanthone, 8. 
M _ _ fliV_!RI._jUl . _ 
8.8 8.6 8.4 8.2 8.0 7.8 7.6 7.4 7.2 pp 
ppm 
Figure 2.2: 'HNMR spectrum of methylpyridyl-azaxanthone 8 (CDCh, 700 MHz, 298 K) 
2.1.2 2 -Pyrazoy l -azaxanthone 
The synthesis o f pyrazole azaxanthone 11 was achieved in 90 % yield by nucleophilic 
aromatic substitution between chloro-azaxanthone, 6, and 3-methylpyrazole, using NaH 
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as a base (Scheme 2.3).'^ Bromination o f 11 to the corresponding mono (12) and di-
brominated (13) analogues was performed in an analogous method to that described for 
pyridyl-azaxanthone, 8. 
CI N O 
6 
3-Me pyrazole, NaH 
T H F 
9 0 % 
N 
N 
0 
K 
N O 
11 
Me 
NBS, (C6H5CO)202 
CCI4 
- N '' • 0 - ' ' ' - - = 
N 
Br 
12 56 % 
I 
1)1 O 
N 
Br 
Br 
13 31 % 
'Pr2NEt, (C2H50)2P(0)H 
6 7 % 
Scheme 2.3: Synthesis ofbromopyrazoyl-azaxanthone, 11. 
Examination o f the X-ray crystal structure ofbromopyrazoyl-azaxanthone, 12 (Figure 
2.3), confimied as expected, that covalent linkage to the azaxanthone moiety was through 
the desired nitrogen atom. There was no evidence to suggest that the constitutional 
pyrazole isomer is formed or reacts during the aromatic substitution reaction. 
Figure 2.3: X-ray crystal structure ofbromopyrazoyl-azaxanthone, 12. 
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Jl. I L . 
8.8 8^6 8.4 8.2 8X) 7.8 7.6 7^ 4 7.2 7.0 6.8 6.6 6.4 ppm 
jL,..,t_ 
ppm 
Figure 2.4: 'HNMR spectrum of methylpyrazoyl-azaxanthone, 11, (CDCI3, 700 MHz). 
2.1.3 Tetraazatr iphenylene 
The tetraazatriphenylene chromophore (dpqC) 14, is an established sensitiser for 
lanthanide luminescence. A triplet energy o f the order o f 24,000 cm"' means that the 
moiety is suitable for both europium and terbium sensitisation. Furthermore, a fast rate o f 
intersystem crossing ensures the triplet excited state is efficiently populated in aqueous 
media. 
The dpqC moiety may serve as a bidentate ligand, binding via two pyridyl nitrogen 
atoms. This coordination enables nine-coordinate complexes to be prepared based upon a 
cyclen macrocycle. Such complexes possess no bound water molecules, and for this 
reason form emissive complexes with an effective sensitiser. 
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MeLi. T H F , 0 ° C '" H2SO4, HNO3, KBr ^ . ° H2N N N 
N Mn02 ,MgS04 ^ N O N N 
14 
HO CI 
i) S e 0 2 , dioxane ^ ^ , P C I 3 , C H C I 3 ^ ^ 
ii) NaBH4, EtOH 
N N N N 
15 
Scheme 2.4: Synthesis of chloromethyl dpqC, 15. 
The 2-chloromethyl dpqC derivative, 15, is synthesised by reaction o f 1,10-
phenanthroline with one equivalent o f methyl li thium, followed by oxidation with Mn02 
in the presence of MgS04. Oxidation o f the 9-10-double bond with molecular bromine 
under strong acidic conditions yields the corresponding dione. Condensation o f the dione 
with 1,2-diaminocyclohexylamine affords 2-methyl-tetraazatriphenylene, 14. Stepwise 
derivatisation o f the methyl group to the corresponding 2-chloromethyl (15) is achieved 
by oxidation with Se02, reduction with sodium borohydride and chlorination with PCb.'^ 
Compound 15 was supplied by Cisbio International for work during this thesis. 
2.2 C h r o m o p h o r e C h a r a c t e r i s a t i o n 
Having isolated chromophores 2-pyridyl-azaxanthone, 8, and 2-pyrazoyl-azaxanthone, 
11, their respective photophysical properties were assessed. 
2.2.1 Absorption Spec tra 
The absorption spectra o f chromophores 8 and 11 were recorded in MeOH at 298 K 
(Figure 2.5). 
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— Pyridine Azaxanthone 
- Pyrazole Azaxanthone 
3 0.12 
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Figure 2.5: Absorption spectra for chromophores 8 (blue) and 11 (red) (MeOH, 298 K) 
The absorption spectra o f chromophores 8 and 11 show moderately intense long 
wavelength bands at 348 (e = 10,100 dm^ mol"' cm"') and 346 (s = 15,400 dm^ mof ' 
cm"') nm respectively. A strong absorption is also apparent at 355 nm, a common laser 
excitation wavelength. The extension o f the chromophore conjugation is accompanied by 
a red shift in >.max by ~ 10 nm when compared to the parent rerf-butyl azaxanthone ( l a 
shown in Table 2.1). In addition, the molar extinction coefficients show a two fold 
increase in comparison to the parent azaxanthone and dqpC. This increase indicates an 
increase in light absorption efficiency and subsequent population o f the singlet excited 
state. 
2.2.2 F l u o r e s c e n c e Emission S p e c t r a 
Emission spectra o f chromophores 8 and 11 were recorded in MeOH at 298 K . Both 
chromophores were shown to exhibit minimal ligand fluorescence at room temperature, 
wi th weak broad bands observed between 390 - 430 nm. This radiative decay o f the 
singlet excited state suggests that the rate o f fluorescence is competitive with the rate of 
inter-system crossing. The fluorescence, which is not observed in the parent azaxanthone 
systems, is consistent wi th an enhanced degree o f TIJI* character in the singlet excited 
state o f the pyridyl- and pyrazoyl-azaxanthones. 
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2.2.3 P h o s p h o r e s c e n c e Emission Spec tra 
Phosphorescent emission spectra o f chromophores 8 and 11 were measured to distinguish 
their respective triplet state energies. This would ultimately indicate which lanthanides 
these chromophores could potentially sensitise. The spectra are shown in Figure 2.6, and 
were measured at 77 K in a diethyl ether - isopentane - ethanol (EPA) frozen glass. 
400 
350 
= 300 
•S. 
• f 250 
c 
2 
S 200 
c 
o 
1.150 
o w 
•9 100 
< 
— Pyridine Azaxanthone 
— Pyrazole Azaxanthone 
50 
477 nm 426 nm 
300 350 400 600 650 700 450 500 550 
Wavelength (nm) 
Figure 2.6: Phosphorescence emission spectra for compounds 8 (blue) and 11 (red) 
(77 K. EPA) 
The highest energy vibrational band in each spectra is the 0,0 (Ti (v = 0) ^ So (v = 0)) 
transition band, corresponding to the respective triplet energies o f the chromophores. The 
phosphorescence spectra show that chromophores 8 and 11 have triplet energies (Ej) o f 
477 nm (20,960 cm"') and 426 nm (23,470 cm' ' ) respectively. 
It can be concluded f rom this experimental data that pyrazoyl-azaxanthone, 11, should 
allow Eu and Tb sensitisation, while pyridyl-azaxanthone 8 is only applicable for Eu 
sensitisation. The triplet energy o f 8 (20,960 cm"') is too low to allow efficient Tb 
sensitisation ( 'D4 = 20,400 cm"') at ambient temperature without the prospect o f 
thermally activated back energy transfer (Figure 2.7). 
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Pyridyl-azaxanthone Pyrazoyl-azaxanthone 
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dpqC 
Figure 2.7: Bar chart showing the triplet energies of chromophores 8, 11 and dpqC 
and the respective lanthanides they can sensitise 
Fine structure was observed in both chromophores, wi th each phosphorescence 
spectrum exhibiting three bands, separated by ~ 1650 cm' ' . This characteristic is typical 
o f carbonyl vibrational fine structure, behaviour that is distinctive and consistent with 
dominant rni* character o f the triplet states.'^ '^ Confirmation o f the rni* triplet character 
was achieved by recording absorption spectra in media o f varying polarity. Here, a small 
red shift in the longest wavelength band was observed upon increasing the solvent 
polarity (e.g. for pyridyl-azaxanthane, 8, a shift f rom 344 m (EPA) to 348 rmi in MeOH 
was observed). 
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2.2.4 S u m m a r y 
A summary o f the photophysical properties o f pyridyl-azaxanthone, 8, and pyrazoyl-
azaxanthone, 11, is shown below, Table 2. 
Chromophore Amax (nm)' £ (dm^ mol ' c m ' ) " E T (cm-^)" 
0 
11 
330 6,900 24,800 
0 
336 9,380 24,600 
0 I 
348 10,090 20,960 
0 
^ N ^ C 346 15,380 23,470 
1 
N • N 
348 6,400 23,400 
Table 2.2: Photophysical properties of selected sensitising chromophores 
C MeOH, 295 K; * 77K in an EtiO-isopentane-ethanol (EPA) frozen glass) 
The extended conjugation in the pyridyl- and pyrazoyl-azaxanthone moieties is 
accompanied by an increase in both Xmax and extinction coefficients (when compared to 
the parent azaxanthone). Examination o f the triplet excited state energies indicate the 
pyrazoyl-azaxanthone is applicable for both europium and terbium sensitisation. For the 
pyridyl-azaxanthone, a T i o f 20,960 cm"' implies thermally activated back energy 
transfer would be problematic for terbium sensitisation. Consequently, only europium 
complexes w i l l be studied using this heterocyclic chromophore. 
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2.3 Ligand a n d C o m p l e x Synthesis 
The fol lowing section w i l l describe the synthesis o f neutral carboxylate and cationic 
phenyl amide complexes incorporating the pyridyl-azaxanthone, pyrazoyl-azaxanthone 
and dpqC chromophores. 
2.3.1 D 0 3 A C o m p l e x e s 
l,4,7,10-Tetraazacyclododecane-l,4,7-triacetic acid ( D 0 3 A , 16) was synthesised f rom 
reaction o f cyclen with ^er/-butyl bromoacetate, under SN2 conditions (acetonitrile, 
K2CO3). Purification by column chromatography on silica yielded D 0 3 A , 16, in 32 % 
yield. The synthesis o f ligands [ L ' J , [ L ^ J and [ L ^ J involved alkylation o f D 0 3 A , wi th the 
appropriate halomethyl chromophores. Following chromatographic purification on 
neutral alumina, treatment with CF3CO2H - C H 2 C I 2 removed the BOC protecting groups. 
Complexation o f the deprotected ligands was performed using the appropriate Ln(OAc)3 
salt in water at pH 5. Removal o f excess lanthanide was achieved by precipitation o f 
Ln(0H )3 at pH 10. Finally, chromatography on neutral alumina (20 % C H 3 O H - C H 2 C I 2 ) 
led to the isolation o f the neutral complexes [ E U L ' ] , [LnL^] and [LnL'*]. 
I 
N U 
N 
° 6 f " ' "'^  " ° ° O ° 0 
\ H 
N N B r ^ N N 1 ) CH2CI2, T F A 9 8 % N N - , ^ 
I 9 0 % O N 6 8 % O r , N 
o „ o 
° o ~~ \ ° o 
16 [L^] [EuL^] 
Scheme 2.5: Synthesis of ligand [iJ] and the neutral complex [EuL*] 
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Scheme 2.6: Synthesis ofligand [L ] a n J neutral complexes [ L n L ] 
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Scheme 2.7: Synthesis ofligand [L ] a n J neutral complexes [ L n L ] 
2.3.2 Tri-Amide C o m p l e x e s 
Selective mono-substitution o f cyclen was achieved via alkylation o f tri-BOC cyclen 17, 
under SN2 condifions (acetonitrile, K2CO3), using the respecfive halomethyl 
chromophores. Deprotection o f the BOC groups (CF3CO2H / CH2CI2) yielded the 
tetraamines 19, 21 and 23 (Schemes 2.7, 2.8 and 2.10). Alkylation with (S)-N-2-
chloroethanoyl-2-phenylethylamine under basic conditions in acetonitrile afforded the 
triamide ligands [L'*], [L^], [L^] which were purified by chromatography on neutral 
alumina. Reaction o f the triamide ligands with one equivalent o f Ln(CF3S03)3 in 
anhydrous acetonitrile gave the desired cafionic complexes as triflate salts. Excess ligand 
was removed via sonification in CH2CI2, while trituration in water removed any excess 
lanthanide salt. Finally, the respective complexes were converted to the more water 
soluble chloride salts by anion exchange chromatography. 
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Scheme 2.8: Synthesis ofligand [L ] and the cationic complex [ E u L ] 
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Scheme 2.8: Synthesis of ligand [L^| and cationic complexes ILnL'"*] 
Alkylation o f tetraamine 21 wi th (5)-2-(2-bromo-acetylamino)-3-phenyl-propionic 
acid ethyl ester under SN2 conditions afforded ligand [L^], after purification by trituration 
in diethyl ether. Complexation o f the ligand was achieved in acetonitrile using 
Ln (CF3S03 )3 , followed by anion exchange chromatography to yield the water soluble 
cationic complex [LnL*] . 
3 + 
H / \ -
N N 
N N r ^ 
H H 
21 
N-N 
N 
O H 
CS2CO3. MeCN, 3 6 % 
Ln(OTf)3.6H20, MeCN 
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HN 
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1 H 
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/ 1 
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N I N N - N 3CI" 
° " NH b r o 
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Scheme 2.9: Synthesis of ligand [L*] and the cationic complexes [LnL*] 
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Scheme 2.10: Synthesis of ligand [L^] and the cationic complexes [LnL^] 
Parallel synthetic protocols were followed for complexes [LnL^] and [LnL^j using 
(/?)-j'V-2-chloroethanoyl-2-phenylethylamine. This yielded the opposing chiral complexes 
(RRR)-[LnlJ] and {RRR)-[hnL^]. These complexes were examined by circularly 
polarised luminescence (Chapter 4) and fluorescence microscopy (Chapter 5) to 
investigate the effect o f chirality on complex characteristics, such as cellular behaviour. 
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2.4 C o m p l e x Character i sat ion 
The photophysical properties o f complexes [ E U L ' ] to [LnL^] were assessed and 
compared to analogous complexes incorporating the parent 2-methyl-l-azaxanthone and 
7-tert-butyl-1 -azaxanthone chromophores. 
2.4.1 Absorption Spec tra 
The absorption spectra for complexes [EuL*] - [LnL^] were recorded in water at 298 K. 
For complexes containing the pyrazoyl-azaxanthone or dpqC chromophores, each 
spectral profile was consistent with those observed for the 'free' chromophores in organic 
solvent. This behaviour suggests there is a small electronic interaction between these 
chromophores and the lanthanide metal. Thus, pyrazoyl-azaxanthone complexes 
exhibited strong absorption at 346 nm, while the dpqC analogues show a major band at 
348 nm. With the pyridyl-azaxanthone complexes, [ E U L ' J and [EuL'*], complexation was 
accompanied by a change in spectral form. A red shift in X,niax was observed to a 
wavelength > 350 nm, while a gradual decrease in absorption was observed above 350 
nm (Figure 2.8). This behaviour differs f rom the free chromophore, which shows a steep 
decline in absorption beyond 350 nm. In conclusion, the pyridyl-azaxanthone complexes 
are well suited to excitation at 355 nm, a wavelength o f several common lasers. 
TbD03A_Pyrazoyl azaxanthone 
EuD03A_Pyridyl azaxanthone 
c 0.15 
250 270 290 310 330 350 
Wavelength (nm) 
370 390 410 
Figure 2.8: Comparative absorption spectra for complexes [ E U L ' ] (blue) 
and [TbL^I (red) (295 K, H2O) 
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2.4.2 Emission Spectra 
The total emission spectra of [ E U L ' | and [EuL^] are shown in Figure 2.9. Emission from 
complex [ E U L ' I reveals the expected Eu spectral fingerprint from the "'DQ emissive state. 
The spectrum also shows azaxanthone fluorescence centred at 445 nm. This ligand-based 
emission (O'em = ~ 20 % ) , whilst limiting the metal-based quantum yield, provides an 
observable band for luminescence microscopy and facilitates flow cytometric studies. 
Interestingly, only very weak Eu emission is observed from the analogous pyrazoyl-
azaxanthone complex, [EuL"]. Instead, the emission spectrum is dominated by ligand 
fluorescence at 410 nm. Initially, this ligand fluorescence was attributed to uncomplexed 
ligand. However, further investigation by HPLC analysis indicated the sample was free of 
any ligand impurity and comprised one species in solution. 
140 I AJ = 2 
120 
•2-100 
EuD03A_Pyrazoyl azaxanthone 
EuD03A_Pyriclyl azaxanfhone 
c 60 
K 40 
380 420 460 500 540 580 620 
Wavelength (nm) 
660 700 
Figure 2.9: Total emission spectra (aerated water, 295 K, lexc 355 nm) for [ E U L ' | (red) 
and [Eul}] (blue) 
Examination of the Tb adduct, |TbL^] (Figure 2.10), showed the expected Tb 
decay with weak ligand fluorescence. 
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Figure 2.10: Total emission spectra for [TbL ] (aerated water, 295 K, Xexc 355 nm) 
Measvirement of the total emission of complex [EuL^] in MeOH (Figure 2 .11) 
revealed an increase in europium emission, with a significant decrease in ligand 
fluorescence. This observation suggests that in aqueous media, the pyrazoyl-azaxanthone 
is displaced from binding with the lanthanide metal by a water molecule. In methanol 
however, the chromophore binding is not adversely affected. It can be postulated that the 
increase in ionic radius from terbium to europium (Tb^ "^  = 1.09 vs Ev^* = 1.12)'^  is 
significant enough to exceed the pyrazoyl-pyridine nitrogen's 'bite angle'. Consequently, 
an apparently weak binding interaction between the lanthanide ion and pyridyl nitrogen is 
observed, which is susceptible to competitive displacement by solvent water molecules. 
n 
O 
N N 
frV 
N ; N ~, 
\ 1 / 
-I I 
o 
N 
OH, 
Figure 2.11: Dissociation of pyrazoyl-azxanthone in [EuL^] 
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Figure 2.12: Total emission spectra for [EuL ] in water (red) and Me OH (blue) at 295 K 
The emission spectra of the cationic triphenylamide complexes [EuL"*] (Figure 2.13) 
and [TbL^I (Figure 2.14) exhibited more intense lanthanide emission compared to their 
D03A analogues. Each complex showed less ligand fluorescence, suggesting a more 
efficient rate of inter-system crossing. The total emission spectral form of complex 
[TbL'^] resembled that observed for [TbL^]. 
3 + 
5*4 
10 
c 
1 3 
c 
o 
0 
1 
UJ 
400 450 500 550 600 
Wavelength (nm) 
aj = 1 
AJ = 4 
Figure 2.13: Total emission spectra (aerated water, 295 K, Xexc ^55 nm) for [EuL'*] 
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Figure 2.14: Total emission spectra (aerated water, 295 K, Xexc 355 nm) for [TbL^] 
The emission spectral forms of the tetraazatriphenylene complexes [EuL^] and [TbL^J 
were found to be identical to those previously published within the literature.'^ The 
complexes exhibited the expected europium and terbium emission bands, with no 
observed ligand fluorescence. 
2.4.3 pH a n d Anion Sensitivity 
The apparent susceptibility of the pyrazoyl-azaxanthone moiety to undergo dissociation 
in [EuL^], prompted an investigation of the pH and anion stability of complexes [EuL'*j 
and [TbL^I. 
Pyrazoyl-azaxanthone, [TbL^] 
Luminescence titrations were carried out to determine any apparent pH sensitivity in 
aqueous media. As shown in Figure 2.15, the emission intensity and ligand fluorescence 
of [TbL^] were found to be pH dependent. This observation coincides with the findings 
for [EuL^], wherein binding of the pyrazoyl-azaxanthone was also susceptible to 
dissociafion. Studies showed that this dissociation is reversible. Addition of anions such 
as citrate, lactate and carbonate to [TbL^], also resulted in a decrease in emission profile, 
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consistent with pronounced sensitivity towards intermolecular anion ligation and pyridyl 
nitrogen dissociation. 
16 
14 
3 
™.12 
^ 10 
I 8 
B c 
c 6 
o 
'in | , 
2 
400 450 500 550 
Wavelength (nm) 
600 
5i 
650 
Figure 2.15: Variation of the terbium emission spectrum o /[TbL'] as a function ofpH 
over the range 3 to 10 ([Complex] = 20 fiM, Xexc = 355 nm, 0.1 MNaCl, 298 K) 
60-
pH 
Figure 2.16: Intensity ratio (554 nm / 440 nm) vs. pHplot for complex [TbL^] 
An intensity ratio plot vs. pH for complex [TbL^] (Figure 2.16) revealed that the 
complex has a pKa of 6.5 in aqueous medium. This value corresponds to the pyridyl 
nitrogen of the azaxanthone rather than the pyrazoyl binding nitrogen. 
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Pyridyl-azaxanthone, [EuL^] 
Luminescent titrations of [EuL'*] revealed no apparent pH sensitivity of the pyridyl 
azaxanthone, with luminescent behaviour remaining constant over the pH range 3 to 9. 
However, incremental addition of biological anions, such as citrate and lactate, caused a 
change in both the emission intensity and spectral form from the europium (III) ion 
(Figure 2.17). Addition of 0.4 mM HSA also led to modest quenching of the total 
emission spectra, with similar changes in the spectral form. 
12.0 
[EuL"] only 
[EuL^l + CISmM Citrate 
[EuL'^ + 0.4 mM HSA 
o 8.0 
c 6.0 
2 4.0 
400 450 650 700 500 550 600 
Wavelength (nm) 
Figure 2.17; Total emission spectra (aerated water, 295 K, Xexc 355 nm)for [EuL'*] with 
0.13 mM citrate (blue) and 0.4 mM HSA (green) 
The most notable changes were an increase in ligand fluorescence and changes in the 
form and intensity of the AJ = 2 and AJ = 4 bands (Figure 2.18). The loss of the 680 nm 
emission band is consistent with dissociation of the axial pyridyl-azaxanthone nitrogen 
atom. This was confirmed by comparison of the absorption spectra of [EuL"*] in the 
absence and presence of citrate. Addition of citrate was accompanied by a blue shift in 
^max, to reveal a spectrum similar to that of the free chromophore, described earlier 
(Figure 2.5). 
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Figure 2.18: Emission spectra (aerated water, 295 K, Xexc 355 nm) for [EuL"*] with 0.13 
mM citrate (blue) and 0.4 mM HSA (green) showing changes in spectral form; 
(Insert): Absorption spectra o/[EuL'*] without (blue) and in the presence of citrate (red) 
Examinafion of the emissive lifetime of [EuL"*] following addition of 0.13 mM citrate 
and 0.4 mM HSA resulted in less than a 10 % decrease compared to that observed in 
water. Thus, neither the presence of citrate nor HSA significantly quenches the lanthanide 
excited state. 
These observations suggest that in a cellular envirormient, the pyridyl-azaxanthone is 
likely to dissociate from the lanthanide ion. However, under such conditions the complex 
remains emissive, with a strong AJ = 2 band providing an emissive parameter to measure. 
2.4.4 Lanthanide Coordinat ion Environment Studies ('H NMR a n d HPLC) 
The paramagnetic nature of lanthanide (III) ions has led to their exploitation in the 
development of shift reagents and MRI contrast agents. The NMR resonances of atoms 
that are either directly coordinated or that are in close proximity to the metal ion exhibit a 
signal shift and broadening, the extent of which is dependent on the lanthanide ion. 
By examining the total optical emission and NMR spectral properties of a complex, it 
is possible to form an understanding on the nature and symmetry of the metal ion 
coordination environment.'^ ^ Of particular importance is the group or atom occupying a 
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position on or close to the principal axis of the complex. The nature and polarisability of 
this group determines the second order crystal field coefficient Bo^ that controls the 
dipolar N M R shift and the degree of splitting of the AJ = 1 manifold in europium 
spectra. '^'^ ^ For cyclen based complexes, this is typically the 'axial' ligand. The more 
polarisable this donor atom is, the greater the relative intensity of the AJ = 2 emission 
band. The ' H N M R spectrum of [EuL'*) is similar to that observed with [EuL^] (298 K , 
D2O) (Figure 2.19). 
il ill 
50 40 30 20 10 0 ' -10 ' -26 
Figure 2.19: 'HNMR spectra o / |EuL^] (upper) and \EuL*\ (lower) (D2O, 298 K) 
most shifted 
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N 
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Each complex presents 4 distinct axial protons on the cyclen ring. These axial protons, 
assigned by COSY as between 25 to 42 ppm, experience the largest paramagnetic 
shielding effect. The spectral behaviour of each complex is consistent with the presence 
of only one isomeric species in aqueous solution at room temperature. Confirmation of 
the presence of one isomeric species was obtained by reverse phase HPLC analysis 
(Figure 2.20). 
n 
3 CI" 
Figure 2.20: Reverse phase analytical HPLC analysis o/[EuL'*] 
(Chromolith performance RPl8e column: Method A;' Xexc = 355 nm, Xe„ = 355 / 613 nm) 
Detailed analysis of the total emission spectra of [EuL'*] and (EuL^j also provides 
information regarding the coordination environment of the europium ion. The fine 
splitting of the respective europium AJ = 1 bands provides information about the number 
of structural isomers present in solution. The presence of three transitions for each 
complex suggests one isomeric species of low symmetry, complementing the 
observations from ' H NMR and H P L C analysis. 
For [EuL'*], the relative heights of the AJ = 1 and AJ = 2 bands indicate that the 
polarisablilty of the axial donor is low. The presence of an emission band corresponding 
to 680 nm in the respective AJ = 4 manifolds is consistent with a nitrogen atom as the 
'axial' donor for complexes of both the tetraazatriphenylene and pyridyl-azaxanthone 
chromophores. 
For HPLC solvents and gradients see Chapter 7: Experimental 
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2.4.5 Luminescent Lifetimes 
Long luminescent lifetimes are highly desirable for complexes which are to be considered 
as practical luminescent probes. As previously discussed in Chapter 1, the excited states 
of europium and terbium are sensitive to quenching by OH and NH oscillators. The 
extent to which these emissive states are quenched by H2O and D2O is different. 
Consequently, measurements of the radiative lifetimes in H2O and D2O permit an 
estimate of the number of coordinated water molecules, q. This is achieved using 
Equations 2.1 and 2,2," which account for the quenching effect of second sphere waters 
and exchangeable NH oscillators of coordinated CO groups. 
= 1.2 ()t"'^  - k^'"" - 0.25 - 0.07X) (2.1) 
X = number of carbonyl-boimd amide NH oscillators 
7Tb = 5r>t"'«-it'*'«-0.06) (2.2) 
The lifetimes and respective q values of complexes [ E U L ' J to [LnL'j are collated in 
Table 2.3, along with analogous complexes containing the parent azaxanthones. Three 
D2O exchanges were performed before each lifetime measurement in D2O, to ensure 
complete H / D exchange for each sample analysed. 
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Figure 2.21: Lanthanide complexes incorporating the pyridyl-, pyrazoyl-azaxanthones, 
dpqC and parent azaxanthones 
(all cationic complexes are as their respective chloride salts) 
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Complex TH20 / ms TD20 / nas 
[EuL'] 1.00 1.34 0 
[EuL^] 0.70 1.76 0.73 
[EuL^] 1.04 1.59 0 
[EuL"*] 1.00 1.34 0 
[EuL^] 1.04 1.59 0 
[EuD03A_Aza'] 0.57 2.02 1.2 
[EuD03A_Aza^] 0.58 1.8 1 
[EuPh3_Aza'] 0.54 1.73 1 
[EuPh3_Aza^] 0.60 1.86 1 
[TbL^] 2.24 2.65 0 
[TbL^] 1.56 1.72 0 
[TbL^] 2.00 2.38 0 
[TbL^] 2.25 2.48 0 
[TbL^] 1.56 1.72 0 
[TbD03A_Aza'] 1.82 2.73 0.60 
[TbPh3_Aza'] 1.65 2.89 1 
Table 2.3: Lifetimes and q values (+/-10 %) for complexes [ E U L ' J - [LnL'j 
The respective q values for complexes containing the pyridyl-azaxanthone show that 
the sensitising moiety binds in a bidentate fashion, through each pyridyl nitrogen atom. 
As a consequence, there are no directly bound water molecules, resulting in the long 
emissive lifetimes. For terbium pyrazoyl-azaxanthone complexes, q values of 0 are again 
consistent with bidentate binding in aqueous media. For complex [EuL^l a q value of 
0.72 is consistent with pyridyl dissociation, leading to hydration of the lanthanide metal. 
2.4.6 L u m i n e s c e n c e Q u a n t u m Yields 
Overall emission quantum yields, (Dcm (Equation 2.3), where (DT is the quantum yield of 
formation of the triplet state, TIET is the efficiency of the energy transfer process, is the 
natural radiative constant of the complex and tobs is the observed luminescence lifetime 
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of the lanthanide ion, (i.e. inverse of the radiative decay constant), were measured in 
water. 
^em = ^jTlET^oTobs (2.3) 
Measurements for complexes [ E U L ' ) , [TbL^], (EuL^), [TbL^] and ITbL**] were made 
using an established integrated sphere method.^ "* The remaining complexes have 
previously been determined relative to two standards: p-cresyl violet (in methanol) and 
rhodamine (in ethanol). Measurements were performed using an excitation wavelength 
corresponding to the lowest energy maximum in the absorption / excitation spectrum. 
These values are 365 nm for pyridyl-azaxanthone complexes, 355 nm for pyrazoyl-
azaxanthone complexes and 348 nm for tetratriphenylene derivatives. 
Complex 0H20 
[EuL'] 375 15 
[EuL^] 348 18 
[EuL^*] 375 25 
[EuL^] 348 1 6 
[EuD03A_Aza'] 336 7 
[EuD03A_Aza^] 336 8 
[EuPh3_Aza'] 336 8 
[EuPh3_Aza^] 336 9 
[TbL^] 355 15 
[TbL^] 348 33 
[TbL^] 355 4 6 
[TbL^] 355 54 
[TbL^] 348 4 0 
[TbD03A_Aza'] 336 2 4 
[TbD03A_Aza^] 336 25 
[TbPh3_Aza'] 336 37 
[TbPh3_Aza^] 336 28 
Table 2.4: Emissive quantum yields (+/- 10 %) for complexes | E U L ' ] - [LnL"'] 
65 
Chopfer Two: Synthesis & Photophysical Characterisation 
The high quantimi yields exhibited by complexes incorporating the dpqC 
chromophore are associated with a high quantum yield of formation of the triplet state 
and an efficient energy transfer step. For the analogous europium complexes, containing 
the pyridyl-azaxanthone, quantum yields are similar i f not higher. For the D03A complex 
[ E U L ' I , emission is comparable; while in the cationic complex [EuL'*) a higher 
efficiency is observed using a longer wavelength of excitation. 
The pyrazoyl-azaxanthone chromophore is shown to exhibit strong terbium emission 
at pH 6.5 with quantum yields of 46 and 54 % for [TbL^) and [TbL^] respectively. 
2.5 C o n c l u s i o n s 
The pyridyl- and pyrazoyl-azaxanthones allow long wavelengths of excitation and ligate 
to the lanthanide metal in a bidenate manner. For the pyrazoyl-azaxanthone systems, this 
binding has been shown to be sensitive to both pH and the presence of biological anions 
in aqueous solution. The pyridyl nitrogen atom possesses a pKa of 6.5, and nitrogen 
dissociation leads to a dramatic decrease in lanthanide emission and subsequent increase 
in ligand fluorescence. Addition of endogenous bioactive anions to the analogous 
pyridyl-azaxanthone system results in a change in spectral form, with the formation of an 
intense AJ = 2 band, and the simplification of the AJ = 4 manifold. 
Exclusion of directiy bound water molecules in their respective complexes gives rise 
to long emissive lifetimes and high quantum yields. The pyridyl-azaxanthone only allows 
efficient europium sensitisation, while the pyrazoyl-azaxanthone systems give rise to 
emissive terbium complexes in aqueous medium. The impressive quantum yields of 
complexes [EuL'*] (25 %) and [TbL^] (46 %) highlight these as suitable candidates with 
which to develop complexes suitable for conjugation (Chapter 7). 
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Chapter Three: Dynamic Quenching Studies 
Consideration o f the mechanistic pathway that leads to sensitised lanthanide emission 
reveals three major processes for lanthanide excited state deactivation.' 
lanthanide 
ligand fluorescence luminescence 
A 
h v 
s e n s — Ln 
energy 
kem rransfer "^e"* 
hv •^'SC k E T 
s e n s — L n ^sens—Ln • •" 'sens—Ln ^ s e n s — L n * 
hv" 
K b e t 
k q [ 0 2 ] k q - I X H ] 
absorption 
keT ,/ K : o : 
Figure 3.1: Photophysicalprocesses during sensitised emission 
The lanthanide excited state is prone to deactivation by vibrational energy transfer, 
involving energy matched X - H oscillators.^ O f particular significance is the close 
proximity o f O - H (water) and N - H (amine) groups. Quenching by energy transfer to 
an energy-matched acceptor group may also occur. Finally, lanthanide excited state 
deactivation may occur via electron or charge transfer processes. The fol lowing chapter 
describes a detailed study o f dynamic quenching o f macrocyclic complexes [ E U L ' ] -
[LnL^] . 
The terbium and europium ^ D q excited states lie 244 and 206 kJ mol"' above the 
ground state, and possess a natural lifetime o f the order o f milliseconds. As a result, this 
free energy may be harnessed to drive deactivation processes via an electron transfer 
process involving electron-rich species.^ 
The feasibility o f such a quenching process can be assessed using the Rehm-Weller 
equation:'' 
n G E T = nF {{E^, - Er,d) - E^"* - / er] J moV' ( 3 . 1 ) 
where: Eqx is the oxidation potential o f the electron donor (the quencher) 
£red is the reduction potential o f the complex 
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is the energy o f the lanthanide excited state (2.52 and 2.13 eV for Tb / Eu) 
/ r,r is a Coulombic attraction correction term correcting for formation o f the 
transient charge-separated species and is usually < 0.2 eV 
3.1 C y c l i c Vol tammetry 
When considering the quenching mechanism involving electron transfer f rom a donor to 
a lanthanide complex, it is likely that charge or electron density w i l l reside on the 
heterocyclic ligand rather than the lanthanide ion. In the l imit , an electron-rich species 
may be f i i l l y oxidised and the metal complex, reduced. It is therefore important to 
consider the susceptibility o f the pyridyl- , pyrazoyl-azaxanthones and dpqC 
chromophores to accept electron density. The one-electron reduction potentials o f 
pyridyl-azaxanthone, 8, and pyrazoyl-azaxanthone, 11, were measured by cyclic 
voltammetry. Measurements were performed in acetonitrile, containing 0.1 M 
«Bu4NC104 as a supporting electrolyte and ferrocene / ferrocinium as an intemal 
standard. The voltammograms for both the pyridyl and pyrazoyl-azaxanthone (Figure 
3.2) chromophores are consistent with reversible reduction processes, occurring at Ep = -
1.78 V and - 1.92 V vs. Fc^ / Fc respectively. 
Ferrocinium Oxidation 
Pyrazoyl-azaxanthone Oxidation 
< 
i— 3 
o 
0-015 
0.005 
0.005 
Ferroanium Reduction 
0.015 
Pyrazoyl-azaxanthone Reduction -0.025 
Potential (V) 
Figure 3.2: Cyclic voltammogram of pyrazoyl-azaxanthone, I I , at 298 K in MeCN. 
Scan rate of 50 mV/s. 
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Chromophore Ered VS FC"" / FC Ered VS NHE 
2-Methyl-1 -azaxanthone -2.00 V ~ - 1.60 V 
7-tert-Buty 1-2-methy 1-1 -azaxanthone - 2.02 V ~ - 1.62 V 
7-tert-Butyl-2-methylpyridyl-1 -azaxanthone -1.78 V ~ - 1.38 V 
7-tert-Butyl-2-methylpyrazoyI-1 -azaxanthone - 1.92 V ~ - 1.52 V 
dpqC n/d ~ - 1.07 V 
Table 3.1: Ered potentials for derivatised azaxanthone chromophores 
The reduction potential o f the pyrazoyl-azaxanthone does not show significant 
difference from the parent azaxanthone moieties (i.e. Ered — 1.60 V vi- ~ - 1.52 V for 
NHE). The lower reduction potential for the pyridyl-azaxanthone suggests complexes 
incorporating this sensitiser may be slightly more susceptible to quenching by electron 
rich species. 
It is important to emphasise that values for the reduction potential o f the 
chromophores were measured in the ground state. In reality, the chromophore may accept 
an electron in the excited state o f the complex. In addition, the reduction potential for 
Eu "^" (-1.1 eV) is lower than that o f the azaxanthone chromophores, suggesting that the 
lanthanide may be preferentially reduced. Therefore measurements o f complex reduction 
potential are important to help clarify the actual electron transfer process. 
3.2 Stern-Volmer Constants 
A key issue in assessing the potential intracellular application of luminescent complexes 
is their sensitivity towards quenching by endogeneous electron-rich species, either when 
free or protein bound (covalent or non-covalent). Studies have shown that it may be the 
extent to which the complexes are quenched in cellulo that limits their ability to be 
observed by fluorescence microscopy,' as much as any preferential cellular uptake 
profile. For this reason, understanding and minimising intracellular quenching is 
extremely important in the development o f emissive probes for biological media. 
The anti-oxidants in the highest concentration within common cell types are ascorbate 
and urate. Each is typically found in the range of 0.1 to 0.2 m M concentration within 
most eukaryotic cells.' Consequently, the quenching o f complexes [ E U L ' J - [LnL^], by 
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urate, ascorbate and the highly polarisable anion iodide, was studied. Stem-Volmer 
analysis was undertaken, where the Stem-Volmer quenching constant (1/Ksv in m M ) 
represents the concentration o f quencher needed to reduce the observed lanthanide 
emission lifetime by 50 %. The Stem-Volmer equation is given below: 
To / T = 1 + k,To I Q l = 1 + ksvIQl ( 3 . 2 ) 
where the term tq is the excited state lifetime in the absence of added quencher Q. 
A l l measurements were made under standard conditions o f 10 complex at pH 7.4, 
with 0.1 M 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES) and 10 m M 
NaCl at 298 K. The range o f quencher concentration was selected carefully, in order for 
ideal Stem-Volmer behaviour to be observed (i.e. linear gradient). The ranges used were 
1.0 - 5.0 mM for iodide, 0.1 - 0.5 m M for ascorbate, and 1 0 - 5 0 \iM for urate. These 
ranges were necessary to avoid curvature (i.e. l imiting value), where the rate o f change of 
To / t versus concentration o f quencher becomes constant. 
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Figure 3 .3 : Selected lanthanide complexes ' 
[LnPh3_Aza] 1 = H 
2 = B^u 
3.2.1 Q u e n c h i n g Studies witli Iodide 
Addition o f potassium iodide to aqueous solutions o f complexes [ E U L ' ] to [LnL^] led to 
a reduction in the excited-state lifetimes. Linear Stem-Volmer plots were obtained by 
plotting the xo / x values as a function o f added iodide concentration. Calculated Stem-
Volmer quenching constants (k^v"' / m M ) are shown in Table 3 . 2 . 
' All cationic complexes are their respective chloride salts 
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Complex Terbium ATjv' / mM Europium K^J^ 1 mM 
[LnL'] 5.4 72 
[LnL-'] 2.10 >io-^ 
[LnL^] 13.8 
[LnL^] 0.92 27 
[LnD03A_Aza-] 53.5 125 
[LnPhiAza'] 9.2 278 
[LnPh^Aza-] 38.2 250 
Table 3.2: Stern - Volmer quenching constants for iodide 
(pH 7.4,0.1 M HEPES, 10 mM Nad 298 K) 
In examining these results, several conclusions can be drawn. Terbium complexes are 
much more sensitive to dynamic quenching than their europium analogues, coinciding 
with the greater 'free' energy o f the terbium excited state. For complexes with a 
common chromophore, the cationic triamide complexes were quenched to a greater 
extent than their neutral D 0 3 A comparators. This trend in sensitivity follows the 
favouring o f collisional encounters by electrostatic attraction. For a common set o f 
pendant cyclen arms, in which the nature o f chromophore is varied, the sensitivity 
mirrors the reduction potential o f the heterocylic moiety. This is shov^ in the series o f 
cationic complexes [TbPh3_Aza'l, [TbL^l and [TbL^l. 
Iodide quenches lanthanide complexes such as those shown in Figure 3.3, in a 
classical collisional encounter model, first proposed by Rehm and Weller.^-^ The 
mechanism, which is shown in Scheme 3.1, involves reversible formation o f an 
encounter complex, under diffusion control, is followed by electron transfer between the 
donor and the acceptor. 
k i . k2 
A + D 
hv 1/ro 
- (A D) -
encounter 
complex 
(A 
+ • 
D ) 
fast 
A + D A + D 
Scheme 3.1: Classical collisional quenching model 
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Quenching by this mechanistic pathway has been confirmed by performing quenching 
o f iodide at varying temperatures and ionic strengths o f NaCl. Studies showed that iodide 
quenching was highly dependent on each parameter. Such behaviour is consistent wi th a 
thermally activated collisional quenching model.^ 
3.2.2 Q u e n c h i n g Studies with A s c o r b a t e a n d Urate 
Stem-Volmer quenching constants for complexes | E U L ' 1 to [ L n L ^ I by urate and 
ascorbate are collated in Table 3.3. 
Tb Complex Urate K^' 1 mlM Ascorbate A^ v"' / mM 
[TbL'] 0.03 1.39 
[TbL-'] 0.005 0.35 
[TbL'] 0.05 0.36 
[TbL'] 0.025 0.18 
[TbD03A_Aza-] 0.012 0.57 
[TbPhjAza'] 0.04 0.37 
[TbPh3_Aza-] 0.02 0.30 
[EuL^] 0.45 8.43 
[EuL^] 0.11 2.92 
[ E U L ' ] 0.07 0.39 
[EuD03A_Aza^] 0.28 8.90 
[EuPh3_Aza'] 0.60 1.50 
[EuPh3_Aza-] 0.27 1.52 
Table 3.3: Stern - Volmer quenching constants for urate and ascorbate 
(pH 7.4, 0.1 M HEPES W mM NaCl, 298 K) 
As observed with iodide quenching, terbium complexes are quenched more strongly 
than their europium analogues. This behaviour is again consistent with a mechanism in 
which it is the excited state energy o f the lanthanide that drives the quenching process. 
Interestingly, the complexes possess a high sensitivity towards urate quenching compared 
to ascorbate. Such behaviour does not correlate with the greater one oxidation potential o f 
the latter (Eox = 0.30 eV* for ascorbate compared to E Q X = + 0.59 eV for urate). 
76 
Chap te r Three: Dynamic Quench /ng Studies 
9 H ? HOH2C HOH2C 
HN ' N - H \ - e - N- ^ O O - H ^ - e • ^ O q 
|| - I ij HO \ • HO 
' ^ ' ^ H H O O H G O 
Urate EQX = + 0 59 eV Ascorbate EQX = + 0.30 eV 
Sclieme 3.2: Half equations for urate (left) and ascorbate (right) 
The apparent absence o f correlation with Coulombic attraction indicates that urate and 
ascorbate quench by a mechanism where electrostatic encounter is not dominant. For 
example, urate is seen to quench the neutral D 0 3 A complexes more strongly than their 
respective cationic analogues. Furthermore, urate quenching behaviour does not fol low 
the typical one electron reduction potential o f the heterocylic chromophores, as observed 
with iodide. The most notable example is the reduced susceptibility o f the pyrazoyl-
azaxanthone complexes to quenching. 
Evaluation o f this behaviour, and the observation o f non-linearity in urate and 
ascorbate quenching (e.g. Figure 3.4), suggests that these anions do not fol low the classic 
Stem-Volmer model o f quenching. This is further supported by the behaviour o f urate 
quenching as a function o f temperature and ionic strength. ^ Given that a biomolecular 
association process is entropically unfavourable, higher temperatures should disfavour 
quenching, a trend which is the opposite o f that expected for a purely collisonally 
controlled mechanism, for which the classical Stem - Volmer approximation holds. 
A G = A H - T A S ( 3 . 3 ) 
As the temperature was increased, quenching by urate became less apparent. In the 
case of iodide, a small positive activation energy. Eg = + 1.5 kJ mol"' was estimated, 
whereas for ascorbate and urate (-6.0 and -3.6 kJ mol"' respectively) negative values 
were determined. The respective activation energies could then be calculated using 
Eyring's transition-state analysis. For urate and ascorbate, negative entropies o f 
activation were estimated (AS = - 260 J mol"' K ' ' ) in keeping with an associative process, 
rather than a collisional Stem - Volmer mechanism. 
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1 • 
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0.25 0.3 
Figure 3.4: Plot showing non-linear quenching behaviour q/[TbL^] in presence of urate 
One alternative quenching mechanism that has been postulated for planar aromatic 
donor-acceptor pairs, is the formation o f a relatively long-lived exciplex, rather than 
through formation o f radical ion pairs. 
A* + D ^ (A D) 
hi/ 
^ encounter ^ 
complex 
2 .5 - S + 
(A D ) 
A + D A + D 
Scheme 3.3: Exciplex Quenching Model 
h i this model, the term ^ s v should be considered as an equilibrium constant associated 
with the reversible exciplex formation, A^ ex = kikj/tiLi, provided that k.2» h. Under 
these conditions, the measured lifetime o f the lanthanide excited state, x, may vary wi th 
the quencher concentration in a non-linear manner.^ 
To = {\+hx^,,[Q]) 
— ( l + ^ e x [ Q J ) 
( 3 . 4 ) 
For Equation 3.4, plots o f t q / t v s [ Q ] have an initial slope different to the apparent 
Stem-Volmer constant, and may reach a l imit equal to 3^X0 at higher quencher 
concentrations. 
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By considering the structure of urate, it is possible to postulate how it may form 
exciplex complexes. Urate is a mono anion, with an electron rich 7t-system where the 
charge is delocalised onto the nitrogen and amide oxygens. It is plausible to suggest that 
exciplex formation may involve a 71 - t i interaction between the electron poor 
chromophore and urate. Such a mechanism would be disfavoured by increased steric 
hindrance o f the lanthanide complexes, thereby impeding the proximity o f the urate 
anion. Analysis o f the Stem-Volmer constants in Table 3.3 indicates that steric inhibition 
created by the local ligand environment may well be a more influential factor than 
Coulombic interactions, in minisimising urate quenching. 
This hypothesis perhaps helps to explain the reduced tendency o f the pyrazoyl-
azaxanthone complexes to quenching. In this respect, the tert-hnty\ substituent o f the 
azaxanthone moiety would be expected to provide some steric inhibition to the approach 
of a urate counter anion. 
3.3 Non C o v a l e n t Protein Associat ion a n d Inhibition of Q u e n c h i n g 
Examination o f complexes analogous to those in Figure 3.3, by either luminescence 
emission or gadolinium relaxivity titrations has highlighted the tendency o f such 
complexes to bind reversibly with proteins.^"" '^ It is envisaged that i f complexes exhibit 
an affini ty towards a given protein, then i f protein bound, they may exhibit a different 
sensitivity towards quenching. Serum albumins constitute the most common endogenous 
protein in mammalian cells. Therefore, the effect o f protein binding on the susceptibility 
of complexes towards dynamic quenching is extremely appropriate in defining complexes 
suitable for cellular applications. 
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Figure 3 .5 : Plot ofzo/r vs. [BSA] for [ThV] and [Th\J\ 
Addition o f bovine semm albumin to [EuL'*] and [TbL^] resulted in less than a 10 % 
decrease in the respective europium and terbium emission lifetimes over the 
concentration range o f 0.01 to 0.7 m M (Figure 3 . 5 ) . It can therefore be concluded that 
non-covalent protein association does not quench the lanthanide exited states o f 
complexes [EuL"*] or [TbL^].'^ However, the addition o f BSA was shown to cause a 
reduction in the overall emission intensity o f between 30 - 40 % for each complex. Such 
behaviour is consistent wi th a modest amount of quenching o f the chromophore excited 
state, presumably via a charge transfer interaction with the pyridyl- / pyrazoyl-
azaxanthones. 
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Figure 3.6: Plot ofzo/r vs. [Urate] for [Tbl/] with and without 0.4 mM BSA 
Interestingly, in the presence o f 0.4 m M bovine serum albumin, O.I m M urate and 0.2 
m M ascorbate, (pH 7.4, 298 K , O.I M HEPES), the emission Ufetime of [TbL'"'] was 
within 10 % o f its value in water, i.e. 2.1 ms, compared to 0.7 ms and 0.5 ms for [TbL^] 
and [TbPh3_Aza'] respectively, under the same conditions.'^ Complex [EuL'*] also 
exhibited similar behaviour (i.e. 1.00 ms in water, 0.89 ms in 0.4 m M BSA), thereby, 
demonstrating that non covalent protein association completely suppresses quenching o f 
complexes [EuL'*] and [TbL^] by endogeneous species (Figure 3 . 6 ) . This characteristic 
augurs well for their application as cellular probes, and their ability to be observed and 
monitored by luminescence microscopy. 
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Chapter Four: Circularly Polarised Luminescence (CPL) 
In the series of cationic triamide complexes (e.g. [EuL"*] - [LnL^]), the stereogenic 
centres at the carbon atoms are 5 to the cyclen ring nitrogen atoms. As a result, 
lanthanide ions form pairs of stereoisomeric complexes of these ligands in aqueous 
solution. Investigation of this chirality is most conveniently signalled by optical 
methods, involving either differential absorption of left- or right-handed circularly 
polarised light (CD), or differential emission (CPL). Circularly dichroism (CD) 
probes the differential absorption of the ground state o f the complex. However, the 
low molar absorption coefficients of lanthanide ions limit the utility o f this technique. 
In contrast, circularly polarised luminescence probes the excited state structure of the 
complex, measuring the differential emission of left and right circularly polarised 
light. Since excitation of the complex is indirect (i.e. sensitised excitation) this 
technique does not suffer from the same limitations as CD. 
CPL can provide a correlation between structural and electronic spectral 
information for lanthanide complexes in aqueous solution. Such data can give highly 
specific local information about the chiral environment of the lanthanide metal ion. 
Furthermore, changes in the circularly polarised luminescence from Eu (or Tb) 
excited states are sensitive to the nature (eg. A or A) and degree of local helicity, 
because this mixes the electric and magnetic dipole transition moments, enhancing the 
'allowedness' (intensity) of a given transition.' Thus, conformational changes may, in 
principle, be signalled by changes in the form and polarisation of the CPL." 
4.1 Complex Conformational Studies 
The lanthanide complexes of cyclen based systems may adopt a number of isomeric 
conformations. For example, upon complexation of 1,4,7,10-tetraazacyclododecane-
tetra-acetate (or DOTA), four stereoisomeric complexes are formed. These systems 
exhibit two elements of chirality, defined as the torsion angles about the macrocyclic 
ring N-C-C-N (which may be + 60° (5) or - 60° (k)) and about the pendant arm N-C-
C-O groups (which may be + 30° (A) or - 30° (A)). Consequently, two pairs of 
enantiomers exist, with a positive 8 or negative X torsion angle confirmation in the 
five-ring NLnN chelates, and a clockwise A or anticlockwise A layout of the four 
pendant arms (Figure 4.1).^ 
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Square Antiprism 
Rotation 
Ring 
nversion Ring 
Inversion 
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A(X>vA/v) 
Twisted Square 
Antiprism 
Figure 4.1: Four stereoisomers of Ln-DOTA complexes, showing ring inversion and 
pendant arm rotation " 
The stereoisomers can adopt one of two geometries: A(5555) and A{l.XkX) each 
adopt a square antiprismatic (SAP) geometry, with a twist angle of approximately 40° 
between the oxygen and nitrogen planes, while ACklXk) and A(5555) adopt a twisted 
square antiprismatic (TSAP) geometry, with a twist angle of approximately 29". In 
solution, the conformational mobility of the ligand allows intramolecular exchange 
between the A and A isomers. This may occur via ring inversion (5 / X, exchange) 
followed by independent reorientation of the ring pendant arms (A / A exchange), 
possibly via a tricapped trigonal prismatic intermediate. Such processes are often slow 
with respect to the timescale of NMR and luminescence emission, with the position of 
equilibrium between the two forms determined by their respective conformational free 
energies. 
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The introduction of a chromophore and more sterically demanding pendant arms 
onto cyclen can impart conformational rigidity. In sucii rigid, non-fluxional 
complexes, arm rotation becomes inhibited, and ring inversion slow, leading to 
preferential formation of one stereoisomer in solution. 
4.2 CPL Spectra 
The CPL spectra for ( 5 S ' S ) - [ E U L ' ] and (/JJ?/?)-[EuL^] (and analogous terbium 
complexes), as their chloride salts in D2O, revealed the expected mirror image 
behaviour (Figures 4.2 and 4.3). 
(SSSHEuLM 
( S S S H E u U ] 
20 640 660 68 
[RRR HEuL ' ] 
700 720 
Wavelength (nm) 
Figure 4.2: Mirror image CPL spectra for {SSS)-\-[EuV] (blue) and{RRR)-K-
[EuL^] (red) (295 K, D2O, 15^M) 
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{RRR)-[lhL 
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"""^'^^ 610 ' ^ f ^ Z 30 650 
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Figure 4.3: Mirror image CPL spectra for iSSS)-A-[TbV] (blue) and (RRR)-A-
[TbL^] (red) (295 K, D.O, ISfiM) 
The sign and sequence of the transitions observed in the CPL of (5',S'5)-[EuL^] 
(and (.S5'5)-[TbL^]) are consistent to those observed for the related C4-symmetric 
tetraamide (555>S)-|EuPh4(H20)| complex shown below: 
The parent tetraamide (5'5'5'5>|EuPh4(H20)| has been shown to exist as one 
predominant isomer (> 90 %) in aqueous solution. The preferred isomer, whose 
absolute configuration has been verified by X-ray crystallography, is a regular mono-
capped square antiprismatic structure. It can be concluded that for the series [EuL^I 
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and [TbL^], a similar square antiprismatic structure is adopted, whereby tiie (SSS)-
[LnL^] complex possesses a A helicity and the {RRR)-\Lnl7] complex a A helicity. 
In contrast, examination of the CPL spectra for complexes (Si'^^-ITbL^I and 
(/f/f/fVfTbL"! reveals quite different behaviour to [LnL'^] (Figure 4.4). This 
opposing helicity around the lanthanide metal is most probably attributed to the 
stericaily demanding chromophore, which appears to impose a twisted square 
antiprismatic geometry on the complexes. Consequently, (S55)-[TbL^l can be 
assigned a A helicity, while (/f/f/f)-[TbL^| possesses a A helicity. 
1.4 
0.9 
0.4 
-0.1 
470 490 
-0.6 
-1.1 
-1.6 
(SSSHTbL^ 
{RRR HTbL^' 
(SSS)-ITbL'] 
570 590 610 630 650 
Wavelength (nm) 
Figure 4.4: Mirror image CPL spectra for {SSS)-A-[ThL^\ (blue) and (RRR)-\-
[Tbl/] (red) (295 K, DyO, 15^M) 
4.3 Emission Dissymmetry Factors 
In circularly polarised luminescence, the emission dissymmetry factor, gem, measures 
the 'degree of chirality' sensed by an electronic transition. Dissymmetry factors are 
described by Equation 4.1: 
gem = 2 ( I L - IR) / ( I I + I R ) ( 4 . 1 ) 
where I l (R ) is the intensity of the left (or right) circularly polarised luminescence 
component. 
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The largest dissymmetry factors are exhibited by transitions which are magnetic-
dipole allowed and electric-dipole forbidden, whereas the most intense CPL 
transitions tend to be both magnetic and electric dipole allowed.^ 
Emission dissymmetry factors were determined for complexes (S55)-[EuL'*l, 
(5'5'5)-[TbL'] and ( i ' ^ ^ - I L n L ' l (Table 4.1). 
g\„ 1 X (nm) 
Complex AJ = 1 (X) AJ = 2 (k) AJ = 4 (k) 
(5555)-[EuPh4(H20)] - 0.09 (594) + 0.08 (614) - 0 . 1 0 ( 6 8 8 ) 
(555)- [EUL' ] - 0 . 1 4 ( 5 9 6 ) + 0.03 (615) - 0.003 (688) 
(555)- [EUL' ] - 0 . 1 6 ( 5 9 5 ) - 0 . 0 4 (614) - 0.08 (686) 
/k(nm) 
Complex AJ = 6 (k) AJ = 5 (k) A J = 4 (k) 
(555S)-[TbPh4(H20)] n/d + 0 .12 (545) n/d 
(555^-[TbL'] + 0.02 (489) - 0 . 1 3 (540) + 0.01 (583) 
(555}-[TbL'] - 0 . 0 3 (492) + 0 .15 (544) - 0.05 (589) 
Table 4.1: Emission dissymmetry factors for Tb and Eu complexes ^ 
The magnitude of the observed emission dissymmetry factors for each complex is 
similar to (5'5'5'S)-|EuPh4(H20)|, suggesting a similar degree of helical twist about the 
principal axis. The solution structures of each of the (5'5'5)-(EuL'*l and (5'5iS)-(LnL'| 
enantiopure complexes possess a A-configuration, in a regular mono-capped square 
antiprismatic structure. In contrast, the (555)-[TbL'l pyrazoyl-azaxanthone is shown 
to have a different helicity around the metal centre, with the complex preferring a A 
configuration. Similar behaviour has been shown in nonadentate dpqC complexes, 
with (•S}-phenylaIanine pendant arms.^ Here, the {SSS) enantiopure complex was 
shown to possess a unique distorted structure, with an amide carbonyl oxygen 
occupying the capping apical site of the monocapped aquare-antiprismatic polyhedron. 
Thus, it can be concluded that the pyrazoyl-azaxanthone complex (5'55)-[TbL"''| 
favours an alternative (and possibly distorted) geometry, compared to analogous 
pyridyl-azaxanthone and dpqC complexes. 
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4.4. Protein Association 
Circularly polarised luminescence has previously been utilised to characterise 
reversible anion binding to lanthanide complexes." In seeking to develop enantiopure 
emissive probes for cellular applications, it was necessary to study complexes [EuL'*] 
to [LnL^I in a biological context. Non-covalent protein associations with complexes 
lEuL"*! and [TbL^j, (Chapter 3) can reduce their susceptibility towards charge or 
electron transfer quenching.'* '^  Consequently, circularly polarised emission spectra 
were measured for each complex in the presence of human (or bovine) serum albumin. 
With (S'5'5)-|EuL''j, no change in emission polarisation or spectral form was 
observed, over a protein concentration range of 0.03 - 0.3 mM (Figure 4.5). 
0.4 
0.3 
0.2 
0.1 
-0.1 
( S S S H E u n 
;SS)-[EuL'*] + B 
5^0 580 700 720 
-0.2 
Wavelength (nm) 
Figure 4.5: CPL spectra for {SSS)-{E\iV\, (295 K, D2O, 15 fiM) in the presence and 
absence of JO equivalents ofBSA (blue = without; red = with BSA) 
For complexes (5'5'^-A-(TbL'*] and (*/?/?)-A-lTbL^], addition of protein was 
accompanied by a large change in the -> '^ Fs band, centred at 545 nm (Figure 4.6). 
In the absence of protein, a dominant single peak is observed, which becomes more 
structured upon protein addition. 
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(SSSHTbL^l + BSA 
$$0 570 590 610 630 650 
3 * 
(SSS)-[TbL^ 
Wavelength (nm) 
Figure 4.6: CPL spectra for {SSS)-[ThL% (295 K, D.O. 15 ^ M) in the presence and 
absence of 10 equivalents of BSA (blue = without; red = with BSA) 
The most interesting behaviour was observed with the tetraazatriphenylene 
complexes [LnL^]. The circular polarised luminescence spectra of (5'5'5)-A-[TbL^| 
and (/f/fif)-A-[TbL^] in the presence of 30 BSA are shown in Figures 4.7 and 4.8. 
6 
5 
4 
3 
^ 2 
1 
(SSS)-[TbL'] 
o 
N N 
Th N 
470 A 
-2 ^ 
-3 
-4 
530 
(SSS)-[TbLV BSA 
(SSS)-rTbJ] 
590 V 620 650 
Wavelength (nm) 
Figure 4.7: CPL spectra for {SSS)-[T\AJ]; (295 K, DiO, 15^M) in the presence and 
absence of 10 equivalents of BSA (blue = without; red = with BSA) 
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{RRR)-\JbL'] 
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Figure 4.8: CPL spectra for iRRR)-[TbV]; (295 K, D2O, 15 fiM) in the presence and 
absence of 10 equivalents of BSA (blue = without; red = with BSA) 
With the A isomer (Figure 4.8), addition of protein gave no change in emission 
polarisation or spectral form. Only an apparent reduction in signal intensity was 
evident, consistent with dynamic quenching of the terbium excited state by the protein. 
In contrast to the A isomer, the A isomer gave rise to very different behaviour (Figure 
4.7). An inversion of the sign o f the emission polarisation was observed, which was 
most well-defined in the magnetic dipole-allowed -> F^s transition around 545 nm. 
This behaviour is consistent with an inversion of the helicity of the complex in the 
protein bound form, for the A isomer only.'" This unique behaviour was not shown by 
structurally-related tetraazatriphenylene analogues, suggesting that the steric 
environment created by the cyclen pendant arms, in addition to the chromophore, 
plays a pivotal role in determining this complex - protein interaction. 
Parallel experiments were performed with (5'5'5)-A-[EuL^| and (^/?/f)-A-[EuL'']. 
Again, protein addition led to a reduction in the overall emission intensity for each 
complex, with no change in CPL spectral form for the A isomer. The A isomer 
showed complementary behaviour to the terbium analogue, with dramatic changes in 
sign and form of the CPL spectrum (Figure 4.9). This behaviour suggests that upon 
protein association, complexes (5'5'5)-A-[TbL^l and (iSiSS^-A-IEuL^] undergo both 
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helicity inversion and changes in the relative orientation of ligand donors around the 
metal centre. 10,11 
(SSSHEuL^l 
560 580 
(SSS)-[EULM 
620 640 660 680\f 700 720 
( S S S H E u L ' l + BSA 
Wavelength (nm) 
Figure 4.9: CPL spectra for (SSS)-[EUL'\ (above) and iRRR)-[Euf] (below); (295 K, 
D2O, 15 f.iM) in the presence and absence of 10 equivalents of BSA 
(blue = without; red = with BSA) 
_K -0.5 
( R R R H E U L V B S A 
{RRR)-[EuC] 
{RRRHEuC] 
Wavelength (nm) 
The different enantiomeric behaviour of complexes (SSS^-lLnL^] and {RRR)-
[LnL^] was mirrored in the reduction of both the intensity and lifetime of the 
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respective complexes after incremental addition of BSA. For (5'5'5)-A-|TbL'] a 
binding isotherm was interpreted in terms of an apparent 1 : 1 binding constant (log K 
= 5.1, 298 K, pH 7.4, HEPES 0.1 M), while (^/?/f)-A-[TbL^| gave different 
behaviour, consistent with stepwise formation of various adducts of lower affinity 
(Figure 4.10). As discussed previously, addition of BSA or HSA to (55S)-|EuL^] or 
(iS'5'5)-|TbL^| is not accompanied by any significant changes in emission lifetimes 
(Figure 4.10). 
o 
1.8 
1.7 
1.6 
1.5 
1.4 
13 
1.2 
1.1 
0.9 
(/?M)-[rbL'] 
• • 
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(5.S'.S)-[TbL^] 
(^.^v.Sl-ITbL'] 
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Figure 4.10: Quenching of the observed terbium emission lifetime, r, (TQ- no added 
protein) as a function of added BSA for (SSS)-\Thlf\ (red), {SSS)-\Tb\J\ (blue) and 
{RRRyyihlJ] (pink) (298 K, pH 7.4, W mMNaCl, 0.1 MHEPES, 30 juM[complex]) 
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4.5 HSA Binding Studies 
i-t 
Drug Site I 
Drug Site II 
Figure 4.11: Summary of the ligand binding capacity of HSA as defined by 
crystallographic studies.^' 
Serum albumin contains two well defined drug binding sites, referred to as drug site 1 
and II respectively.'^ Warfarin {Ki 4 )j.M) is understood to probe drug site 1. while 
A'^ -dansylsarcosine {Kd 6 \iM) is known to selectively bind drug site I I . I t was 
thought that these two compounds could be used as competitive probes to distinguish 
whether complexes (^S'S^-ILnL^] have a preferential binding association with HSA. 
Crystallographic studies of complexes of HSA have suggested that 'drug site IF is the 
more stereo-diiTerentiating binding site in serum albumin.'^ 
An appropriate method for measuring protein binding is by examining changes in 
proton relaxivity of gadolinium complexes in aqueous solution. The proton relaxivity 
r,p, of (5'5'5)-A-[GdL^] and {RRR)-A-\GA\7\ is 3.1 mM' ' s'' (60 MHz, 310 K), and 
increased to 13 mM"' s"' in each case, in the presence of 0.4 mM human serum 
albumin. Incremental addition of warfarin (up to 3 mM) to solutions of {SSS)-A-
[GdL''] and {RRR)-\-{GAl?\ containing protein caused less than a 10 % change in 
the observed relaxivity. 
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(RRR)-[GdL'] 
• • • • 
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In 6 -1 • 
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2 (SSS)-[GdLT 
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1 2 3 
[Dansyl sarcosine] (mM) 
Figure 4.12: Variation of proton relaxivity (310 K, 60 MHz, 0.4 mM HSA, 1.7 mM 
[GdL^J as a function of added N-dansylsacrosine for (SSS)-[GdL'] (blue diamonds) 
and {RRR)-\GdV] (redsquares) 
However, addition of A^-dansylsacrosine over the same concentration range, 
resulted in a reduction of the rip of (55'5)-A-|GdL'] to its original unbound value (3.1 
mM"' s"'). In contrast, addition of TV-dansylsarcosine to the (RRR)-A-\GdL'\ protein 
solution led to less than a 15 % reduction in rip (Figure 4.12). This set of experimental 
data is consistent with the selective reversible binding of (5'5'5)-A-[LnL^] complexes 
to 'drug site IF of serum albumin.'" During this process, the complex structure is 
altered and helicity reversed to enable efficient binding. This conclusion supports 
previous evidence suggesting 'drug site II' is the most stereo-differentiating binding 
site.'^ Future microscopic techniques may allow these complexes to be utilised for 
tracking protein association in vitro and in living cells, via circularly polarised 
luminescence measurements. 
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Chapter Five: Cellular Studies 
In the rational development o f lanthanide complexes as cellular probes, it is important to 
understand their mechanisms of cell entry. In addition, a link must be established 
between the structure o f the complex and its compartmentalisation profile, cytotoxicity 
and any observed intracellular trafficking. The fol lowing chapter describes aspects o f the 
biological analysis o f complexes [EuL'*] and [TbL'''] as potential cellular probes. 
5.1 Cel lular Cytotoxicity Profiles 
The relative cytotoxicity o f complexes was assessed in mouse skin fibroblast (NIH-3T3) 
cells using an established M T T assay.' This spectroscopic technique relies on the 
conversion o f 3-(4,5-dimethylthiazol-3-yI)-2,5-diphenyltetrazolium bromide to a purple 
'formazan' product by mitochondrial dehydrogenase enzymes within viable cells. 
Mitochmdrial Reductase 
Scheme 5.1: Formation of purple formazan' used in MTT assays 
Following a 24 h incubation o f at least 10,000 cells with varying concentrations o f 
complex, the insoluble 'formazan' was dissolved in DMSO and quantified 
spectrophotometrically in a 96-weIl plate reader to yield an IC50 value. This IC50 value 
was defined as the complex concentration required to reduce the absorbance to 50 % of 
that in the untreated control. The procedures were repeated at least three times for each 
complex, and averaged to provide the respective IC50 values. 
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N N 
N N 
Complex ICso/fiM 
[TbPh3_Aza'] >200 
[TbPh3_Aza^] 77(8) 
[EuPh3_A2a''] 102(15) 
[EuL'] 73 (9) 
[TbL^] 41 (9) 
[TbL'] 130(27) 
[ E U L ' ] 108(19) 
HN Q 
NH 
[LnPh3_Aza] 1 = H 
2 = COjMe 
3 = fBu 
Table 5.1: IC^o values for a range oftriamide cationic lanthanide complexes ' 
Examination o f the IC50 values in Table 5.1 shows complexes possessing a /er/-butyl 
substituent exhibit the highest degree o f toxicity. For example, complexes [EuL"*], 
[TbL^] and [EuPh3_A2a"'] show higher IC50 values than analogous unsubstituted 
azaxanthone and tetraazatriphenylene complexes. 
Flow cytometry experiments with the complexes |EuL'*] and [TbL^) were performed 
to help distinguish the mechanism by which these complexes impose cell death (i.e. 
necrosis or apoptosis).^ Apoptosis is a form of programmed cell death, triggered by a 
series o f biochemical events. This mechanism is signalled by an increase in surface 
phospho-serine residues which lead to changes in cell morphology and eventual cell 
death. In contrast, necrosis is a form o f traumatic cell death characterised by loss o f outer 
and nuclear membrane integrity, resulting from acute cellular injury.' ' 
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Each complex was studied in Chinese hamster ovarian (CHO) and NIH-3T3 cells. 
Results were compared to an untreated control and to controls for necrosis (0 °C, 70 % 
EtOH, 3 h) and apoptosis (1 | iM staurosporine, 3 h). Interestingly, despite possessing 
similar structures, in which only the 'linkage' heterocyclic ring has changed, complexes 
[EuL*] and [TbL^l showed different behaviour (Figure 5.1). 
1 0 ' - | " ! : 
1 0 " - ^ ' 
10" 1 0 ' 102 103 
Annex in V FfTC L o g 
101 1 0 ! 
Annex in V F f T C L o g 
101 102 103 
Annex in V F I T C L o g 
Figure 5.1: Left: Flow cytometry plot of cells, 24 h after incubation with [TbL^] (200 
|iM); right: plot of cells after 24 h incubation with [TbPh3_A2a^] (200 pM); middle: plot 
of cells after 24 h incubation with [EuL'*] (200 pM). (In each case flow cytometry 'dot 
images' correlate fluorescence of an Annexin-FITC conjugate (apoptosis marker) on the 
X-axis, with propidium iodide fluorescence (necrosis marker) on the y-axis; apoptosis is 
then revealed in the north east quadrant and necrosis in the north west). 
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The complex [TbPh3_Aza^] clearly exhibits apoptosis, while the analogous pyrazoyl-
azaxanthone complex, [TbL"''], showed necrosis. In contrast, the 'dot plot' for [EuL'*] was 
inconsistent, with no distinct correlation to suggest necrosis or apoptosis. These results 
indicate that the manner in which the azaxanthone moiety is attached to the cyclen 
macrocycle (i.e. CH? or pyridyl / pyrazoyl heterocycles) plays an important role in 
determining how these complexes interact within a cell. In addition, this behaviour 
indicates that the inclusion of the terl-huty\ group does not in itself give rise to cell death 
by a consistent mechanism. 
5.2 Luminescence Microscopy Studies 
Preliminary cell uptake studies with over sixty emissive europium and terbium 
complexes have been performed within the Parker group. Results have shown that uptake 
and compartmentalisation profiles are dependent upon the nature and mode of linkage of 
the heterocyclic sensitising moiety, rather than complex charge or lipophilicity.'^ ""^" '^^  
Three main classes of behaviour have been observed to date. The majority of 
complexes examined ( - 80 %) are taken up relatively quickly and exhibit an endosomal -
lysosomal profile.* A second class of complexes localise in protein dense organelles, such 
as ribosomes and nucleoli. These complexes tend to differ from the latter, by showing 
relatively slow uptake and egress behaviour.^ "^ The final class of complexes reveal very 
fast uptake and slow egress, showing intracellular shuttling between mitochondria and the 
endosomal / lysosomal compartments. This time dependent behaviour has been 
confirmed by co-staining with Mitotracker Green^"^ and Lysotracker GreeV^.^ 
The cellular uptake and localisation profiles of complexes [EuL'*] and [TbL^j were 
examined in Chinese hamster ovarian and mouse skin fibroblast cells using fluorescence 
microscopy. Cultured cells were exposed to a growth medium with complex 
concentrations varying from 10 to 100 \xM. The living cells were then examined by 
fluorescence microscopy at time intervals in the range of 20 min to 24 h. Following 
excitation of the chromophore and by using appropriate filter sets, europium fEuL"*! and 
terbium [TbL"'^ ] emission was readily detected. Optical sections throughout the cells were 
taken to ensure the complex was internalised rather than simply associated with the cell 
membrane. 
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For [EuL'*], within 20 minutes of incubation of a 50 ^iM solution, complex was 
observed that was consistent with mitochondrial localisation. Co-localisation studies at 2 
h incubation with Mitotracker Green '^^  confirmed this compartmentalisation, with 
merged images showing good correspondence (Figure 5.2). 
Figure 5.2: Fluorescence microscopy images for [EuL'*] (50 juM complex, 2 h incubation) 
showing a mitochondrial localisation profile as revealed by co-localisation experiments 
with Mitotracker Green™: upper: [EuL'*], middle: Mitotracker Green™, 
lower: merged image (scale bar 20 microns) 
103 
Chapter Five: Cellular Studies 
At longer incubation periods (> 4 h), merged images between the complex and 
Mitotracker Green "^^  started to show inconsistencies (Figure 5.3). 
Figure 5.3: Fluorescence microscopy images for [EuL**] (50 /uM complex, 4 h incubation) 
showing a partial mitochondrial localisation profile as revealed by co-localisation 
experiments with Mitotracker Green™: left: [EuL'*], middle: Mitotracker Green™, 
right: merged image (scale bar 20 microns) 
In prolonging the incubation period to > 12 h, the complex appeared to migrate from the 
mitochondria to perinuclear endosomes and lysosomes. This hypothesis was confirmed 
by co-staining with commercially available Lysotracker Green™ (Figure 5.4). It has 
been hypothesised that the rate of intracellular trafficking of these complexes to recycling 
vesicles may be associated with their ability to bind reversibly to a given carrier protein. 
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Figure 5.4: Fluorescence microscopy images for [EuL"*] (50 fzM complex, 24 h 
incubation) showing a lysosomal localisation profile as revealed by co-localisation 
experiments with Lysotracjer Green™: left: [EuL*], middle: Lysotracker Green™, 
right: merged image (scale bar 20 microns) 
Like [EuL''], complex [TbL^] exhibited time-dependent intracellular trafficking 
between mitochondrial and endosomal / lysosomal compartments. No change in the 
localisation behaviour was observed upon changing the chirality of the cyclen pendant 
arms (i.e. (^iy?)-[TbL^]). This suggests intracellular shuttling occurs via a process in 
which chirality of the complex is not pivotal. 
No differentiation in cell localisation could be distinguished between complexes 
[TbL^] and [TbL^] (Figure 5.5). These complexes differ only in the strucUire of the 
pendant arms, therefore the behaviour of these complexes suggests that the pendant arm 
structure does not play a significant role in either localisation profile or intracellular 
shuttling processes. Similar conclusions have been independently reached by examining 
six sets of Eu / Tb complexes with a common dpqC sensitising moiety.'° Taken together, 
these observations support the theory that it is the constitution of the sensitising moiety 
that influences the complexes uptake and trafficking behaviour. These condensed 
aromatic groups are most likely to be recognised in protein association, which 
presumably must be a key recognition process in the intracellular trafficking that may 
involve recycling vesicles. 
105 
Ctiapter Five: Cellular Studies 
(SSS)-[TbL^ 
(RR/?)-[TbL^ 
Figure 5.5: Fluorescence microscopy images for (SSS)-[Thl/] and {RRR)-[TbL^\ 
(50 juM complex, 24 h incubation) showing similar localisation profiles 
5.3 Cellular Uptake Mechanism 
Complexes [EuL'*] and [TbL^j have been used in recent research to address the 
mechanism of complex cellular uptake." Using microscope image intensity and ICP-MS 
analysis, an array of established inhibitors and promoters has been examined, to observe 
their effect on intracellular uptake. Suppressed uptake was seen at 4 °C, consistent with 
an energy dependent process (i.e. endocytosis),'^ while effects of inhibitors and 
promoters were consistent with an uptake mechanism of macropinocytosis. This was 
confirmed by suppressed uptake using both wortmannin (blocking PI-3 kinase)'^ and 
amiloride (blocking the Na"^  / H"^  pump).''* 
Macropinocytosis involves the formation of endocytotic vesicles generated by the 
invagination of the plasma membrane. This mode of cell uptake is attractive, as 
macropinosomes are regarded as leakier vesicles than other endosomes.'^  Therefore, the 
lanthanide complexes can escape from encapsulation more readily than from other 
components, and hence be transferred to other organelles. 
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Figure 5.6: Endocytotic cellular uptake mechanisms 
5.4 Conclusions 
The cellular localisation studies of complexes [EuL'*] and [TbL^] highlights the need for 
flirther investigation into potential cellular applications. The pH sensitivity (Chapter 2, 
section 2.4.3) and time-dependent localisation of [TbL^] may allow the real time 
monitoring of pH change within ageing lysosomes. A change in pH could be followed 
ratiometrically using the terbium AJ = 5 band and residual ligand fluorescence, with pH 
estimated using a calibration curve. 
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The high luminescent quantum yields, long emissive lifetimes and cellular profiles 
associated with complexes [EuL"*], [TbL'''] and [LnL^] augur well for their application as 
biological emissive probes. In addition, the tendency for the collisional quenching of 
[EuL'*] and [TbL'' |^ to be completely inhibited by the presence of serum albumin at 
concentrations typically found in cells (0.2 - 0.7 mM). becomes vitally important in 
identifying and selecting complexes to be developed for potenfial cellular probes or 
HTRF bio-assays components. 
In order for complexes to be applicable in HTRF (homogeneous time resolved 
fluorescence), it is imperative that they possess a point of potential conjugation, through 
which the complex can be linked to an appropriate 'tag' or 'acceptor'. Research has 
previously been undertaken in which a sensitising azaxanthone chromophore has been 
functionalised to an activated NHS ester to allow conjugation (Figure 6.1).' 
HN ^ 
N 
H O 
NH ° N 
Figure 6.1: Complex [LnPh3_AzaNHS], containing an azaxanthone activated NHS ester 
The introduction of different substituents at the azaxanthone 7 position was shown to 
strongly influence the intracellular uptake and distribution profile of the respective 
complexes.^ This route was deemed inappropriate for the pyridyl- and pyrazoyl-
azaxanthone derivatives due to the presence of the /er/-butyl group which was required to 
enhance solubility. With the dpqC chromophore, there is no obvious point of conjugation 
directly associated with the chromophore. Consequently, linkage through the trans 
pendant arm on the macrocyclic ring was investigated. This position provided the most 
feasible alternative, without compromising the photophysical properties of the 
complexes. Complexes such as [TbPh2_NH2] (Figure 6.2) have previously been 
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synthesised in an attempt to utilise this lanthanide complex linkage point. However, the 
structure of the linkable pendant NH2 arm resulted in the observation of numerous 
stereoisomers by HPLC analysis.^ 
3 * 
HN ^ 
N / \ 
NH H2N . '^ '^  H O " " 
Figure 6.2: Conjugalable dpqC complex |TbPh2_NH2] 
For complexes to be applicable as HTRF components they should preferably exist as a 
single stereoisomer. Therefore, to eradicate this problem, new targets were designed, in 
which the linkage pendant arm resembles the other ring N-substituents. The target 
complexes are shovra below: 
3 + 3 + 
0 HN Q 
- N 1 N - / 
0 N-N J \_ \ N N 1 N ''"\' ^ ^ N 
HI 0 NH 0 ° N H o . " °  n O " NH 
I 
[EuL^] X [TbL^°] A [LnL^^l 
6.1 Amide Conjugate Ligand and Complex Synthesis 
6.1.1 Trans Pendant Arm Synttiesis 
4-[(S)-l-(2-Chloro-acetylamino)-ethyl]-benzoic acid methyl ester 28 was synthesised 
from commercially available (iS)-l-(4-bromophenyl)ethylamine in a five step process 
(Scheme 6.1)."* Reaction of (5)-l-(4-bromophenyl)ethylamine with acetyl chloride 
selectively protected the amine group, allowing conversion of the para-substituted 
n 
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bromide into a cyano group (25) in 71 % yield, using Cu(I)CN. Subsequent acid 
hydrolysis using 1 M HCl(aq) yielded the acid 26 in quantitative yield. 
, 0 f o 
^ " CuCN,DMF X ^ , 6MHCI(3<„ ' 
24 25 ° 26 
o o 
O • NEt3, EtzO O " 
J 7 5 % I 
29 30 
Scheme 6.1: Synthesis of 4-[(S)-l-(2-chloro-acetylamino)-ethyl]-benzoic acid methyl 
ester 30 
The acid, 26, was also synthesised from the more readily available (5)-(-)-a-
methylbenzylamine as shown in Sclieme 6.2."^  Reaction of (5)-(-)-a-methylbenzylamine 
with trifluoroacetic acid, followed by treatment with methanesulfonic acid and 1,3-
dibromo-5,5-dimethylhydantoin afforded 27, in 51 % yield. Cyanation with Cu(I)CN in 
dimethylformamide yielded the cyano derivative 28, which was subsequently converted 
into 26 by acid hydrolysis in 1 M HCl(aq). Finally, esterification and reaction with 
chloroacetyl chloride afforded the functionalised arm 30. 
1 o o \ o i o 
NH2 " 0 C F 3 N " C F 3 P^*^ N ^ C F 3 
MeS03H ^ Br ' " «° NC ' " 
O Br 
/ N 27 28 
Br 
51 % 
Scheme 6.2: Synthesis of intermediate 28 
6.1.2 Functionalisation of Cyclen 
The use of appropriate protecting group strategies enabled the synthesis of the tri-
substituted mono- alkylated cyclen ligands [\}\, [ L ' " ] and [ L " ] . 
The synthesis of the trans-bis(benzylcarbamate) protected cyclen, 3 L was undertaken 
following established literature procedures,^ using pH control to ensure selective trans-
disubstitution (Scheme 6.3). Purification was achieved through selective extraction 
112 
Chapter 5/x: Conjugate Complexes 
using diethyl ether and dichloromethane to afford the product in 74 % yield. Alkylation 
of 31 under SN2 conditions (CS2CO3, MeCN) using (5)-A^-2-chloroethanoyl-2-
phenylethylamine proceeded to give the tetrasubstituted cyclen 32, which was reacted 
under standard hydrogenation conditions (40 psi, Pd(0H)2/C, CH3OH - H2O) to remove 
the Cbz protecting groups (33). 
H / \ H 
N N^, 
N N ' 
H - H 
Ph 
O 
ll 
O CI BnO 
Na2HP04, pH 2.5 
74% 
N N 
N N 
Ph O 
I I  
N 
H 
CI 
OBn CS2CO3, MeCN 
74% 
31 
HN 
/ 
tk N , H2, Pd{0H)2/C 
HN 
.0 
^ r , 
87 % 
NH 
N N 
• 
NH 
32 33 
Scheme 6.3: Synthesis of disubstituted cyclen 33 
Attempts to synthesise the desired pyrazoyl-azaxanthone ligand [ L ' " ] centred around 
the mono-alkylation of di-substituted cyclen 33 (Scheme 6.4). Despite using mild 
alkylating conditions (NaHC03, MeCN, 55 °C) using an excess of cyclen 33, both the 
mono and di-alkylated derivatives were apparent by mass spectrometry (34; MS (ES^ 
m/z = 1067.7, [M + Na]^ 35; MS (ES"") m/z = 1179.6, [M + Na]"^). Similar values for 
compounds 34 and 3 5 meant that purification by column chromatography on neutral 
alumina was extremely difficult. 
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UN O N N O HN Q o r O HN ^ 
' /• \ H ' • N : s 
N N ^ Br N N . N N ^ I N N + ! I N - N 
N N ' NaHCO,, MeCN, 55°C N N N N 
H H N N 
° ' NH ° ' NH / ' ) O O ^^ NH o 
33 34 35 
Scheme 6.4: Alkylation of cyclen 33 with bromopyrazoyl-azaxanthone, 12. 
Consequentiy, the crude material of 34 (~ 85 % pure by N M R analysis) was alkylated 
with the methyl carboxylate arm derivative 30 under SN2 conditions to yield | L ' " ] , which 
was purified by column chromatography on neutral alumina. Complexation was 
performed using Tb(CF3S03)3 in acetonitrile, followed by anion exchange 
chromatography to yield the corresponding water soluble chloride salt [TbL'"] (Scheme 
6.5). 
HN „ 1 ) O -^.^ H 
3 + 
O 
O 
- N N^, . CS2CO3, MeCN, 79 % 
N-N -1: ^ 
N N 2.) Tb(OSOCF3)3, MeCN, 
H — N Ion Exchange 
o»-<. y-\ „ 55% 
NH o ° 
r 
N . N 
M N 
34 [TbL^°] 
Scheme 6.5: Synthesis of complex [TbL'"] 
The water solubility of [TbL'"] enabled discrimination between the complex and the 
di-alkylated ligand by-product 35. HPLC purification was avoided by simple syringe 
filtration in aqueous solution, leading to isolation of JTbL'"] as a single species, as 
revealed by analytical HPLC (Figure 6.3). 
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Figure 6.3: Reverse phase analytical HPLC analysis o/ITbL'"] 
(Chromolith performance RP18e column; Method A;' Xexc = 355 nm, X^m = 355 / 516 nm) 
The problem of di-alkylation observed with bromopyrazoyl-azaxanthone (Scheme 
6.4) was not apparent with the analogous dpqC intermediate, 15 (below). 
CI 
N 
N 
15 
This observation is consistent with the lower reactivity of benzyl chlorides, with 
respect to benzyl bromides. This enabled the mono-alkylated cyclen 36 to be synthesised 
from di-substituted cyclen 33 under mild conditions (NaHC03, acetonitrile, 55 "C) 
(Scheme 6.6). Following purification by column chromatography on neutral alumina, 
alkylation with 4-[(5)-l-(2-chloro-acetylamino)-ethyl]-benzoic acid methyl ester 30 gave 
| L " ] after purification by column chromatography on neutral alumina. Complexation of 
the ligand was achieved in acetonitrile using Ln(CF3S03)3, followed by anion exchange 
chromatography to yield the water soluble cationic complexes, [ E U L " ] and [TbL"], as 
their chloride salts (Scheme 6.6). 
For HPLC solvents and gradients see Chapter 7: Experimental 
115 
/ 
HN 
H 
N N ^ 
N - ' 
H L , 
NH 
N 
NaHCOs, MeCN 
55 °C 
56% 
HN 
N N 
HI r 
Chapter S/x: Conjugate Complexes 
CI 
CS2CO3, MeCN 
92 % 
33 
6 ° "V o 
36 
0 ° o 
N N ^  W \ N. , - Ln(0Tf)3.6H20, MeCN ^ N | N ^ \ , 
\ A 1 N--^^ \ ;> o 4 r - ^ 
1 „ " - N N ' \ . „ Anion Exchange ^ A ^^N 
^, N (D0WEX1X-8 CI Resin) ^ - ,^  
68 - 72 % 
NH 
3 + 
3 0 ' 
[LnL^^] 
Ln = Eu, Tb 
Scheme 6.6: Synthesis of complexes [LnL"]7^ow disubstituted cyclen, 33. 
A different approach was undertaken for the synthesis of ligand [L^]. In considering 
the problems associated with the bromopyrazoyl-azaxanthone system, it was deemed 
appropriate to use suitable protecting groups to ensure only mono-alkylation of cyclen 
33. Reaction of di-substituted cyclen 33 with di-?ert-butyl dicarbonate in anhydrous 
MeOH led to the formation of the mono and di-BOC protected derivatives 3 7 and 38 
(Scheme 6.7).^  Separation of the compounds was achieved using column 
chromatography on silica. The di-BOC alkylated species was then deprotected 
(CF3COOH - CH2CI2) to recover the cyclen start material 33, after appropriate washing. 
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N N . 
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33 37 
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96 % 
Scheme 6.7: Synthesis of mono-BOC alkylated cyclen, 37. 
Alkylation of mono-BOC alkylated cylen 37 with bromopyridyl-azaxanthone, 
followed by deprotection with CF3CO2H - CH2CI2, yielded the mono-alkylated species 
40 (Scheme 6.8). The ' H N M R (Figure 6.4) and HPLC analyses of ligand 40 indicated 
that the BOC protecting group had successfully prevented any di-alkylation. 
HN N 0 
HN 
H 
N N ^ 
N N 
Br N N 
TFA.CHsClz N N - . 
K2CO3, MeCN ' 
o 
8 9 % 
n ^ 0 
" NH NH o 
-
J N 
NH 
37 39 40 
Scheme 6.8: Synthesis of mono-pyridyl-azaxanthone cyclen, 40. 
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HN 
40 
ppm 
Figure 6.4: 'H NMR spectrum of pyridyl-azaxanthone alkylated cyclen, 40, 
(CDCh, 700 MHz). 
Complexation of ligand 40 was undertaken to examine any potential anion sensitivity 
of the octadentate complex, [EuL*] (Scheme 6.9). Alkylation of ligand 40 with 4-[(5)-l-
(2-chloro-acetylamino)-ethyl]-benzoic acid methyl ester 30, followed by complexation in 
acetonitrile with Eu(CF3S03)3, yielded the complex [EuL^| (Scheme 6.9). 
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3 + 
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o 
- 3 CI 
NH 
[EuL^ ] 
• 
Scheme 6.9: Synthesis of complexes [EuL^J and [ E U L ' ] 
The selectively protected intermediate 37 was also utilised at a later stage for the 
synthesis of [LnL"] . The BOC protecting group enabled a less cautious alkylation 
approach, using strong Sn2 conditions to couple dpqC (Scheme 6.10). Finally, 
deprotection using CF3CO2H - CH2CI2 yielded the desired mono-alkylated compound 36, 
which was converted into [LnL"] using the procedures outlined previously in Scheme 
6.6. 
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tk N - ' i \ N TFA,CH2Cl2 , N N , H 
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41 36 
Scheme 6.10: Synthesis of mono-alkylated dpqC cyclen 36 
Complexes [ E U L ' ] , (TbL'"] and [LnL"] provide carboxylate functional groups 
through which to perform conjugation. An attempt to transform these functional groups 
into primary amine derivatives was investigated. This would provide an alternative group 
through which to conjugate appropriate 'tags' or 'acceptors'. Direct reaction of [TbL'"] 
with ethylenediamine as both a reagent and solvent led to the formation of numerous 
products, including decomplexation. An attempt to react | L ' " 1 with ethylenediamine at 
80 (in DMF) also proved unsuccessful. It was concluded that although the methoxy 
ester is conjugated to an aromatic group, it was not sufficiently activated to undergo 
nucleophilic substitution under conditions compatible with the stability of the complex. 
Consequently, the synthesis of a primary amine conjugate arm was undertaken. 
Reaction of A^-hydroxysuccinimide and chloroacetic acid in the presence of EDC, 
afforded l-(2-chloroacetyl)pyrrolidine-2,5-dione* in 41 % yield after chromatographic 
purification on silica. Selective acylation of intermediate (S)-4-(l-aminoethyl)benzoic 
acid 26 was achieved using l-(2-chloroacetyl)pyrrolidine-2,5-dione and anhydrous 
triethylamine to yield compound 42, in 60 % yield. Subsequent in situ generation of an 
NHS active ester, followed by reaction with commercially available iV-Boc 
ethylenediamine yielded the functionalised arm 43 (Scheme 6.11). 
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Scheme 6.11: Synthesis offunctionalised arm 43 
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Figure 6.5: 'HNMR spectrum of functionalised arm, 43, (CDCI3, 500 MHz). 
Preliminary attempts to alkylate the dpqC cyclen intermediate 36 with pendant arm 43 
proved difficult, with the compounds proving unreactive (CS2CO3, MeCN, 80 °C). This 
behaviour may be due to the steric hindrance created by the tert-h\i\y\ group. 
Consequently, any further investigations into the use of this compound may require 
utilisation of less sterically demanding cyclen substrates. 
121 
Chap te r 5/x: Conjugate Complexes 
6.2 Complex Characterisation 
Photophysical characterisation of the conjugate complexes [EuL^] and [LnL"] 
unsurprisingly resembled that of the analogous triamide derivatives [EuL''] and [LnL^] 
respectively. However, the total emission spectrum of [TbL'"| (Figure 6.7) showed 
reduced ligand fluorescence compared to the triamide [TbL"'']. This observed increase in 
intersystem crossing efficiency is accompanied by an increase in the overall emissive 
quantum yield (Oyb = 61 %, measured at 355 nm using an integrated sphere). 
10.0 
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Figure 6.6: Total emission spectrum o / [EuL ] (aerated water, 295 K, Xexc 355 nm). 
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Figure 6.7: Total emission spectrum of\Tbh ] (aerated water, 295 K, Xexc 255 nm). 
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Figure 6.8: Total emission spectrum o / f E u L " ! (aerated water, 295 K, X^xc S48 nm). 
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Figure 6.9: Total emission spectrum o / [TbL"l (aerated water, 295 K, Xexc 348 nm). 
6.3 Anion Sensitivity of [EuLS] 
The complex [EuL*] was synthesised to examine its potential as a responsive cellular 
probe. In developing responsive optical probes, it is important that the lanthanide 
emission encodes information about the chemical composition of the local environment 
through either modulation of spectral form or lifetime. Such complexes must operate 
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under cellular conditions, (i.e. in the presence of protein, oxygen and variable 
concentration of competing ions and quenching species) and report on the target analyte 
by ratiometric analysis. 
For these reasons, europium complexes constitute suitable candidates as emissive 
probes. The relative simplicity of the europium spectral emission profile has been 
correlated to the speciation of the metal ion. In particular, the nature and polarisability of 
the group occupying a position on or close to the principal axis of the complex, primarily 
determine the magnitude of the second order crystal field coefficient. The magnitude of 
this coefficient determines the degree of splitting in the AJ = I manifold.^ For cyclen 
derivatives, this is typically the 'axial' ligand occupying the ninth site, which caps the 
square anti-prismatic polyhedron. The more polarisable the axial donor atom, the greater 
the relative intensity of the hypersensitive and electric-dipole allowed AJ = 2 emission 
band. Thus, changes in the coordination environment of the Eu(lll) ion can give rise to 
large changes in the AJ = 2 / 1 intensity ratio and in the overall spectral form. 
The binding affinity of the octadentate complex [EuL*] to four bio-active oxy-anions 
(lactate, citrate, HCO3' and H P 0 4 ^ ' ) was examined by monitoring changes of both 
intensity and form in the europium emission. The emission spectrum of [EuL ) in water 
(Figure 6.10) shows both ligand fluorescence and metal based emission. Measurements 
of the radiative lifetimes in H 2 O and D 2 O gave an esfimated q value (number of bound 
water molecules) of I 
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Figure 6.10: Total emission spectrum (aerated water, 295 K, X^xc ^55 nm) for [ E u L " ) 
For each oxy-anion, the europium spectral form was recorded as a function of anion 
concentration. With lactate, HCO3" and HP04^", changes in the spectral form were not 
very significant, but were still sufficient to allow ratiometric analysis of the intensity of 
two emission bands (616 nm / 687 nm). By plotfing these intensity rafios as a funcfion of 
anion concentration, it was possible to calculate apparent affinity constants (Table 6.1). 
The observafion of only minor changes in spectral form and relative intensity after the 
addition of lactate, HCO3' and HP04^', suggests that the nature of the axial donor is 
conserved. 
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Figure 6.11: Total emission spectrum o /[EuL*l as a function of lactate concentration 
(aerated water 295 K, Xexc 355 nm) 
Complex Lactate (pH 6.0) HCOj (pH 7.4) HPO4' (pH 7.4) Citrate (pH 7.4) 
[EuL'] 2.83 (1.05) 3.57(1.15) 3.26(1.38) 5.26 
Table 6.1: Affinity constants of\Euh^] for selected anions (298 K, 0.1 MNaCl) 
The most distinctive changes in europium emission were observed following 
incremental addition of citrate (Figure 6.12), which gave rise to a large change in the 
intensity of the AJ = 2 / 1 ratio. Changes in lifetime measurements were consistent with 
the formation of a ternary adduct with no bound water molecules {q = 0). 
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Figure 6.12: Total emission spectrum of\EuL^] as a function of citrate concentration 
(aerated water, 295 K, X^xc 355 nm) 
The affinity of [EuL ] to citrate anions probably makes the complex unsuitable for ' in 
cellulo' anion sensing. In the presence of only 0.05 mM citrate, a complete change in the 
emission spectral profile is observed. This spectral form does not alter despite further 
addition of citrate. Consequently, ratiometric measurement of putative biological 
concentrafions (0-0.13 mM citrate) is not applicable with this complex. 
6.4 HTRF 
Homogeneous time resolved fluorescence (HTRF) is based on fluorescence resonance 
energy transfer (FRET) between two interacting components. One of the constituents is 
labelled with a donor fluorophore and the other is labelled with an acceptor fluorophore. 
Energy transfer from the excited donor to the acceptor is only seen when the two 
fluorophores are in close proximity, typically below 10 nm. This distance dependence 
(1/r^) of FRET allows HTRF systems to address molecular interacfions on the 1 - 10 nm 
scale." 
A common problem with the majority of resonance energy transfer techniques is a low 
signal-to-noise ra t io .These problems are often encountered due to the intrinsic 
fluorescence of proteins and the overlap between the emission spectra of the FRET 
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donors and acceptors. HTRF technology alleviates this problem by using long-lived 
donor fluorophores such as europium cryptates. These complexes allow the use of time 
gated detection to enhance the signal-to-noise ratio. In addition, acceptors such as Alexa 
Fluor 647 and d2 (a fluorophore developed by Cisbio International) have very limited 
emission at 665 nm, and therefore provide an accurate emission parameter with which to 
measure FRET interactions. 
For HTRF to occur, the two components must interact with one another. To date, 
various strategies have been employed to achieve this interaction, with one common 
method being the use of protein antibodies. Although it increases the assay complexity, 
this technique is a widely employed approach despite the large molecular volumes (150 
kDa, 160 A in length) and multiple labelling characteristics of protein antibodies." 
SNAP-tag technology provides an alternative labelling approach which eliminates the 
need for antibodies and reduces the assay complexity. Developed by Covalys, the SNAP-
tag method allows the covalent labelling of proteins (acceptors) with compatible donor 
fluorophores, labelled with benzyl guanine moieties. SNAP-tag is a mutant DNA repair 
enzyme, human 0^-alkylguanine-DNA alkyltransferase (hAGT),'^ which irreversibly and 
specifically reacts with 0^-alkylguanine (BG) derivatives to form a thioether bond and 
release free guanine (Scheme 6.12). The labelled synthetic probe of the BG derivative is 
then transferred to a reactive cysteine residue.'^ 
F K B P 
8 
F K B P 
^^^^^^^^^^^^^ 
o 
N N N H , » ^ 
N ' N ^ NH 
H 
Scheme 6.12: Mechanism of SNAP-TAG activation with BG 
For the conjugate complexes [EuL^], [TbL'**| and [LnL"] to be applicable as HTRF 
assay donors, it was necessary to establish a method of conjugation that allows the 
covalent linkage of the BG 'tag' BG_NH2. A synthetic preparation of BG_NH2 is shown 
in Scheme 6.13.'^ 
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CH3NH2 
< I 1 
BG_NH2 
Scheme 6.13: One synthetic route to BG_NH2 
6.4.1 Complex Activation and Conjugation 
Hydrolysis of the methyl ester functionalities within (EuL^I, (TbL'**] and [LnL"j was 
achieved under basic conditions (0.02 M KOH, pH 10), at ambient temperature. A 
mixture of 0.02 M KOH - MeOH (1:1, 4 ml) drove the reactions to completion (10 mg 
complex) within 2 h. Neutralisation to pH 7 and evaporation of the solvents yielded the 
acid derivafives (as salts) in quantitative yield. The acid complexes were then activated to 
the corresponding iV-hydroxysuccinimide esters without any further purification. To 
avoid the use of two activating agents (e.g. DCC or EDCl.HCl with A^ -
hydroxysuccinimide), the coupling agent TSTU was utilised. Subsequently, activation 
was achieved by incremental addition of DIPEA and TSTU to a solution of the complex 
in anhydrous DMF. The reaction was monitored by reverse phase HPLC. Following 
completion, semi-preparative HPLC was performed to purify the respective NHS 
derivatives. However, after purification, the separated materials were shown by analytical 
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HPLC to be composed of the NHS and acid derivatives. This highlighted the instability 
of the NHS esters in aqueous soludons. Consequently, following formation of the NHS 
derivatives, the material was either coupled directly without isolation, or the solution 
dropped onto diethyl ether to induce precipitation of the complex. This material could 
then be stored in a freezer without any apparent hydrolysis. Reaction of the in situ NHS 
derivatives proceeded quickly following the introduction of excess BG -NH2 (3 
equivalents). Purification of the complexes was achieved by preparative reverse phase 
HPLC using a Chromolith performance RP-18e column. The BG-derivatives were then 
characterised by HPLC, absorption and emission spectroscopy and electrospray mass 
spectrometry before being screened in an HTRF assay. 
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Scheme 6.11: Activation and conjugation of complex [ E U L " ] 
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Photophysical characterisation of the conjugate complexes resembled that observed 
for the parent systems (i.e. [EuL^J, [TbL""), [LnL"]). For example, the total emission 
spectrum of [ E U L ' _ B G ] (Figure 6.13) shows 3 bands in the AJ = 1 band, indicating one 
chiral species. This was confirmed by reverse phase HPLC analysis. The europium 
emission lifetime was found to be 1.00 ms in water (compared to 1.02 ms for [EuL^]), 
suggesting that the aromatic BG vector does not quench the lanthanide excited state. 
AJ = 2 
ni 3,00 
£ 2.00 
! i J=0 
[EuL»_BG] 
•S 1.00 
0.00 
400 450 500 550 600 
W a v e l e n g t h (nm) 
9 
650 700 
Figure 6.13: Total emission spectrum of\EuL'^_BG] (aerated water, 295 K, X^xc 355 nm). 
6.4.2 HTRF Application and Screening 
The complex [EuL^_BGl, and analogous complexes [ T b L ' " _ B G ] and [ L n L " _ B G ] , wil l 
be examined by Cisbio International to determine their performance as components in 
homogeneous time resolved fluorescence (HTRF) assays. The assay format is comprised 
of a BG labelled complex (e.g. [ E U L ' _ B G ] ) , and the protein FRB. This protein is 
coupled with the FRET acceptor, d2, and the protein FKBP-SNAPTAG when in the 
presence of rapamicine. Addition of the respective lanthanide donor results in FRET, 
which can be monitored as a function of concentrafion. This allows the calculation of a 
FRET efficiency as a fiincfion of BG concentration. Figure 6.14 shows the components 
present in a HTRF assay. 
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Rapamicine j 
355 nm SNAP TAG Interaction / Ml Emission 
Excitation 
F 
Figure 6.14: Diagram representing the components present for successful FRET 
during a HTRF assay 
6.5 Alternative Conjugation Complexes 
The cationic nature of the complexes [ E U L ' J , [TbL'"] and [LnL^] resuhs in a high 
degree of electrostatic adhesion. To alleviate this property, the synthesis of a neutral 
carboxylate conjugate complex was also pursued. 
6.5.1 Carboxylate Conjugate Complex Synthesis 
hi exploring the possibility of synthesising a carboxylate conjugate complex, it was 
important to identify a chiral compound that would resemble the remaining cyclen 
pendant arms. Compound 45 (Scheme 6.12) was deemed appropriate, as it could be 
attached to cyclen through alkylation with the bromine atom, while deprotection of the 
BOC group would enable coordination to the lanthanide ion. Finally, removal of the Cbz 
group would provide a carboxylate group through which to conjugate, in a similar 
manner to those described previously in Scheme 6.11. 
The synthesis of the (5)-2-bromo-pentanedioic acid 5-benzyl ester l-?er?-butyl ester, 
45, is outlined in Scheme 6.12. Reaction of (5)-glutamic acid 5-benzyl ester with 
sodium nitrite, followed by treatment with 1 M HBr led to the formation of (5)-2-bromo-
pentanedioic acid 5-benzyl ester, 44, in 58 % after chromatographic purification.'* 
Finally, conversion to the tert-b\xty\ ester, 45, was achieved using /er/-butyl acetate and 
HCIO4 to afford the product in 88 % yield. 
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Scheme 6 .12 : Synthesis of derivatised carboxylate arm 45 
Using the previously synthesised di-Cbz protected cyclen 3 1 , it was possible to 
incorporate 45 selectively onto cyclen (Scheme 6 . 1 3 ) . Alkylat ion o f the protected cyclen 
3 1 with tert-h\xXy\ bromoacetate ( C S 2 C O 3 , MeCN), followed by removal o f the Cbz 
protecting groups, under standard hydrogenation conditions (40 psi, Pd(0H)2/C), yielded 
cyclen D 0 2 A , 47 , in 61 % overall yield. 
BnO ' : 
H 
N N 
N N 
0 
OBn 
CS2CO3. MeCN 
31 
61 
O -
° S"* K OBn 
4 6 
H2, Pcl(0H)2/C 
99% 
N N 
h 1 
4 7 
o 
CI 
NaHCOs, MeCN 
84 % 
4 8 
• 
N 
K2CO3, MeCN 
/ 
V r ui N 
O ~'\ / 
Scheme 6 .13: Synthesis ofD02A 47, anddpqC ligand [ L ' ^ ] 
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Reaction o f D 0 2 A cyclen, 47, wi th dpqC (NaHCOs, 60 "C, MeCN) gave the mono-
alkylated dpqC ligand, 48, in 8 4 % yield fol lowing column chromatography o f neutral 
alumina. Analysis o f the product by reverse phase analytical HPLC showed that the 
material was free of any ligand and comprised only one species in solution (> 9 8 % pure). 
Alkylation o f 48 with a large excess o f (5)-2-bromo-pentanedioic acid 5-benzyl ester 1 -
tert-huty\ ester (45) was shown by mass spectrometry to form some o f the desired 
product | L ' ^ ] . However, the reaction did not run to completion despite using forceful 
conditions (100 °C, DMF) . It was concluded that ligand 48 is too sterically demanding for 
efficient coupling with the bulky substrate, 45. Attempts to purify the two materials by 
column chromatography proved unsuccessful, with both materials showing a tendency to 
elute together. HPLC analysis confirmed that the isolated material was composed o f 
compounds 48 and [ L ' ^ | . 
In attempting to overcome this unreactivity, i t was decided to utilise the apparent 
steric demand o f (5)-2-bromo-pentanedioic acid 5-benzyl ester l-/er/-butyl ester 45. 
Reaction o f 45 with D 0 2 A cyclen (47) using mi ld alkylation conditions enabled the 
synthesis o f the mono-alkylated derivative 49 in 60 % yield after chromatographic 
purification (Scheme 6.14). Finally, reaction with bromomethylpyridyl-azaxanthone, 9. 
(K2CO3, MeCN) yielded [ L ' ^ ] after chromatographic purification. 
0 o I 
NaHCOs, MeCN 
55 °C 
61 % 
H 
47 
N N N N 
K2CO3, MeCN 
39% 
N N N N 
Scheme 6.14: Synthesis of ligand [V^]froin D02A cyclen, 47. 
Analysis o f ligand [ L * ^ ] by reverse phase analytical HPLC showed that the material 
was free o f any starting materials and was comprised o f only one species in solution 
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(Figure 6 . 1 5 ) . ' H N M R and mass spectrometry ( M S ( E S ^ ) m/z 1 0 1 9 . 6 ( 1 0 0 % , [ M + 
H]^)) confirmed the structure. 
N N 
{r= 1 2 . 0 mm 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
Figure 6 .15: Reverse phase analytical HPLC analysis o / | L ' ^ ] 
(Chromolith performance RP18e column; Method A;" Xexc = 355 nm, Xgm = 355 nm) 
Literature precedent has demonstrated the potential to deprotect Cbz and BOC 
protecting groups in a one pot reaction.'^ Consequently, ( L ' ^ ] was stirred in neat HBr / 
acetic acid at 4 0 "C for 4 h (Scheme 6 . 1 5 ) . Examination of the reaction mixture by ' H 
N M R showed the disappearance of both the characteristic benzyl C H i (Cbz) and tert-
butyl (Hoc) signals, suggesting complete deprotection. Analysis o f the material by HPLC 
showed the formation o f a new single product, exhibiting a significant shift in retention 
time (tR (SM) = 12.0 min; tR (Prod) = 10.8 min). Complexation of the crude reaction 
product was performed in MeOH - H 2 O ( 1 : 1 v/v) at pH 5.5 using Eu(OAc )3 .6H20. 
Finally, removal o f excess lanthanide was achieved by precipitation o f E u ( 0 H ) 3 at pH 10. 
HO 
HBr, CH3CO2H 
100 % 
HO 
O 
HO 
N N 
OH 0 V 
Eu(OAc)36H20 
MeOH - H2O N 
\ ° 0 " \ 
\__ - o HO 
Scheme 6 .15: Reaction of[V^] with HBr/acetic acid and subsequent complexation 
For HPLC solvents and gradients see Chapter 7: Experimental 
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Figure 6.16: Reverse phase analytical HPLC analysis of [L^^] following HBr / acetic acid 
deprotection 
6.5.2 C a r b o x y l a t e C o n j u g a t e C o m p l e x Character isat ion 
Photophysical characterisation o f the carboxylate conjugate complex [ L ' " ' ] resembled that 
of the analogous D 0 3 A complex [ E u L ' j . Examination o f the total emission spectrum 
showed both azaxanthone fluorescence and the Eu spectral fingerprint f rom the ^Do 
emissive state. The luminescent lifetime was determined as 0.90 ms in H 2 O , with the 
complex exhibiting a q value o f 0 in aqueous media. Although the ligand-based emission 
i^^em = ~ 20 % ) lowers the europium quantum yield when compared to the tri-amide 
derivative, | E u L ^ | , the presence o f a distinct A.I = 2 band provides an observable 
parameter through which the complex can be monitored in an HTRF assay. Future work 
w i l l involve analogous synthesis o f the BG conjugate complex to that described for 
1 E U L ' ' | . 
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Figure 6.17: Total emission spectrum q/"[EuL'^] (aerated water, 295 K, lexc 355 nm). 
6.6 Conc lus ions 
Para-methoxy fiinctionalised cationic amide complexes incorporating the pyridyl-, 
pyrazoyl-azaxanthone and dpqC chromophore have been synthesised. A convenient and 
reproducible method o f activation via a A^-hydroxysuccinimide ester has enabled the 
conjugation o f a benzyl guanine vector. The respective complexes w i l l be examined 
under HTRF assay conditions to determine their FRET efficiencies. 
A neutral carboxylate conjugate complex has been synthesised to alleviate the high 
electrostatic adhesion o f complexes [EuL^], [TbL"*] and [ L n L " | . This complex is 
amenable to conjugation via a carboxylate function, and w i l l be assessed for potential 
HTRF applicafion by Cisbio International. 
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Future Work 
6.7 C h r o m o p h o r e Optimisation 
Coupling o f 2-chloro-azaxanthone with commercially available pyrazoles was undertaken 
to investigate the effect o f substitutents on the chromophores extinction coefficient and 
triplet energy (Ti ) . Preliminary findings show that the inclusion o f a carboxylic acid 
group was accompanied by a large increase in the molar extinction coefficient, without 
comprising other photophysical attributes (Table 6.2). In addition to providing 
favourable photophysical characteristics, a carboxylate group provides a means o f 
conjugation. 
Chromophore Amax (nm)' £ (dm^ moi"' c m " 
0 1 
346 15,380 23,470 
/ T - N N O ^ " ^ ^ 
J - N - ^ N ^ O - ^ 
330 10,090 23,800 
/ 
0 1 
/ T - N N 0 ^ ' ^ ^ 
/ 
0 1 
353 20,000 23,500 
/ ~ - - N N 0 ^ ^ ^ 
350 25,000 23,300 
Table 6.2: Photophysical properties of selected sensitising chromophores 
C MeOH, 295 K. * 77K in an EtiO-isopentane-ethanol (EPA) frozen glass) 
For phosphorescence emission spectra see Chapter 7: Experimental appendix 
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Figure 6.19: Absorption spectra offunctionalisedpyrazoyl-azaxanthones (298 K, MeOH) 
The commercial availability o f 2-bromo-6-methyl-isonicotinic acid could also allow the 
investigation o f a carboxylate functionalised pyridyl-azaxanthone and its potential 
conjugation. 
6.8 Phosphinate C o n j u g a t e C o m p l e x e s 
A n attractive alternative to carboxylic acid donor groups are phosphinic acid derivatives. 
Tri-phosphinic acid cyclen derivatives incorporating dpqC or azaxanthone chromophores 
have been shown to form kinetically stable and emissive complexes in aqueous 
solutions.^ The pentavalency o f phosphorus means that an alkyl, aryl or other 
ftinctionalities may be introduced readily, permitting not only control over complex 
lipophilicity but also providing a potential route o f conjugation. By using selective 
protection and deprotection strategies, the synthesis o f phosphinate conjugate complexes 
could be investigated. Literature precedents show synthetic procedures for synthesising 
two different phosphinate linkers.'^'^ The two compounds provide contrasting 
fimctionalities (i.e. CO2H and NH2) with which to conjugate appropriate vectors. 
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Scheme 6.17: Synthesis of the o-mesyl phosphinale P 
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Scheme 6.18: Synthesis of the o-mesyl phosphinate P 
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Figure 6.20: Structures of potential conjugate phosphinate complexes 
Initial alkylation reactions o f the mesylate derivatives P' and P^  highlighted the lack o f 
reactivity o f these compounds towards sterically demanding cyclen deriviatives. 
Consequently, attempts to incorporate these moieties onto cyclen should be performed 
earlier in the synthetic route, and on a non-sterically demanding cyclen compound. 
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Chapter 7: Experimental 
General Procedures 
Reagents and Solvents 
A l l commercially available reagents were used as received, f rom their respective 
suppliers. Solvents were dried using an appropriate drying agent when required. 
Reactions requiring anhydrous conditions were carried out using Schlenk-line techniques 
under an atmosphere o f dry argon. Water and H2O refer to high purity water with 
conductivity <0.04 \xS cm"' obtained from the 'PuritesriLL plus' purification system. 
Chromatography 
Thin-layer chromatography was carried out on neutral alumina plates (Merck Art 5550) 
or silica plates (Merck 5554) and visualised under U V (254 nm / 365 nm) or by staining 
with iodine. Preparative column chromatography was carried out using neutral alumina 
(Merck Aluminium Oxide 90, activity I I - I I I , 70-230 mesh), pre-soaked in ethyl acetate, 
or silica (Merck Silica Gel 60, 230-400 mesh). 
Spectroscopy 
' H and '^C N M R N M R spectra were recorded on a Varian Mercury 200 ( ' H at 199.98 
MHz, '^C at 50.29 MHz) , Varian Unity 300 ( ' H at 299.91 MHz, '^C at 75.41 MHz) , 
Varian V X R 400 ( ' H at 399.97 MHz, '^C at 100.57 MHz) , Bruker A M X 500 ( ' H at 
499.76 MHz, '^C at 125.66 MHz) or Varian Unity 700 spectrometer ( ' H at 699.73 MHz, 
'^C at 175.94 MHz) . Spectra were referenced internally to the residual protio-solvent 
resonances and are reported relative to TMS. Chemical shifts are reported as ppm and 
coupling constants in Hz. Splitting patterns are described as singlet (s), doublet (d), triplet 
(t), quartet (q) or multiplet (m). 
Electrospray mass spectra were recorded on a V G Platform I I (Fisons instrument), 
operating in positive or negative ion mode as stated, with methanol as the carrier solvent. 
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Accurate mass spectra were recorded using a Thermo Finnigan LTQ FT mass 
spectrometer. 
UVA^is absorbance spectra were recorded on a Perkin Elmer Lambda 900 
UVA(^is/NIR spectrometer. Samples were contained contained in quartz cuvettes with a 
path length o f 1 cm and measurements obtained relative to a reference o f pure solvent 
contained in a matched cell. 
Emission Spectra were recorded at 298 K using a Fluorolog 3-11 spectrometer using 
DataMax v 2.1 for Windows. Luminescence spectra o f the europium ( I I I ) and terbium 
(III ) complexes were recorded using a 420 nm cut-off filter, fol lowing indirect excitation 
o f the lanthanide ( I I I ) ion, via the pyridyl-, pyrazoyl-azaxanthone or dpqC at 355 nm or 
348 nm respectively, except where stated. A n integration time o f 0.5 seconds, increment 
of 0.5 nm and excitation and emission slit widths o f 2 and 1 nm, respectively, were 
employed throughout. 
Circularly Polarised Luminescence (CPL) measurements were made using a home-
built (Glasgow University, U K ) CPL spectrometer based on a Spex Fluopomax-2-
spectrofluorimeter wi th the assistance o f Dr. R. D . Peacock. Samples were run using D2O 
as a solvent. 
Relax ivity measurements were performed at 37 °C and 60 M H z on a Bruker Mini spec 
mq60 instrument. The mean value o f three separate measurements was recorded and an 
average taken. 
Melting points were recorded using a Kofler block and are uncorrected 
pH Measurements 
pH measurements were peformed using a Jenway 3020 or a Jenway 3320 pH meter 
attached to an Aldrich Chemical Company micro-pH combination electrode. Calibration 
was achieved using pH 4.01, pH 7.00 and pH 10.03 buffer solutions supplied by Aldrich. 
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Triplet Energy Meaurements 
Low temperature phosphorescence spectra were performed using an Oxford Instruments 
optical cryostat operating at 77 K. Samples were dissolved in EPA (diethyl ether -
isopentane - ethanol ( 2 : 5 : 5 : v/v)) and contained in 10 mm cuvetttes. The triplet energy 
was obtained from the extrapolation o f the highest energy phosphorescence band, 
corresponding to the 0 - 0 transition, using time-gated detection. 
Europium and Terbium Lifetime Measurements 
Emissive lifetimes were recorded at 298 K using a Perkin Elmer LS55 luminescence 
spectrometer using PL Winlab software. The lifetimes o f the Eu and Tb complexes were 
measured by exciting the sample using a short pulse o f light, followed by the monitoring 
of the integrated intensity o f light (545 nm for terbium, 620 nm for europium) emitted 
during a fixed gate time, /g, after a delay time, / j . A t least 20 delay times were used 
covering 3 or more lifetimes. A gate time o f 0.1 ms was employed, and the excitation and 
emission slits set to bandpass o f 10 nm. The obtained exponential decay curves were 
fitted to the equation below 
where: 
I = Ao + Aie\p(-kt) 
I = intensity at time t after the flash 
Ao = intensity after the decay has finished 
A1 = pre-exponential factor 
k = rate constant for decay o f the excited state. 
The excited state lifetime, T , is the inverse o f the rate constant, k. 
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Quantum Yield Measurements' 
The Photoluminescence Quantum Yields (PLQY) were determined using a method based 
upon that origninally developed by de Mello et al." In this approach the PLQY ((I>PL) is 
given by: 
<t>PL = 
with 
where: 
E\niX) is the integrated luminescence from direct excitation o f the film 
Eoui(?^) is the integrated luminescence from secondary excitation 
-^ empty(^ ) IS the integrated excitation profile with the empty sphere 
a is the film absorptance (Absorptance, a, is the fraction o f light absorbed, equal to one 
minus the transmittance, which is obtained by measuring the integrated excitation bands 
Xin(k) is the integrated excitation when the sample lies directly in the excitation path 
XouiQ^) is the integrated excitation when the excitation light flrst hits the sphere wall 
Measurements were performed at 298 K using solutions with absorption o f less than 0.15 
at the chosen excitation wavelength (in a 1 cm pathlength cuvette). The samples were 
measured in a homemade cylindrical optical quartz cuvette with a diameter o f 8 mm, 
equipped with a homemade Tefion stopper. A HORIBA Jobin-Yvon Fluorolog 3-22 Tau-
3 fluorimeter was used, incorporating a Labsphere® optical Spectralon integrating sphere 
(diameter 100 nm, reflectance > 99 % over 400 - 1500 nm range). 
' L . Porres, A. Holland, L - 0 . Palsson, A. P. Monkman, C. Kemp and A. Beeby, ./. 
Fluorescence, 2006, 16, 267. 
J. C. de Mello, H . F. Wittmann and R. H . Friend, Adv. Mater., 1997, 9, 230. 
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H P L C A n a l y s i s 
Durham 
Analytical reverse phase HPLC analysis were performed at 298 K on a Perkin Elmer 
system comprising o f Perkin Elmer Series 200 Pump, Perkin Elmer Series 200 
Autosampler, Perkin Elmer Series 200 Diode array detector and Perkin Elmer Series 200 
Fluorescence detector. 
A l l analysis was perfomed using a Chromolith performance RP18e 100 x 4.6 nm column, 
using a f low rate o f 1 ml / min and solvent Method A. 
Method A: 
Time (min) H2O + 0.1 % HCO2H CH3CN + O.I % HCOjH 
0 95 5 
2 95 5 
15 0 100 
17 0 100 
22 95 5 
Cisbio International, France 
Analytical and semi-preparative HPLC were performed at 298 K using a Waters HPLC 
system equipped with a diode array detector. 
Analytical HPLC was performed using a Chromolith performance RP18e 100 x 4.6 mm 
column, using a flow rate o f 3 ml / min and one o f the selected methods shown below; 
Method B: 
Time (min) H2O + 0.1 % HCO2H CH3CN + 0.1 % HCO2H 
0 95 5 
1 95 5 
8 35 65 
10 0 100 
11 85 15 
13 95 5 
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Method C: 
Method D: 
Time (min) H2O + 0.1 % HCO2H CH3CN + 0.1 % HCO2H 
0 85 15 
1 85 15 
10 0 100 
11 85 15 
13 85 15 
Time (min) H2O + 0.1 % HCO2H CH3CN + 0.1 % HCO2H 
0 90 10 
1 90 10 
11 30 70 
12 0 100 
14 0 100 
15 90 10 
17 90 10 
Semi-preparative HPLC was performed using a Chromolith performance RP18e 100 x 10 
mm column, using a f l ow rate o f 14.1 ml / min and one of the selected methods shown 
below; 
Method E: 
Time (min) H2O + 0.1 % HCO2H CHjCN + 0.1 % HCO2H 
0 80 20 
1 80 20 
8 45 55 
10 0 100 
11 0 100 
12 80 20 
13 80 20 
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Method F: 
Time (min) H2O + 0.1 % HCO2H CHjCN + 0.1 % HCO2H 
0 85 15 
3 85 15 
30 0 100 
33 0 100 
36 85 15 
40 85 15 
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Ligand and Complex Synthesis 
7.1 Sensitising Chromophores 
2-(4-terf-Butyl'phenoxy)-nicotinic ac id ^ (1) 
O 
^OH 
2', 
4-/e/-/-Butylphenol (15.2 g, 101 mmol) was added to a stirred solution o f sodium metal 
(1.02 g, 44.4 mmol) in anhydrous CH3OH (25 ml) to form a thicic cream coloured 
solution. The solvent was removed under reduced pressure to afford a cream coloured 
residue. 2-Chloronicotinic acid (3.31 g, 21.0 mmol) was added to the residue and the 
resulting mixture heated at 190 °C, with stirring, for 20 h. The reaction mixture was 
allowed to cool to 100 °C, then poured into H2O (200 ml) . The aqueous solution was 
extracted with diethyl ether (2 x 150 ml), and acidified to pH 5 by the addition o f glacial 
acetic acid to afford a fine precipitate. The precipitate was filtered, washed with H2O 
(100 ml) and dried under vacuum to yield the title compound 1 as a colourless crystalline 
solid (4.89 g, 18.0 mmol, 86 % ) ; m.p. 180-181 { l i t . 179-181 ° C } ; ' H N M R (CDCI3, 
500 MHz) 5 1.37 (9H, s, 'Bu CH3) , 7.14 (2H, d, J = 8.5 Hz, H^"), 7.20 ( I H , dd, J = 7.5; 
5.0 Hz, H^), 7.49 (2H, d, J = 9.0 Hz, H^"), 8.35 ( I H , dd, J = 4.5; 2.0 Hz, H ' ) , 8.55 ( I H , 
dd, . / = 8.0; 2.0 Hz, H^); '^C N M R (CDCI3, 125 MHz, ' H decoupled 500 MHz) 6 31.7 
(3C, C^'), 34.8 ( I C , C^'), 113.5 ( I C , C*), 119.7(1C, C^), 121.4 ( I C , C^'), 127.1 ( I C , C^'), 
143.8 ( I C , C \ 149.3 ( I C , C^"), 149.8 ( I C , C' ), 152.4 ( I C , C') , 161.5 ( I C , C^), 164.9 
( I C , C=0) ; MS (ES-) m/z 270.2 (100 %, [ M - H]"); HRMS (ES") m/z found 270.1135 [ M 
- H]" C,6Hi603N, requires 270.1135; C e H n N j O (%): calcd C 70.83, H 6.32, N 5.16; 
found C 70.54, H 6.20, N 4.91. 
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6-tert-Butyl-9-oxa-1-aza-anthracen-10-one ^ (2) 
A stirred mixture o f polyphosphoric acid (70 g) and 2-(4-/er/-butyl-phenoxy)-nicotinic 
acid 1 (2.15 g, 7.93 mmol), was heated at 120 °C, for 16 h. The brown reaction mixture 
was allowed to cool to rt, before being poured onto iced water (400 ml) to afford a pale 
yellow solution. The pH o f the aqueous solution was adjusted to pH 7 by the addition o f 
cone. NaOH (aq). The aqueous solution was then extracted with diethyl ether (3 x 300 ml). 
The organic extracts were combined, dried over MgS04, filtered and the solvent removed 
under reduced pressure to yield the title compound 2 as a yellow coloured solid (1.79 g, 
7.08 mmol, 89 % ) ; m.p. 97-98 °C { l i t . 98-100 °C}; ' H N M R (CDCI3, 500 MHz) 6 1.42 
(9H, s, 'Bu CH3), 7.45 ( I H , dd, J = 7.5; 4.5 Hz, H^), 7.58 ( I H , d, J = 8.5 Hz, H ' % 7.86 
( I H , dd, J = 9.0; 3.0 Hz, H \ 8.30 ( I H , d, J = 2.5 Hz, H ^ 8.73 ( I H , d, J = 7.5 Hz, H ' ) , 
8.76 ( I H , d,J= 7.5 Hz, H^); '^C N M R ( C D C l 3 , 125 MHz, ' H decoupled 500 MHz) 5 31.6 
(3C ,C") ,35 .1 ( 1 C , C " ) , 117.0(1C, C') , 118.4 ( I C , C"'), 121.1 ( I C , C^), 121.1 (1C,C ' ) , 
122.7 ( I C , C') , 133.9 ( I C , C') , 137.6 ( I C , C^), 148.2 ( I C , C') , 154.1 ( I C , C') , 154.3 ( I C , 
160.6 ( I C , C " ) , 178.1 ( I C , C^); MS (ES^) m/z 254.2 (100 %, [ M + H f ) ; HRMS 
(ES^) m/z found 254.1177 [ M + H]^ d s H i e O i N , requires 254.1176; C ,6H,5N02 ( % ) : 
calcd C 75.87, H 5.97, N 5.53; found C 75.80, H 5.91, N 5.61. 
6-teit-Butyl-1 -methyl-9-oxa-1 -aza-anthracen-10-one trifluoromethylsulfonate 
(3) 
+ N O 
Me "SO3CF3 
A solution o f 6-/eA-/-butyl-9-oxa-l-aza-anthracen-10-one 2 (1.00 g, 3.95 mmol) in 
anhydrous toluene (20 ml) was stirred at 0 °C, under an atmosphere o f argon. Methyl 
trifiuoromethanesulfonate (6 ml , 8.70 g, 53.0 mmol) was added to the solution dropwise 
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over 10 min. The solution was stirred at 0 °C for 1 h, to afford a fine precipitate. The 
precipitate was filtered and dried under vacuum to afford the title compound 3 as a 
colourless solid (1.49 g, 3.58 mmol, 91 % ) ; ' H N M R ( C D 3 0 D , 400 MHz) 5 1.43 (9H, s, 
'Bu CH3), 4.51 (3H, s, CH3), 7.84 ( I R d, J = 9.0 Hz, H ' " ) , 7.99 ( I H , dd, J = 8.0; 6.0 Hz, 
H^), 8.15 ( I H , dd , . ; = 9.0; 2.5 Hz, H \ 8.33 ( I H , d, J = 2.5 Hz, H \ 9.14 ( 1 H , dd, . / = 6.0; 
2.0 Hz, H ' ) , 9.30 ( I H , dd, J = 8.0; 2.0 Hz, H^); ' ^C N M R (CD3OD, 100 MHz, ' H 
decoupled 400 MHz) 5 30.3 (3C, C ' \ 34.8 ( I C , C'^), 41.7 ( I C , CH3), 118.2 ( I C , C'°) , 
120.4 ( I C , C"*), 120.8 ( I C , 121.2 ( I C , C^), 122.6 ( I C , C^), 135.4 ( 1 C , C \ 145.9 ( I C , 
C \ 149.1 ( I C , C'), 151.1 ( I C , C \ 152.4 ( I C , C " ) , 156.3 ( I C , C'"), 173.8 ( I C , C^); '^F 
N M R (CD3OD, 188 MHz, ' H decoupled 400 M H z ) 5 80.5 (s, CF3); MS (ES^) m/z 268.2 
(100 %, [ M f ) ; HRMS (ES^) m/z found 268.1332 [ M f C T H I S O Z N , requires 268.1332. 
6-fe/t-Butyl-1-methyl-9-oxa-1-aza-anthracen-10-one chloride (4) 
Me CI 
Ion exchange of 6-/e/-/-butyl-l-methyl-9-oxa-l-aza-anthracen-10-one 
trifluoromethylsulfonate 3 to the corresponding chloride salt was performed to enhance 
water solubilty. D O W E X 1x8 2 0 0 - 4 0 0 mesh C I ion exchange resin was refluxed in 
CH3OH overnight, followed by washing with H2O ( 5 0 0 ml) , then 0.1 M HCl ( 2 0 0 ml) 
and finally H2O until the eluted solvent was o f neutral pH. 6-/e/-/-Buty!-l-methyl-9-oxa-
1-aza-anthracen-lO-one trifluoromethylsulfonate (1 .00 g, 2 . 4 0 mmol) was dissolved in a 
mixture o f H2O and CH3OH (1:1, v/v 2 0 ml) and added to an excess o f prepared 
D O W E X resin (0 .5 g). The mixture was stirred at rt for 2 h, filtered and the solvent 
removed under reduced pressure to yield the corresponding chloride salt 4 in quantitative 
yield; ' H N M R ( C D 3 0 D , 5 0 0 MHz) 5 1.46 (9H, s, 'Bu CH3), 4 . 5 5 ( 3 H , s, CH3), 7.88 ( I H , 
d, . / = 9.0 Hz, H ' \ 8.03 ( I H , t, J = 6.5 Hz, H^), 8.18 ( I H , dd, . / = 9.0; 2 .0 Hz, H^), 8.36 
( I H , d, J = 2 . 0 Hz, H \ 9 .22 ( I H , d , . / = 6.5 Hz, H ' ) , 9.33 ( I H , d , . / = 7.5 Hz, H^); '^C 
N M R (CD3OD, 125 MHz, ' H decoupled 5 0 0 MHz) 5 3 0 . 4 ( 3 C , C^" ) , 3 4 . 8 ( I C , C), 4 1 . 8 1^3^  
( I C , CH3), 118.2 ( I C , C ' \ 120.5 ( I C , C), 120.8 ( I C , C°), 121.2 ( I C , C^, 122.6 ( I C , 
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C \ 135.4 ( I C , C \ 145.9 ( I C , C^), 149.1 ( I C , C ' ) , 151.1 ( I C , C*), 152.4 ( I C , C " ) , 
156.3 (1C,C ' - ) , 173.8 ( I C , C^). 
6-fert-Butyl-1 -methyl-1 H-9-oxa-1 -aza-anthracene-2,10-dione (5) 
O ^ N 
A solution o f 6-/e/-/-butyl-l-methyl-9-oxa-l-aza-anthracen-lO-one chloride 4 (0.361 g, 
1.18 mmol) in H2O (10 ml) was added dropwise over 30 min, to a stirred solution of 
potassium hexacyanoferrate ( I I I ) (1.16 g, 3.54 mmol) in H2O (6 ml), at 0 °C. This was 
followed by the dropwise addition o f a solution of NaOH (0.850 g, 21.2 mmol) in H2O 
(10 ml) to the stirred solution over 30 min. The solution was allowed to warm to rt and 
stirred for 8 h. The solution was acidified to pH 3 by the addition of cone. H2SO4 (aq) to 
afford a green precipitate. The precipitate was filtered, dissolved in CHCI3 (50 ml) and 
washed with H2O (2 x 50 ml). The organic phase was separated, dried over MgS04, 
filtered and the solvent removed under reduced pressure to yield the title compound 5 as a 
red coloured solid (0.251 g, 0.872 mmol, 74 % ) ; m.p. 243-244 °C; ' H NMR (CDCl3 , 500 
MHz) 5 1.41 (9H, s, 'Bu CH3), 3.76 (3H, s, CH3), 6.54 ( I H , d , . / = 9.5 Hz, H^), 7.47 ( I H , 
d, J = 8.5 Hz, H ' \ 7.79 (1H, dd, J = 9.0; 2.0 Hz, H \ 8.21 (1H, d, J = 9.5 Hz, H^), 8.29 
( I H , d , . / = 2.0 Hz, H^); '^C N M R (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 28.5 
( I C , CH3), 31.6 (3C, C " ) , 35.2 ( I C , C ' \ 102.8 ( I C , C^), 116.0 ( I C , C^), 117.3 ( I C , C ' \ 
121.6 ( I C , C^), 122.9 ( I C , C') , 132.3 ( I C , C') , 135.7 ( I C , C \ 149.7 ( I C , C^), 152.0 ( I C , 
C " ) , 156.5 ( I C , C'^), 162.3 ( I C , C') , 174.2 ( I C , C^); MS (ES"") m/z 284.3 (100 %, [ M + 
H]") ; HRMS (ES^) m/z found 284.1281 [ M + H]^ C,7H,803N, requires 284.1281; 
C|7H,7N03 (%): calcd C 72.07, H 6.05, N 4.94; found C 72.02, H 5.99, N 4.90. 
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6-ferf-Butyl-2-chloro-9-oxa-1 -aza-anthracen-10-one (6) 
A stirred solution o f 6-/e/-/-butyl-l-methyl-lH-9-oxa-l-aza-anthracene-2,10-dione 5 
(0.180 g, 0.636 mmol) in POCl3 (10 ml) and A',A^-dimethylaniline (0.30 ml , 0.313 g, 2.59 
mmol) was heated at reflux, for 18 h. The mixture was allowed to cool to rt and slowly 
added dropwise to iced water (300 ml) in a well ventilated fumehood. The aqueous 
solution was extracted with CHiCU (2 x 200 ml) and the organic phases combined. The 
organic phase was washed with 0.1 M K2CO3 (aq) (100 ml) , dried over K2CO3, filtered and 
the solvent removed under reduced pressure. The residue was dried onto silica and 
purified by column chromatography on silica (gradient elution: Hexane to 10 % EtOAc : 
Hexane, utilising 1 % EtOAc increments) to yield the title compound 6 as a pink coloured 
solid (0.090 g, 0.313 mmol, 49 % ) ; Rv = 0.33 (Silica, Hexane - EtOAc, 9 : 1 v/v); m.p. 
132-133 °C; ' H N M R ( C D C I 3 , 500 MHz) 5 1.41 (9H, s, 'Bu CH3) , 7.43 ( I H , d , . / = 8.0 
Hz, H^), 7.54 ( I H , d, J = 9.0 Hz, H ' ° ) , 7.86 ( I H , dd, J = 9.0; 2.5 Hz, H^), 8.27 (1H, d, J = 
2.5 Hz, H^), 8.65 ( I H , d , 7 = 8.0 Hz, H^); '^C N M R (CDCI3, 125 MHz, ' H decoupled 500 
MHz) 5 31.5 (3C, C"*), 35.1 ( I C , C ' \ 115.6 ( I C , C \ 118.4 ( I C , C " \ 121.1 ( IC , C^), 
121.9 ( I C , C^), 122.7 ( I C , C^), 134.1 ( I C , C\ 139.9 ( I C , C^), 148.8 ( I C , C\ 153.8 ( I C , 
C " ) , 155.6 ( I C , C'^), 159.7 ( I C , C"), 177.2 ( I C , C^). 
7.1.1 Pyridyl-azaxanthone 
2-Methyl-6-tributylstannanyl-pyridine ^ (7) 
«-Butyllithium (1.94 ml , 3.13 mmol, 1.6 M in hexane) was added dropwise to a stirred 
solution o f 2-bromo-6-methylpyridine (0.50 g, 0.33 ml , 2.90 mmol) in anhydrous THF 
(15 ml), at - 78 "C. After stirring the solution at - 78 °C for 2 h, tributyltinchloride (0.94 
ml, 3.49 mmol) was added dropwise, and the mixture stirred while allowed to warm to rt. 
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H2O (20 ml) was poured into the reaction mixture and the phases separated. The aqueous 
phase was extracted with diethyl ether (2 x 20 ml). The combined organic extracts were 
dried over MgS04, filtered, and the solvent removed under reduced pressure to yield the 
crude title compound 1. The material was used directly without any further purification. 
6-ferf-Butyl-2-(6-methyl-pyridin-2-yl)-9-oxa-1 -aza-anthracen-10-one (8) 
Procedure A; Stille Cross-Coupling 
6-^e?-/-Butyl-2-chloro-9-oxa-anthracen-l 0-one 6 (0.201 g, 0.696 mmol) and 6-methyl-2-
(tributylstannyl)pyridine 7 (0.293 g, 0.766 mmol) were added to a Schlenk tube which 
was evacuated and back filled with argon three times. Degassed toluene (5 ml) was added 
to the vessel which was then evacuated and back filled with argon five times. 
Tetrakis(triphenylphosphine)palladium (0) (0.040 g, 0.034 mmol) was added to the 
solution under an atmosphere o f argon. The reaction mixture was stirred and heated at 
reflux, under argon, for 16 h. The reaction mixture was allowed to cool to rt, filtered, and 
the solute concentrated under reduced pressure to afford a residual brown oi l . The crude 
material was triturated with diethyl ether (10 ml) to yield a fine precipitate in red solute. 
The solvent was decanted and the solid dried under vacuum to yield the title compound 8 
as a colourless solid (0.145 g, 0.422 mmol, 61 % ) ; m.p. 191-192 "C; ' H N M R (CDCI3, 
700 MHz) 5 1.37 (9H, s, 'Bu CH3), 2.60 (3H, s, CH3), 7.18 ( I H , d, J = 8.0 Hz, H^ ), 7.53 
( I H , d, J = 8.0 Hz, W\ 7.69 ( I H , t , J = 8.0 Hz, H'*"), 7.79 ( I H , dd , .y= 8.0; 2.0 Hz, H\ 
8.26 ( I H , d, . / = 2.0 Hz, H ^ 8.29 ( I H , d, J = 8.0 Hz, H^ ), 8.54 ( I H , d, . / = 8.5 Hz, H^), 
8.74 ( I H , d, J - 8.5 Hz, H^); '^C N M R (CDCI3, 176 MHz, ' H decoupled 700 MHz) 5 
24.8 ( I C , CH3), 31.5 (3C, C'^), 35.0 ( I C , C ' ^ 116.4 ( I C , C \ 118.3 ( I C , C'°) , 118.5 
( I C , C^), 119.7 ( I C , C^"), 121.3 ( I C , C^), 122.7 ( I C , C^), 124.9 ( I C , C^'), 133.6 ( I C , C \ 
137.4 ( I C , C" ), 138.2 ( I C , C \ 148.0 ( I C , C \ 153.6 ( I C , C' ), 154.2 ( IC , C " ) , 158.6 
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( I C , C^"), 160.2 ( I C , C'), 160.6 ( I C , C'^), 177.8 ( I C , C^); MS (ES^) m/z 345.2 (100 %, 
[ M + H f ) ; HRMS (ES^) m/z found 345.1596, C22H2,02N2 requires 345.1597, [ M + H ] \ 
Procedure B; Suzuki-Miyaura Cross-Coupling 
6-/er/-Butyl-2-chloro-9-oxa-anthracen-10-one 6 (0.040 g, 0.14 mmol), 6-methyl-2-
pyridineboronic acid A^-phenyldiethanolamine ester (0.047 g, 0.17 mmol) and CS2CO3 
(0.054 g, 0.17 mmol) were added to a Schlenk tube which was evacuated and back filled 
with argon three times. Degassed 1,4-dioxane (4 ml) was added to the vessel, which was 
evacuated and back filled wi th argon three times. Pd2(dba)3 (2 mg, 1.5 % mol) and 
P('BU)3 (1 mg, 3.6 % mol) were added to the reaction mixture, which was stirred and 
heated at 85 °C, under argon, for 18 h. After 18 h a further addition o f Pd2(dba)3 (2 mg, 
1.5 % mol) and P('Bu)3 (1 mg, 3.6 % mol) were introduced to the vessel, with heating 
continued at 85 "C for a further 24 h. The reaction mixture was allowed cool to rt and the 
solvent removed under reduced pressure. The residue was dissolved in diethyl ether (50 
ml) and washed with H2O (50 ml), followed by brine (50 ml) . The organic phase was 
dried over K2CO3, filtered and the solvent removed under reduced pressure. The crude 
material was purified by column chromatography on silica (gradient eludon: CH2CI2 to 8 
% CH30H:CH2Cl2, utilising 0.1 % C H 3 O H increments). The product was recrystallised 
f rom warm EtOH and dried under vacuum to yield the title compound 8 as a colourless 
solid (0.008 g, 0.015 mmol, 16 % ) ; RF = 0.38 (Silica, C H 3 O H - CH2CI2, 9 : 1 v/v). 
Characterisation as reported in procedure A. 
2-(6-Bromomethyl-pyridin-2-yl)-6-terf-butyl-9-oxa-1-aza-anthracen-10-one 
(9) 
O 
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Procedure A: 
A stirred mixture o f 6-/tf/-/-butyl-2-(6-methyl-pyridin-2-yl)-9-oxa-l-aza-anthracen-10-one 
8 (0.200 g, 0.581 mmol), A^-bromosuccinimide (0.129 g, 0.725 mmol) and benzoyl 
peroxide (0.010 g, 0.041 mmol) in CCI4 (5 ml) was heated at reflux, for 16 h. The 
reaction progress was monitored by ' H N M R analysis. After 8 h, A'-bromosuccinimide 
(0.100 g, 0.562 mmol) and dibenzoyl peroxide (0.010 g, 0.041 mmol) were added to the 
reaction mixture, which was heated at reflux for a further 16 h. The reaction mixture was 
allowed to cool to rt, filtered and the solvent removed under reduced pressure to yield a 
yellow residue. The crude materia! was purified by column chromatography on silica 
(using 100 % CH2CI2 elution) to yield the title compound 9 as a colourless solid (0.101 g, 
0.406 mmol, 41 % ) ; /?F = 0.35 (Silica, CH2CI2, 100 v) ; m.p. 186-187 "C; ' H N M R 
( C D C I 3 , 500 MHz) 5 1.42 (9H, s, 'Bu CH3) , 4.66 (2H, s, CHjBr ) , 7.56 ( I H , d, 7 = 7.5 Hz, 
H^"), 7.60 (1H, d, J = 9.0 Hz, H"^), 7.85 (1H, dd , . / = 8.5; 2.5 Hz, H^), 7.90 (1H, t , . / = 8.0 
Hz, H"*"), 8.32 ( I H , d, J = 2.5 Hz, H ^ 8.48 ( I H , d,J= 8.0 Hz, H^"), 8.63 ( I H , d, J = 8.0 
Hz, H^), 8.82 ( I H , d, J = 8.0 Hz, H^); '^C N M R ( C D C I 3 , 126 MHz, ' H decoupled 500 
MHz) 6 31.6 (3C, C'^), 34.0 ( I C , CH2Br) , 35.1 ( I C , C'^), 116.8 ( I C , C \ 118.3 ( I C , C'°), 
118.7 ( I C , C^), 121.3 ( I C , C^), 121.8 ( I C , C^'), 122.8 ( I C , C^), 125.1 ( IC , C^"), 133.8 
( I C , C^), 138.4 ( I C , C*), 138.6 ( I C , C^), 148.2 ( I C , C \ 154.0 ( I C , C' ), 154.2 ( I C , 
C " ) , 157.0 ( I C , C^), 160.0 ( I C , C') , 160.2 ( I C , C'^), 177.9 ( I C , C') ; MS (ES^) m/z 
423.2 (100 %, [ M + H]^); HRMS (ES^) m/z found 423.0700, C22H2o02N2^'^Br, requires 
423.0702, [ M + H f . 
Procedure B: 
A solution o f 6-/er/-butyl-2-(6-dibromomethyl-pyridin-2-yl)-9-oxa-I-aza-anthracen-10-
one 10 (0.060 g, 0.120 mmol), 'Pr2NEt (0.062 g, 0.084 m l , 0.480 mmol) and diethyl 
phosphite (0.066 g, 0.062 ml , 0.478 mmol) in anhydrous THE (5 ml), was stirred at rt, for 
16 h. The solvent was removed under reduced pressure and the residue partitioned 
between C H C I 3 (10 ml) and H2O (10 mi). The organic phase was separated and 
concentrated under reduced pressure to afford a residual o i l . The crude material was 
purified by column chromatography on silica (using 100 % CH2CI2 elution), to yield the 
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title compound 9 as a colourless solid (0.042 g, 0.095 mmol, 79 % ) . Characterisation as 
reported in procedure A. 
6-fert-Butyl-2-(6-dibromomethyl-pyridin-2-yl)-9-oxa-1-aza-anthracen-10-one 
(10) 
O 
B r " "Br 
6-/er/-Butyl-2-(6-dibromomethyl-pyridin-2-yl)-9-oxa-l-aza-anthracen-l 0-one 10 was 
isolated using an identical procedure to that described for 2-(6-bromomethyl-pyridin-2-
yl)-6-rerr-butyl-9-oxa-l-aza-anthracen-10-one 9. The procedure yielded the title 
compound 10 as a colourless solid (0.061 g, 0.119 mmol, 33 % ) ; Rr = 0.71 (Silica, 
CH2CI2, 100 v); ' H N M R (CDCI3, 500 MHz) 5 1.41 (9H, s, 'Bu CH3), 6.78 ( I H , s, 
CHBr2), 7.58 ( I H , d, . / = 8.5 Hz, H ' \ 7.84 ( I H , dd, . / = 9.0; 2.5 Hz, U\ 7.92 ( I H , d, J = 
8.0 Hz, H^ ), 7.98 ( I H , t, J = 8.0 Hz, H'*"), 8.30 ( I H , d, J = 2.5 Hz, H\ 8.50 ( I H , d, ./ = 
7.5 Hz, H^'), 8.59 ( I H , d, J = 8.0 Hz, H\ 8.81 ( I H , d,J= 8.0 Hz, H^); '^C NMR (CDCl3 , 
126 MHz, ' H decoupled 500 MHz) 5 31.6 (3C, C'"), 35.1 ( I C , C'^), 41.6 ( I C , CHBr2), 
116.9 ( I C , C^), 118.3 ( I C , C ' \ 118.7 ( I C , C^), 121.3 ( I C , C^), 122.8 ( I C , C^), 122.9 
( I C , C^ ), 123.6 ( I C , C^ ), 133.9 ( I C , C \ 138.7 ( I C , C \ 139.1 ( I C , C^ ), 148.3 ( I C , C^), 
152.7 ( I C , C^'), 154.2 ( I C , C " ) , 159.0 ( I C , C^"), 159.1 ( I C , C') , 160.2 ( IC , C ' \ 177.8 
( I C , C^); MS (ES") m/z 503.2 (100 %, [ M + H]^). 
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7.1.2 Pyrazoyl-azaxanthone 
6-fe/t-Butyl-2-(3-methyl-pyrazol-1 -yl)-9-oxa-1 -aza-anthracen-10-one (11) 
O 
Sodium hydride (0.030 g, 1.25 mmol) was added to a stirred solution o f 3-methylpyrazole 
(0. 880 g, 1.07 mmol) in anhydrous THF (5 ml), under an atmosphere o f argon. A 
solufion o f 6-/£f/-/-butyl-2-chloro-9-oxa-anthracen-l 0-one 6 (0.281 g, 0.972 mmol) in 
anhydrous THF (5 ml) was added to the reaction mixture, which was heated at 65 "C, for 
16 h. The reaction mixture was allowed to cool to rt and H2O (10 ml) added to the 
solution to induce precipitation. The precipitate was collected via centrifugation and the 
resultant solid triturated with a minimum volume o f diethyl ether (10 ml) . The solvent 
was decanted and the solid dried under vacuum to yield the title compound 11 as a 
colourless solid (0.294 g, 0.882 mmol, 90 % ) ; m.p. 128-130 °C; ' H N M R (CDCI3 , 400 
MHz) 5 1.39 (9H, s, 'Bu CH3) , 2.37 (3H, s, CH3), 6.31 ( I H , d, J = 3.0 Hz, H ' ), 7.51 ( I H , 
d, . / = 9.0 Hz, H " ' ) , 7.80 ( I H , dd, J = 9.0; 3.0 Hz, H \ 7.99 ( I H , d, . / = 8.5 Hz, H^), 8.27 
( I H , d, J = 3.0 Hz, R \ 8.51 ( I H , d , . / = 3.0 Hz, H ' ), 8.72 ( I H , d , . / = 8.5 Hz, H^); '^C 
N M R (CDCI3 , 100 MHz, ' H decoupled 400 MHz) 5 14.2 ( I C , CH3) , 31.6 (3C, C ' \ 35.1 
( I C , C ' \ 109.7 ( I C , C-), 110.1 ( I C , C-"), 113.9 ( I C , C \ 118.1 ( I C , C"'), 121.4 ( I C , 
C^), 122.7 ( I C , C') , 129.0 ( I C , C' ) , 133.4 ( I C , C ^ 140.1 ( I C , C \ 148.3 ( I C , C \ 153.7 
( I C , C " ) , 153.9 ( I C , C " ) , 154.0 ( I C , C^"), 160.0 ( I C , C') , 177.0 ( I C , C^); MS (ES^) m/z 
334.1 (100 %, [ M + H]^) ; HRMS (ES^) m/z found 334.1551 [ M + H]^ C20H20O2N3 
requires 334.1550. 
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2-(3-Bromomethyl-pyrazol-1-yl)-6-te/t-butyl-9-oxa-1-aza-anthracen-10-one 
(12) 
O 
Procedure A: 
A stirred mixture o f 6-/£'r/-butyl-2-(3-methyl-pyrazol-l-yl)-9-oxa-l-aza-anthracen-10-one 
11 (0.212 g, 0.636 mmol), iV-bromosuccinimide (0.113 g, 0.635 mmol) and benzoyl 
peroxide (0.010 g, 0.041 mmol) in CCU (15 ml) was heated at reflux, for 16 h. The 
reaction mixture was allowed to cool to rt, filtered and the solvent removed under 
reduced pressure to afford a residual yellow oi l . The crude material was purified by 
column chromatography on silica (using 100 % CH2CI2 elution) to yield the title 
compound 12 as a colourless solid (0.148 g, 0.362 mmol, 56 % ) ; R\- = 0.28 (Silica, 
CH2CI2, 100 v); m.p. 184-185 "C; ' H N M R ( C D C I 3 , 500 MHz) 6 1.42 (9H, s, 'Bu CH3), 
4.56 (2H, s, CH2Br) , 6.62 ( I H , d , . / = 2.5 Hz, H^"), 7.56 ( I H , d , . / = 9.0 Hz, H ' ° ) , 7.85 
( I H , dd, J = 9.0; 2.5 Hz, H \ 8.06 ( I H , d, . / = 8.0 Hz, H^), 8.31 ( I H , d, . / = 2.5 Hz, H^), 
8.63 ( I H , d , . / = 2.5 Hz, H ' ), 8.80 ( I H , d , . / = 8.5 Hz, H^); '^C N M R ( C D C I 3 , 125 MHz, 
' H decoupled 500 MHz) 5 24.6 ( I C , CH2Br) , 31.6 (3C, C'^), 35.1 ( I C , C ' \ 109.7 ( I C , 
C- ) , 110.0 ( I C , C-), 114.6 ( I C , C^), 118.1 ( I C , C'°), 121.4 ( I C , C^), 122.8 ( I C , C \ 
129.8 ( I C , C'"), 133.6 ( I C , C \ 140.5 ( I C , C \ 148.6 ( I C , C*), 153.3 ( I C , C " ) , 153.7 
( I C , C^ ), 153.9 ( I C , C ' \ 159.9 ( I C , C') , 177.0 ( I C , C^); MS (ES^) m/z 409.3 (100 %, 
[ M + H]^); HRMS (ES^) m/z found 434.0475 [ M + Na]^ C2oH,802N3^'^Br,^^Nai requires 
434.0475. 
Procedure B: 
A solution o f 6-/er/-butyl-2-(3-dibromomethyl-pyrazol-l-yl)-9-oxa-l-aza-anthracen-10-
one 13 (0.150 g, 0.307 mmol), 'Pr2NEt (0.157 g, 0.211 ml , 1.22 mmol) and diethyl 
phosphite (0.168 g, 0.157 ml , 1.22 mmol) in anhydrous THF (10 ml) was stirred at rt, for 
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16 h. The solvent was removed under reduced pressure and the residue partitioned 
between C H C I 3 (10 ml) and H2O (10 ml). The organic phase was separated and 
concentrated under reduced pressure. The crude material was purified by column 
chromatography on silica (using 100 % CH2CI2 elution) to yield the title compound 12 as 
a colourless solid (0.085 g, 0.208 mmol, 67 % ) . Characterisation as reported in 
procedure A. 
6-ferf-Butyl-2-(3-dibromomethyl-pyrazol-1-yl)-9-oxa-1-aza-anthracen-10-one 
(13) 
6-/eA-/-Butyl-2-(3-dibromomethyl-pyrazol-1 -yl)-9-oxa-1 -aza-anthracen-10-one 13 was 
isolated using an identical procedure to that described for 2-(3-bromomethyl-pyrazol-l-
yl)-6-/er/-butyl-9-oxa-l-aza-anthracen-10-one 12. The procedure yielded the title 
compound 13 as a colourless solid (0.970 g, 0.199 mmol, 31 % ) ; /?F = 0.33 (Silica, 
CH2CI2, 100 v) ; ' H N M R ( C D C I 3 , 500 MHz) 5 1.42 (9H, s, 'Bu CH3) , 6.79 ( I H , s, 
CHBr2) , 6.89 ( I H , d,J= 2.5 Hz, H^"), 7.56 (1H, d, 7 = 8.5 Hz, H ' ° ) , 7.85 (1H, dd, J = 8.5; 
2.5 Hz, U \ 8.03 ( I H , d, J = 8.5 Hz, H^), 8.31 ( I H , d, J = 2.5 Hz, H^), 8.67 ( I H , d, J = 
2.5 Hz, H^"), 8.81 ( I H , d , J = 8 . 5 Hz, H^); '^C N M R ( C D C l 3 , 125 MHz, ' H decoupled 500 
MHz) 5 31.0 ( I C , CHBr2) , 31.6 (3C, C'"), 35.1 ( I C , C'^), 108.8 ( I C , C^'), 110.0 ( I C , C"), 
114.9 ( I C , C \ 118.1 ( I C , C \ 121.3 ( I C , C \ 122.8 ( I C , C') , 130.1 ( I C , C^"), 133.8 
( I C , C \ 140.6 ( I C , C^), 148.6 ( I C , C \ 153.1 ( I C , C'^), 153.9 ( I C , C " ) , 157.0 ( I C , 
C ' ) , 159.8 ( I C , C') , 177.0 ( I C , C^); MS (ES*) m/z 486.3 (100 %, [ M + H f ) . 
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7.2 D03A Complexes 
(4,7-bis-fe/t-Butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1 -yl)-acetic 
acid tert butyl ester ^ (16) 
' \ M M N N -
A mixture of cyclen (2.54 g, 14.7 mmol), /erZ-butyl bromoacetate (8.67 g, 44.2 mmol) 
and NaHC03 (3.72 g, 44.2 mmol) in anhydrous CH3CN (75 ml) was stirred at rt, under 
argon, for 24 h. The solution was filtered and the filtrate concentrated under reduced 
pressure to afford a residual orange oi l , which crystallised upon standing. The crude 
material was purified by column chromatography on silica (gradient elution: CH2CI2 to 5 
% CH3OH : CH2CI2, utilising 0.1 % CH3OH increments) to yield the title compound 16 
as a colourless crystalline solid (2.41 g, 4.68 mmol, 32 % ) ; m.p. 179-181 °C; ' H N M R 
(CDCI3, 500 MHz) 5 1.47 (27H, s, 'Boc CH3), 2.88 (12H, br s, cyclen CH2), 3.11 (4H, br 
s, cyclen CH2), 3.30 (2H, s, CH2C02 'Bu), 3.39 (4H, s, CH2C02'Bu), 10.04 ( I H , br s, 
NH) ; '^C N M R (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 28.4 (9C, 'Boc CH3), 30.6-
31.2 (6C, cyclen CH2), 47.8 ( I C , cyclen CH2), 49.4 (2C, CH2CO), 51.4 ( I C , cyclen 
CH2), 58.5 ( I C , CH2CO), 81.9 (2C, 'BoC(q)), 82.1(1C, 'BoC(q)), 169.9 (2C, C = O), 170.8 
( I C , C = O); MS (ES^) m/z 515.6 (100 %, [ M + H f ) . 
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7.2.1 Pyridyl-azaxanthone D03A Complexes 
{4,7-bis-te/t-Butoxycarbonylmethyl-10-[6-(6-fert-butyl-10-oxo-10H-9-oxa-1 -
aza-anthracen-2-yl)-pyridjn-2-ylmethyl]-1,4,7,10-tetraaza-cyclododec-1-yl}-
acetic acid te/t-butyl ester ([L^]) 
A stirred mixture o f (4,7-bis-/e/-/-butoxycarbonylmethyi-l,4,7,10-tetraaza-cyclododec-l-
yl)-acetic acid tert butyl ester 16 (0.032 g, 0.062 mmol), 2-(6-bromomethyl-pyridin-2-yl)-
6-rerr-butyl-9-oxa-l-aza-anthracen-10-one 9 (0.024 g, 0.057 mmol) and CS2CO3 (0.026 g, 
0.080 mmol) in anhydrous CH3CN (5 ml), was heated at reflux, under argon, for 16 h. 
The mixture was allowed to cool to rt, syringe filtered and the filtrate concentrated under 
reduced pressure to afford a residual yellow oi l . The crude material was purified by 
column chromatography on alumina (gradient elution; CH2CI2 to 2 % CH3OH : CH2CI2, 
utilising 0.1 % CH3OH increments) to yield the title compound [ L ' I as a pale yellow 
crystalline solid (0.035 g, 0.042 mmol, 74 % ) ; = 0.22 (Alumina, CH2CI2 - CH3OH, 19 
: 1 v/v); ' H N M R ( C D C I 3 , 700 MHz) 5 1.29 (9H, s, 'Bu C H 3 ) , 1.32 (18H, br s, 'Boc C H 3 ) , 
1.35 (9H, br s, 'Boc CH3), 2.71 (8H, br s, cyclen CH2), 3.24 (8H, br s, cyclen CH2), 3.50 
(4H, br s, CH2C02 'Bu), 3.55 (2H, br s, CH2C02 'Bu), 3.69 (2H, s, CH2 pyridine), 7.25 
( I H , d, J = 8.0 Hz, H ' ), 7.45 ( I H , d, J = 8.5 Hz, H ' ° ) , 7.69 ( I H , t, J = 8.0 Hz, H ' ), 7.71 
( I H , dd, . / = 9.0; 3.0 Hz, H \ 8.17 ( 1 H , d, J = 3.0 Hz, H ^ 8.32 ( I H , d, J = 8.0 Hz, H ^ ) , 
8.36 ( I H , d, J = 7.0 Hz, H"), 8.64 ( I H , d , .y= 8.0 Hz, H^); '^C N M R ( C D C I 3 , 176 MHz, 
' H decoupled 700 MHz) 6 28.3 (3C, C"*), 31.5 (6C, 'Boc C H 3 ) , 35.1 (3C, 'Boc C H 3 ) , 50.6 
(2C, cyclen CH2), 51.8 (2C, cyclen CH2), 56.1 (2C, cyclen CH2), 56.7 (2C, cyclen CH2), 
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57.1 ( I C , CH2 pyridine), 82.4 (4C, C'Bu), 116.4 ( I C , C), 118.2 ( IC , C ' \ 118.3 ( I C , 
C^), 121.0 ( I C , C^"), 121.2 ( I C , C \ 122.6 ( I C , C \ 126.2 ( I C , C'"), 133.6 ( I C , C \ 
137.4 ( I C , C^"), 138.2 ( I C , C^), 148.0 ( I C , C \ 153.6 ( I C , C' ) , 154.2 ( I C , C " ) , 158.6 
( I C , C^"), 160.2 ( I C , C') , 160.6 ( I C , C'"), 177.8 ( I C , C^); MS (ES^) m/z 857.5 (100 %, 
[ M + H]^); HRMS (ES^) m/z found 857.5176 [ M + H]^ C48H69O8N6 requires 857.5171. 
[EuL^] 
N N 
A solution o f {4,7-bis-/£?/-/-butoxycarbonylmethyl-10-[6-(6-/m-butyl-10-oxo-10//-9-oxa-
l-aza-anthracen-2-yl)-pyridin-2-ylmethyl]-l,4,7,10-tetraaza-cyclododec-l-yl}-acetic acid 
rer/-butyl ester [ L ' | (0.035 g, 0.0419 mmol) in CHjCh - TFA (1 : 1 v/v, 2 ml) was stirred 
at rt, in a sealed flask, for 16 h to afford an orange solution. The solvent was removed 
under reduced pressure to yield a glassy solid. The crude material was repeatedly (x 3) 
dissolved in CH2CI2 (5 ml) and the solvent removed under reduced pressure to facilitate 
elimination o f excess acid and tert-huty\ alcohol. The desired ligand, as its TFA salt, was 
examined by ' H N M R to ensure complete ester hydrolysis, with the material used 
immediately for complexation. 
The hydrolysed ligand was dissolved in CH3OH - H2O (1:1 v/v, 4 ml) and 
Eu(OAc)3.6H20 (0.017 g, 0.039 mmol) added to the mixture. The pH of the solution was 
raised to 5.5 by the addition o f 1 M K O H (aq), then stirred and heated at 80 "C, for 15 h. 
The reaction mixture was allowed to cool to rt before raising the pH o f the solution to 
10.0 using dilute K O H (aq). The reaction mixture was stirred for 1 h to allow precipitation 
of excess Eu metal as its hydroxide salt, Eu(0H)3. The solid precipitate was removed by 
syringe filtration and the pH o f the colourless aqueous filtrate lowered to pH 5.5 using a 
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solution o f 1 M HCl (aq). The solvent was removed under reduced pressure using a freeze-
drier to yield a colourless solid. The material was purified by column chromatography on 
neutral alumina (elution; CH2CI2 : CH3OH, 8 : 2 v/v) to yield the title complex [ E U L ' J as 
a colourless solid (0.024 g, 0.028 mmol, 68 % ) ; = 0.41 (Alumina, CH2CI2- CH3OH, 7 
•• 3 v/v); (H2O) = 356 nm; x (H2O) = 1.00 ms; x (D2O) - 1.34 ms; (H2O; pH 7.4; 
?^xc365 n m ) = 1 4 % . 
7.2.2 Pyrazoyl-azaxanthone D03A Complexes 
{4,7-bis-fert-Butoxycarbonylmethyl-10-[1 -(6-ferf-buty 1-10-oxo-10H-9-oxa-1 -
aza-anthracen-2-yl)-1 H-pyrazol-3-ylmethyl]-1,4,7,10-tetraaza-cyclododec-1 -
yl}-acetic acid ferf-butyl ester ([L^]) 
A stirred mixture o f (4,7-bis-/er/-butoxycarbonylmethyl-] ,4,7,10-tetraaza-cyclododec-l-
yl)-acetic acid tert butyl ester 16 (0.075 g, 0.146 mmol), 2-(3-bromomethyl-pyrazol-l-
yl)-6-/er/-butyl-9-oxa-l-aza-anthracen-10-one 12 (0.060 g, 0.146 mmol) and CS2CO3 
(0.050 g, 0.153 mmol) in anhydrous CH3CN (5 ml) was heated at reflux, under argon, for 
16 h. The reaction mixture was allowed to cool to rt, syringe filtered and the filtrate 
concentrated under reduced pressure to afford a residual yellow oi l . The crude material 
was purified by column chromatography on silica (gradient elution; CH2CI2 to 8 % 
CH3OH : CH2CI2, utilising 0.1 % CH3OH increments) to yield the title compound as 
a pale yellow coloured solid (0.090 g, 0.106 mmol, 73 % ) ; = 0.36 (Silica, CH2CI2 -
C H 3 O H , 1 9 : 1 v/v); ' H N M R ( C D C I 3 , 500 MHz) 8 1.40 (9H, s, 'Bu C H 3 ) , 1.51 (27H, br 
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s, 'Boc CH3), 2.67 (8H, br s, cyclen CH2), 3.27 (8H, br s, cyclen CH2), 3.44 (4H, br s, 
CH2C02 'Bu), 3.51 (2H, br s, CH2C02 'Bu), 3.55 (2H, s, CH2-pyrazole), 6.57 ( I H , d, J = 
2.5 Hz, H^"), 7.56 ( I H , d, J - 8.0 Hz, H ' ^ ) , 7.86 (1H, dd, . / = 9.0; 2.5 Hz, H \ 8.23 (1H, d, 
J = 8.0 Hz, H^), 8.27 ( I H , d , . / = 2.5 Hz, H \ 8.57 ( I H , d, . / = 2.5 Hz, H ' ), 8.62 ( I H , d , . / 
= 8.5 Hz, H^); '^C NMR(CDCl3, 125 MHz, ' H decoupled 500 Mz) 5 28.3 (3C, C'"), 31.5 
(6C, 'Bu CH3), 35.1 (3C, C'Bu), 50.6 (2C, cyclen CH2), 51.8 (2C, cyclen CH2), 56.1 (2C, 
cyclen CH2), 56.7 (3C, cyclen CH2; CH2_PyAza), 82.4 (4C, C'Bu), 110.8 ( I C , C^), 110.9 
( I C , C^ ), 114.3 ( I C , C), 118.2 ( 1 C , C ' % 121.1(1C, C^), 122.7 ( I C , C^), 129.6 ( I C , C" ), 
133.9 ( I C , C \ 140.1 ( I C , C^), 148.7 ( I C , C*^ ), 153.6 ( I C , C " ) , 153.9 ( I C , C'^), 155.3 
( I C , C^), 159.8 ( I C , C') , 172.9 (3C, C=Oes,er), 176.9 ( I C , C^); MS (ES^) m/z 846.5 (100 
%, [ M + H]^). 
[TbL^] 
o 
r l J r b ^ . - ^ N - N . 
A solution of {4,7-bis-/£'A-r-butoxycarbonylmethyl-10-[l-(6-/e/-/-butyl-10-oxo-10//-9-oxa-
1 -aza-anthracen-2-yl)-1 //-pyrazol-3 -y Imethyl]-1,4,7,10-tetraaza-cyclododec-1 -y l} -acetic 
acid /er/-butyl ester [ L ^ ] (0.045 g, 0.053 mmol) in CH2CI2 - TFA (2 : 1 v/v, 3 ml) was 
stirred at rt, in a sealed flask, for 16 h. The solvent was removed under reduced pressure 
to yield a glassy solid. The crude material was repeatedly (x 3) dissolved in CH2CI2 (5 
ml) and the solvent removed under reduced pressure to facilitate elimination o f excess 
acid and tert-huty\ alcohol. The desired ligand, as its TFA salt, was examined by ' H 
N M R to ensure complete ester hydrolysis, with the material used immediately for 
complexation. 
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The deprotected ligand was dissolved in CH3OH - H2O (2 : 3 v/v, 5 ml) and 
TbCl3.6H20 (0.010 g, 0.028 mmol) added to the solution. The pH o f the solution was 
raised to 5.4 by the addition o f 1 M KOH (aq), then stirred and heated at 90 "C, for 14 h. 
Over this period the pH o f the solution lowered to 3.4. The pH was adjusted to 5.4 and 
the solution stirred and heated at 90 "C, for a further 16 h. The reaction mixture was 
allowed to cool to rt before raising the pH of the solution to 10.0 using dilute KOH (aq). 
The reaction mixture was stirred for 1 h to allow precipitation o f excess Tb metal as its 
hydroxide salt, Tb(0H)3. The solid precipitate was removed by syringe filtration and the 
pH o f the colourless aqueous filtrate reduced to pH 5.5 using a solution o f 1 M HCl (aq). 
The solvent was removed under reduced pressure using a freeze-drier to yield an off -
white solid. The material was purified by column chromatography on neutral alumina 
(elution; CH2CI2 : CH3OH, 8 : 2 v/v) to yield the title complex [ T b L ^ | as a colourless 
solid (0.026 g, 0.032 mmol, 61 % ) ; Rv = 0.39 (Alumina, CH2CI2 - CH3OH, 7 : 3 v/v); 
W x (H2O) = 350 nm; i (H2O) = 2.24 ms; T (D2O) = 2.65 ms; f i b (H2O; pH 6.0; X,^, 355 
n m ) = 15%. 
[EuL^] 
An analogous procedure to that described for [ T b L " j was followed using {4,7-bis-/er/-
butoxycarbonylmethyl-10-[ 1 -{6-tert-huty\-10-oxo-1 OH-9-oxa-1 -aza-anthracen-2-yl)-1H-
pyrazol-3-ylmethyl]-l,4,7,10-tetraaza-cyclododec-l-yl}-acetic acid tert-huty\ ester [ L ^ | 
(0.024 g, 0.035 mmol) and EUCI3.6H2O (0.014 g, 0.038 mmol) in CH3OH - H2O (1 : 1 
v/v, 6 ml). The procedure yielded the title complex [EuL^] as a colourless solid (0.015 g, 
0.018 mmol, 52 % ) ; (H2O) = 350 nm; x (H2O) = 0.70 ms; x (D2O) = 1.76 ms. 
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7.2.3 Tetraazatriphenylene D03A Complexes 
1-(3-Methyl-10,11,12,13-tetrahydrodlpyrido[3,2-a:2',3'-c]phenazlne)-4,7,10-
tris-ferf-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane * ([L^) 
N N 
N N 
A stirred mixture o f (4,7-bis-/er/-butoxycarbonyImethyl-1,4,7,10-tetraaza-cyclododec-1-
yl)-acetic acid tert butyl ester 16 (0.150 g, 0.290 mmol), 3-chloromethyl-10,11,12,13-
tetrahydrodipyrido-[3,2a:2',3'-c] phenazine (0.112 g, 0.290 mmol) and K2CO3 (0.201 g, 
1.45 mmol) in anhydrous C H 3 C N , was heated at reflux, under argon, for 16 h. The 
reaction mixture was allowed to cool to rt, syringe filtered and the filtrate concentrated 
under reduced pressure. The crude material was purified by column chromatography on 
silica (gradient elution: CH2CI2 to 3.5 % C H 3 O H : CH2CI2, utilising 0.1 % C H 3 O H 
increments) to yield the title compound as a yellow coloured solid (0.169 g, 0.209 mmol, 
72 % ) ; R F = 0.47 (Silica, C H 2 C I 2 - C H 3 O H , 9 : 1 v/v); m.p. 137-139 °C; ' H N M R 
( C D C I 3 , 500 MHz) 5 1.08 (18H, s, 'Boc C H 3 ) , 1.41 (9H, s, 'Boc C H 3 ) , 2.05 (4H, m, H ' ° ; 
H ' ^ ) , 2.25-3.58 (28H, br m, cyclen C H 2 ; H " ; H ' ^ ) , 7.65 ( I H , m, H\ 7.75 ( I H , m, H ' ) , 
8.76 ( I H , dd, . / = 4.5; 1.5 Hz, H^), 9.42 ( I H , m, H ' ) , 9.48 ( I H , m, H^); '^C N M R ( C D C I 3 , 
125 MHz, ' H decoupled at 500 MHz) 6 27.9 (9C, 'Boc C H 3 ) , 50.9-60.4 (8C, cyclen C H 2 ) , 
81.6-82.7 (3C, C H 2 C O ) , 123.6 ( I C , C^), 123.9 ( I C , Ar) , 126.2 ( I C , C Ar) , 127.7 ( IC , 
Ar) , 133.5 ( I C , Ar) , 133.9 ( I C , Ar) , 137.2 ( I C , C^), 137.5 ( I C , C') , 145.8 ( I C , C Ar) , 
146.4 ( I C , Ar) , 151.0 ( I C , C^), 154.2 ( I C , Ar) , 154.5 ( I C , Ar) , 160.4 ( I C , Ar ) , 172.5 
(2C, C = O), 172.9 ( I C , C = O); MS (ES^) m/z 836.4 (100 %, [ M + N a f ) . 
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[EuL^ 
O - i E i T - ^ N 
A solution o f l-(3-methyl-10,l l,12,13-tetrahydrodipyrido[3,2-a:2',3'-c]phenazine)-
4,7,10-tris-^er^butoxycarbonylmethyl-l,4,7,10-tetraazacyclododecane [L^ l (0.037 g, 
0.045 mmol) in CH2CI2 - TFA (2 : 1 v/v, 3ml) was stirred at rt, in a sealed flask, for 8 h 
to afford a red coloured solution. The solvent was removed under reduced pressure to 
yield a glassy solid. The crude material was repeatedly (x 3) dissolved in CH2CI2 (5 ml) 
and the solvent removed under reduced pressure to facilitate elimination o f excess acid 
and /er/-butyl alcohol. The desired ligand, as its TFA salt, was examined by ' H N M R 
analysis to ensure complete ester hydrolysis, with the material used immediately for 
complexation. 
The deprotected ligand was dissolved in CH3OH - H2O (1:1 v/v, 2 ml) and 
Eu(OAc)3.6H20 (0.021 g, 0.049 mmol) added to the solution. The pH of the solution was 
raised to 5.5 by the addition o f 1 M K O H (aq), then stirred and heated at 90 °C, for 22 h. 
The reaction mixture was allowed to cool to room temperature before raising the pH o f 
the solution to 10.0 using dilute K O H (aq). The reaction mixture was stirred for 1 h to 
allow precipitation o f excess Eu metal as its hydroxide salt, Eu(0H)3. The solid 
precipitate was removed by syringe filtration and the pH o f the colourless aqueous filtrate 
reduced to pH 5.5 using a solution o f 1 M HCl (aq). The solvent was removed under 
reduced pressure using a freeze-drier to yield an off-white solid, which was purified by 
column chromatography on neutral alumina (elution; CH2CI2: CH3OH, 8 : 2 v/v) to yield 
the lille complex [EuL^ | as a colourless solid (0.020 g, 0.025 mmol, 56 % ) ; = 0.33 
(Alumina, CH2CI2 - CH3OH, 7 : 3 v/v); >^ax (H2O) = 348 nm; x (H2O) = 1.08 ms; i^Eu 
(H2O; pH 7.4; 348 nm) = 18 %. 
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[GdL^ 
A n analogous procedure to that described for [EuL^] was followed using l-(3-methyl-
10,11,12,13-tetrahydrodipyrido[3,2-a:2',3 '-c]phenazine)-4,7,10-tris-/er/-
butoxycarbonylmethyl-l,4,7,10-tetraazacyclododecane [L"^] (0.043 g, 0.067 mmol) and 
Gd(OAc)3.6H20 (0.025 g, 0.067 mmol) in CH3OH - H2O (1:1 v/v, 2 ml). The procedure 
yielded the title complex [GdL'*] as a pale yellow coloured solid (0.012 g, 0.015 mmol, 
22 % ) ; / ?F = 0.33 (Alumina, CH2CI2- CH3OH, 7 : 3 v/v); (H2O) = 348 nm; MS (ES^) 
m/z 822.3 (100 %, [ M + Na]^). 
7.3 Triamide Complexes 
1,4,7-Tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-ferf-butyl ester ^  
(17) 
A solution o f di-/er/-butyl dicarbonate (6.08 g, 27.8 mmol) in anhydrous CH2CI2 (100 ml) 
was added dropwise to a stirred solution o f cyclen (2.00 g, 11.61 mmol) in anhydrous 
CH2CI2 (300 ml) . The reaction mixture was stirred at rt, for 18 h. The solvent was 
removed under reduced pressure to afford a transparent o i l . The crude material was 
purified by column chromatography on silica (gradient elution: CH2CI2 to 5 % CH3OH : 
CH2CI2, utilising 0.1 % CH3OH increments) to yield the title compound 17 as a 
colourless crystalline solid (3.08 g, 6.51 mmol, 56 % ) ; Rp = 0.29 (Silica, CH2CI2 -
CH3OH, 9 : I , v/v); ' H N M R (CDCI3, 500 MHz) 6 1.42 (18H, s, 'Boc CH3), 1.44 (9H, s, 
'Boc CH3), 2.81 (4H, br s, cyclen CH2), 3.28 (8H, br s, cyclen CH2), 3.60 (4H, br s, 
cyclen CH2); '^C N M R (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 28.9 (6C, 'Boc 
CH3), 29.0 (3C, 'Boc CH3), 46.1 (2C, cyclen CH2), 49.9 (2C, cyclen CH2), 51.2 (4C, 
cyclen CH2), 79.4 (2C, 'Boc(q)), 79.6 ( I C , 'Boc(q)), 155.8 (2C, 'Boc C = O), 156.0 ( I C , 
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'Boc C = O); MS (ES^) m/z 473.3 (100 %, [ M + H]^); HRMS (ES^) m/z found 473.3330 
[ M + H]^ C23H45O6N4 requires 473.3333. 
7.3.1 Pyridyl-azaxanthone Triamide Complexes 
10-[6-(6-terf-Buty 1-10-oxo-10H-9-oxa-1 -aza-anthracen-2-y l)-py ridin-2-
ylmethyl]-1,4,7,10-tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-fert-
butyl ester (18) 
N N 
A stirred mixture o f l,4,7-tetraaza-cyclododecane-l,4,7-tricarboxylic acid tri-/eA-/-butyl 
ester 1 7 (0.117 g, 0.248 mmol), 2-(6-bromomethyl-pyridin-2-yl)-6-/er/-butyl-9-oxa-l-
aza-anthracen-lO-one 9 (0.100 g, 0.236 mmol) and K2CO3 (0.049 g, 0.354 mmol) in 
anhydrous CH3CN (4 ml), was heated at reflux, under argon, for 16 h. The reaction 
mixture was allowed to cool to rt, syringe filtered and the filtrate concentrated under 
reduced pressure to afford a residual yellow oi l . The crude material was purified by 
column chromatography on silica (gradient elution: CH2CI2 to 3 %> CH3OH : CH2CI2, 
utilising 0.1 % CH3OH increments) to yield the title compound 1 8 as a pale yellow 
coloured solid (0.173 g, 0.212 mmol, 90 % ) ; Rf = 0.70 (Silica, CH2CI2 - CH3OH, 49 : 1, 
v/v); ' H N M R (CDCI3, 700 MHz) 6 1.29 (9H, s, 'Bu CH3), 1.32 (9H, s, 'Boc CH3), 1.35 
(18H, br s, 'Boc CH3), 2.71 (4H, br s, cyclen CH2), 3.24 (8H, br s, cyclen CH2), 3.50 (4H, 
br s, cyclen CH2), 3.87 (2H, s, CH2 pyridine), 7.25 ( I H , d, J = 8.0 Hz, H ^ ) , 7.45 ( I H , d, J 
= 8.5 Hz, H ' \ 7.69 ( I H , t,J= 8.0 Hz, H^"), 7.71 ( I H , dd, J = 9.0; 3.0 Hz, H^), 8.17 ( I H , 
d, J - 3.0 Hz, H^), 8.32 ( I H , d, . / = 8.0 Hz, H^) , 8.36 ( I H , d, J = 7.0 Hz, H^), 8.64 ( I H , d, 
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. / = 8.0 Hz, H^); '^C N M R ( C D C I 3 , 176 MHz, ' H decoupled 700 MHz) 5 28.6 (9C. 'Boc 
CH3), 31.5 (3C, C"*), 35.0 ( I C , C'^), 47.3 ( I C , cyclen CH2), 47.7 ( I C , cyclen CH2) , 48.0 
( I C , cyclen CH2), 48.4 ( I C , cyclen CH2) , 50.1 ( I C , cyclen CH2) , 51.1 ( I C , cyclen CH2), 
54.4 ( I C , cyclen CH2) , 55.2 ( I C , cyclen CH2) , 57.1 ( I C , CH2 pyridine), 79.5 (4C, 'Boqo; 
C'^), 116.4 ( I C , C \ 118.2 ( I C , C ' \ 118.3 ( I C , C^), 121.0 ( I C , C^'), 121.2 ( I C , C^), 
122.6 ( I C , C \ 126.2 ( I C , C ' ), 133.6 ( I C , C \ 137.4 ( I C , C^"), 138.2 ( I C , C \ 148.0 
( I C , C^), 153.6 ( I C , C' ), 154.2 ( I C , C " ) , 155.9 (3C, Boc C = O), 158.6 ( I C , C^"), 160.2 
(1C,C ' ) , 160.6 (1C,C'^) , 177.8 ( I C , C') ; MS (ES^) w/z 815.4 (100 %, [ M + H]^); HRMS 
(ES^) m/z found 815.4710 [ M + H]^ C45H63O8N6 requires 815.4710. 
6-tert-Butyl-2-[6-(1,4,7,10-tetraaza-cyclododec-1-ylmethyi)-pyridin-2-yl]-9-
oxa-1-aza-anthracen-10-one (19) 
N N 
N 
H 
A solution o f 10-[6-(6-/eA-/-butyl-10-oxo-10//-9-oxa-l-aza-anthracen-2-yl)-pyridin-2-
ylmethyl]-l,4,7,10-tetraaza-cyclododecane-l,4,7-tricarboxylic acid tri-/er/-butyl ester 18 
(0.173 g, 0.212 mmol) in CH2CI2 - TFA (2 : 1 v/v, 3 ml) was stirred at rt, in a sealed 
flask, for 6 h, to afford an orange solution. The solvent was removed under reduced 
pressure to yield a glassy orange solid. The crude material was repeatedly (x 3) dissolved 
in CH2CI2 (5 ml) and the solvent removed under reduced pressure to facilitate elimination 
of excess acid and /er/-butyl alcohol. The residue was finally taken into KOH(aq) (1 M , 10 
ml) and extracted with CH2CI2 ( 3 x 5 ml). The organic extracts were combined, dried 
over K2CO3, filtered and the filtrate concentrated under reduced pressure to yield the title 
compound 19 as an orange coloured crystalline solid (0.065 g, 0.129 mmol, 94 % ) ; ' H 
N M R (CDCI3, 500 MHz) 5 1.36 (9H, s, 'Bu CH3), 2.54 (4H, s, cyclen CH2), 2.68 (8H, s. 
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cyclen CH2), 2.77 (4H, s, cyclen CH2), 3.85 (2H, s, CH2 pyridine), 7.44 ( I H , d, J = 7.5 
Hz, H^ ), 7.54 ( I H , d, J = 9.0 Hz, H ' \ 7.79 ( I H , dd, J = 8.5; 2.5 Hz, H^"), 7.81 ( I H , t, J = 
7.5 Hz, H \ 8.26 (1H, d, J = 2.5 Hz, H ' ) , 8.38 (1 H, d, J = 7.5 Hz, H^"), 8.62 (1H, d, J = 
8.0 Hz, H^), 8.73 ( I H , d, J = 8.0 Hz, H^); '^C N M R (CDCI3, 126 MHz, ' H decoupled 500 
MHz) 5 31.5 (3C, C'^), 35.0 ( I C , C'^), 45.3 (2C, cyclen CH2), 46.6 (2C, cyclen CH2), 
47.4 (2C, cyclen CH2), 51.8 (2C, cyclen CH2), 60.8 ( I C , CH2 pyridine), 116.4 ( I C , C \ 
118.2 ( I C , C'°) , 118.6 ( I C , C \ 121.0 ( I C , C^"), 121.3 ( I C , C*^ ), 122.6 ( I C , C \ 124.6 
( I C , C^"), 133.7 ( I C , C \ 137.8 ( I C , ), 138.1 ( I C , C^), 148.1 ( I C , C^), 153.5 ( I C , C' ), 
154.2 ( I C , C " ) , 159.7 ( I C , C^), 160.2 ( I C , C') , 160.6 ( I C , C'^), 178.0 ( I C , C^); MS 
(ES^) m/z 289.4 (100 %, [ M + Zn]^^); HRMS (ES"") m/z found 515.3130 [ M + H f ; 
C30H39O2N6 requires 515.3129. 
(S)-M-2-Chloroethanoyl-2-phenylethylamine ^ 
Chloroacetyl chloride (10.5 g, 7.40 ml , 93.0 mmol) was added dropwise to a stirring 
solution o f (5)-l-phenylethylamine (9.40 g, 10.0 ml , 77.50 mmol) and anhydrous NEt3 
(13.0 ml , 93.00 mmol) in anhydrous diethyl ether (70 ml) at - 10 °C, under argon The 
solution was allowed to warm to room temperature then stir for a further 3 h. The reaction 
mixture was washed with H2O (150 ml) followed by HCl(aq) (0.1 M , 150 ml). The organic 
phase was separated, dried over Na2S04, filtered and the filtrate concentrated under 
reduced pressure to afford a colourless solid. Recrystallisation from warm diethyl ether 
yielded the lUle compound as colourless needle-like crystals (10.46 g, 53.09 mmmol, 69 
% ) ; m.p. 95-96 "C; ' H N M R (CDCI3, 500 MHz) 5 1.56 (3H, d , . / - 6.5 Hz, CH3), 4.05 
(2H, dd, . / = 15.5; 8.0 Hz, CH2), 5.15 ( I H , q, J = 7.5 Hz, CH), 6.83 ( I H , br s, NH) , 7.34-
7.39 (5H, m, Ph); '^C N M R (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 21.9 ( I C , 
CH3), 42.9 ( I C , CH2), 49.5 ( I C , CH), 126.4 (2C, Ph(o)), 127.9 ( I C , Ph(p)), 129.1 (2C, 
Ph<ni)), 142.6 ( I C , Ph(q)), 165.2 ( I C , C = O); C10H12CINO (%): calcd C 60.80, H 6.12, N 
7.08; found C 60.06, H 6.15, N 6.94. 
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(/?)-M-2-Chloroethanoyl-2-phenylethylamine 
An analogous procedure to that described for 2-chloro-/V-[(S)-methy!benzyl]ethanamide 
was followed using chloroacetyl chloride (5.25 g, 3.70 ml , 46.5 mmol) and a stirring 
solution o f (/?)-!-phenylethylamine (4.70 g, 5.00 ml , 38.8 mmol) and anhydrous NEt3 
(6.51 m l , 46.52 mmol) in anhydrous diethyl ether (100 ml) at - 10 °C. The procedure 
yielded the title compound as colourless needle-like crystals (3.71 g, 18.83 mmol, 49 % ) . 
Characterisation was identical to that reported for 2-chloro-N-[(S)-
methylbenzylJethanamide. 
2-{4-[6-(6-fe/t-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-py ridin-2-
ylmethyl]-7,10-bis-[((S)-1 -plieny l-ethylcarbamoyl)-methy l]-1,4,7,10-tetraaza-
cyclododec-1 -yl}-/V-((S)-1 -phenyl-ethyl)-acetamide ([L'^) 
N N 
N N 
A stirred mixture o f 6-/er/-butyl-2-[6-(l,4,7,10-tetraaza-cyclododec-l-ylmethyl)-pyridin-
2-yl]-9-oxa-l-aza-anthracen-10-one 19 (0.060 g, 0.116 mmol), (5)-A'-2-chloroethanoyl-2-
phenylethylamine (0.080 g, 0.408 mmol) and K2CO3 (0.064 g, 0.466 mmol) in anhydrous 
CH3CN (5 ml), was heated at reflux, under argon, for 16 h. The resultant mixture was 
allowed to cool to rt, syringe filtered and the filtrate concentrated under reduced pressure 
to afford a residual yellow oi l . The crude material was purified by column 
chromatography on neutral alumina (gradient elution: CH2CI2 to 2 % CH3OH : CH2CI2, 
utilising 0.1 % CH3OH increments) to yield the title compound [L'*] as a free flowing pale 
yellow coloured solid (0.074 g, 0.0741 mmol, 64 % ) ; = 0.21 (Alumina, CH2CI2 -
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CH3OH, 1 9 : 1 , v/v); ' H N M R (CDCI3, 700 MHz) 51.38 (9H, s, 'Bu CH3), 1.45 (9H, br s, 
CH3), 2.60 (8H, br s, cyclen CH2), 2.92 (8H, br s, cyclen CH2), 3.06 (2H, br s, CH2CO), 
3.54 (2H, br s, CH2CO), 3.67 (2H, br s, CH2CO), 3.96 (2H, br s, CH2 pyridine), 4.96 ( I H , 
q, CH), 5.11 (2H, q, CH), 7.11-7.30 (15H, m, Ph), 7.45 ( I H , br s, H^ ), 7.58 ( I H , d , . / = 
9.0 Hz, H"^ ) , 7.70 ( I H , br s, H ' ), 7.82 (1H, dd, J = 9.0; 2.0 Hz, H ^ 8.28 (1H, d , . / = 3.0 
Hz, H ' ) , 8.43 ( I H , br s, H^"), 8.62 ( I H , d, . / = 8.5 Hz, H^), 8.77 ( I H , d, J = 8.5 Hz, H^); 
MS (ES^) m/z 998.6 (100 %, [ M + H f ) ; HRMS (ES^) m/z found 998.5667 [ M + H]^; 
C60H72O5N9 requires 998.5651. 
[ E u L l 
3 CI 
A solufion of 2-{4-[6-(6-/e/'/-butyl-10-oxo-10//-9-oxa-l-aza-anthracen-2-yl)-pyridin-2-
ylmethyl]-7,10-bis-[((S)-l-phenyl-ethylcarbamoyl)-methyl]-l,4,7,10-tetraaza-cyclododec 
.l.yl}.A^.((S)-l-phenyl-ethyl)-acetamide [L'*) (0.040 g, 0.040 mmol) and Eu(OTf)3.6H20 
(0.034 g, 0.041 mmol) in anhydrous CH3CN (1 ml) was heated at reflux, under argon, for 
18 h. The resultant solution was allowed to cool to rt followed by the removal o f solvent 
under reduced pressure to afford a glassy orange solid. CH2CI2 (10 ml) was added to the 
solid, and the mixture sonicated for 10 min. The solvent was then decanted and the solid 
material dissolved in a minimum volume o f CH3CN (0.5 ml) . The solufion was added 
dropwise onto diethyl ether (25 ml) to induce precipitation. The solid material was 
isolated by centrifijgafion, and the process o f induced precipitation repeated twice more 
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to yield the complex as its triflate salt. The o f f white solid was made water soluble by the 
exchange of triflate anions for chloride anions using 'DOWEX 1 x 8 200-400 mesh CV 
resin. The solid material was dissolved in a mixture o f H2O - C H 3 O H (1:1 v/v, 16 ml) 
and 0.8 g o f prepared resin added to the solution, which was stirred at room temperature, 
for 3 h. The resin was removed by filtration, and the filtrate concentrated under reduced 
pressure to yield the title complex \EUL'^] (0.034 g, 0.027 mmol, 68 % ) ; X^ax (H2O) = 356 
nm; x (H2O) = 1.00 ms; T (D2O) = 1.34 ms; (j) (H2O; pH 7.4; A^^ c 365 nm) = 24 %; HPLC 
(Method A ) = 10.9 min. 
7.3.2 Pyrazoyl-azaxanthone Triamide Complexes 
10-[1 -(6-fe/t-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-1 H-py razol-3-
ylmethyl]-1,4,7,10-tetraaza-cyclododecane-1,4,7-tricarboxylic acid tn-tert-
butyl ester (20) 
I N -
A stirred mixture o f l,4,7-tetraaza-cyclododecane-l,4,7-tricarboxylic acid tn-tert-huty\ 
ester 17 (0.045 g, 0.109 mmol), 2-(3-bromomethyl-pyrazol-l-yl)-6-/e/-/-butyl-9-oxa-l-
aza-anthracen-lO-one 12 (0.057 g, 0.119 mmol), K2CO3 (0.019 g, 0.131 mmol) and a 
catalytic amount o f K I (2 mg) in anhydrous C H 3 C N - CH2CI2 ( 1 : 1 , v/v, 5 ml) , was 
heated at reflux, under argon, for 16 h. The reaction mixture was allowed to cool to rt, 
syringe filtered and the filtrate concentrated under reduced pressure to afford a residual 
oi l . The crude material was purified by chromatography on silica (gradient elution: 
CH2CI2 to 3 % C H 3 O H : CH2CI2, ufilising 0.1 % C H 3 O H increments) to yield the title 
compound 2 0 as a pale yellow coloured solid (0.075 g, 0.093 mmol, 85 % ) ; /?F = 0.41 
178 
Chapter Seven: Experimental 
(Silica, CH2CI2 - CH3OH, 24 : 1, v/v); ' H N M R ( C D C I 3 , 500 MHz) 5 1.44 (36H, br s, 3 
'Boc CH3; 'Bu CH3), 2.78 (4H, br s, cyclen CH2), 3.39 (8H, br, cyclen CH2), 3.59 (4H, s, 
cyclen CH2), 3.89 (2H, s, CH2 pyrazole), 6.44 ( I H , d, . / = 3.0 Hz, H^ ) , 7.56 ( I H , d, J = 
8.5 Hz, H ' \ 7.86 (1H, dd, . / = 9.0; 2.5 Hz, H \ 8.04 ( I H , d, .7 = 8.5 Hz, H^), 8.30 (1H, d, 
J = 2.5 Hz, H^), 8.60 ( I H , d , . / = 2.0 Hz, H ' ) , 8.78 ( I H , d, J = 8.5 Hz, H^); '^C N M R 
(CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 28.7 (9C, 'Boc CH3), 31.5 (3C, C ' \ 35.5 
( I C , 47.5 ( I C , cyclen CH2), 47.9 ( I C , cyclen CH2), 48.4 (2C, cyclen CH2), 50.1 
(2C, cyclen CH2), 53.6 ( I C , cyclen CH2), 54.0 ( I C , cyclen CH2), 55.3 ( I C , CH2 
pyrazole), 79.5 (3C, 'BoC(q)), 109.9 ( I C , C^), 110.8 ( I C , C^ ), 114.2 ( I C , C^), 118.1 ( IC , 
C'°), 121.4 ( I C , C^), 122.8 ( I C , C^), 129.0 ( I C , C'"), 133.6 ( I C , C^), 140.3 ( I C , C^), 
148.5 ( I C , C^), 153.6 ( I C , C " ) , 153.9 ( I C , C'^), 155.6 ( I C , C \ 155.9 (3C, 'Boc C = O), 
159.9 ( I C , C ' ) , 177.0 ( I C , C^). MS (ES^) m/z 804.3 (100 %, [ M + H]") . 
6-teft-Butyl-2-[3-(1,4,7,10-tetraaza-cyclododec-1-ylmethyl)-pyrazol-1-yl]-9-
oxa-1-aza-anthracen-10-one (21) 
N - N , 
N 
A solution o f 10-[l-(6-/er/-butyl-10-oxo-10//-9-oxa-1-aza-anthracen-2-yl)-l//-pyrazol-3-
ylmethyl]-l,4,7,10-tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-rer/-butyl ester 2 0 
(0.110 g, 0.137 mmol) in CH2CI2 - TFA (2 : 1 v/v, 3 ml) was stirred at rt, in a sealed 
flask, for 16 h, to afford a red solution. The solvent was removed under reduced pressure 
to yield an orange glassy solid. The crude material was repeatedly (x 3) dissolved in 
CH2CI2 (5 ml) and the solvent removed under reduced pressure to facilitate elimination of 
excess acid and /er/-butyl alcohol. The residue was taken into I M KOH(aq) (15 ml) and 
extracted with CH2CI2 ( 3 x 1 5 ml). The organic extracts were combined, dried over 
K2CO3, filtered and the filtrate concentrated under reduced pressure to yield the title 
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compounds as an orange coloured solid (0.065 g, 0.129 mmol, 94 % ) ; ' H NMR (CDCl3 , 
200 MHz) 6 1.39 (9H, s, 'Bu CH3), 2.70 (4H, br s, cyclen CH2), 2.80 (8H, br s, cyclen 
CH2), 2.85 (4H, br s, cyclen CH2), 3.83 (2H, s, CH2*), 6.51 (1 H,d,J = 3.0 Hz, H^"), 7.54 
( I H , d, J = 8.5 Hz, H"^ ) , 7.82 ( I H , dd, J = 9.0; 2.0 Hz, H \ 8.04 ( I H , d, J = 8.5 Hz, H ' ) , 
8.28 ( I H , d, J= 2.0 Hz, H^), 8.58 ( I H , d , . / = 2.0 Hz, H ' ), 8.74 ( I H , d , . / = 8.5 Hz, H^). 
2-{7-[1 -(6-fe/t-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-1 H-pyrazol-3-
ylmethy l]-4,10-bis-[((S)-1 -pheny l-ethylcarbamoyl)-methy l]-1,4,7,10-tetraaza-
cyclododec-1 -yl}-/V-((S)-1 -phenyl-ethyl)-acetamide ([L^) 
A stirred mixture o f 6-/er/-butyl-2-[3-(l ,4,7,10-tetraaza-cyclododec-1-ylmethyl)-pyrazol-
l-yl]-9-oxa-l-aza-anthracen-10-one 2 1 (0.039 g, 0.078 mmol), (5)-A^-2-chloroethanoyl-2-
phenylethylamine (0.050 g, 0.250 mmol) and CS2CO3 (0.081 g, 0.251 mmol) in 
anhydrous CH3CN (5 ml), was heated at reflux, under argon, for 16 h. The reaction 
mixture was allowed to cool to rt, syringe filtered and the filtrate concentrated under 
reduced pressure to afford an orange glassy solid. The crude material was sonicated in 
diethyl ether (15 ml) to yield a fine pale yellow precipitate which was isolated via 
centrifugation. The material was sonicated in diethyl ether and centrifuged twice more to 
yield the title compound [L^] as a free flowing pale yellow solid (0.062 g, 0.063 mmol, 
81 % ) ; ' H N M R (CDCI3, 500 MHz) 5 1.41 (9H, s, 'Bu CH3), 1.52 (9H, br, CH3), 2.48-
3.12 (20H, br m, cyclen CH2; CH2CONH), 3.77 (2H, s, CH2), 4.05 (2H, s, CH2 pyrazole), 
5.01 (3H, m, 3 x CH), 6.38 ( I H , br s, H^"), 7.03-7.19 (15H, br m, 3 x Ph), 7.54 ( I H , d,J = 
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8.0 Hz, H ' % 7.84 (1H, dd,./ = 8.0 ; 2.0 Hz, u \ 7.96 (1H, d, . / = 8.0 Hz, H^), 8.30 (1H, d, 
J= 2.5 Hz, H^), 8.60 ( IH , d, J = 2.0 Hz, H ' ), 8.81 ( I H , d, J = 8.0 Hz, H^); MS (ES^) m/z 
998.4(100%, [M + H f ) . 
2-{7-[1 -(6-fert-Butyl-10-oxo-10W-9-oxa-1 -aza-anthracen-2-yl)-1 H-pyrazol-3-
ylmethyl]-4,10-bis-[((/?)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododec-1 -y\}-N-((R)-A -phenyl-ethyl)-acetamide 
An analogous procedure to that described for 2-{7-[l-(6-/er/-butyl-10-oxo-10//-9-oxa-l-
aza-anthracen-2-yl)-l//-pyrazol-3-ylmethyl]-4,10-bis-[((S)-l-phenyl-ethylcarbamoyl)-
methyl]-1,4,7,10-tetraaza-cyclododec-1 -y 1}-A^-((S)-1 -phenyl-ethy[)-acetamide [L^] was 
followed using 6-/e/-/-butyl-2-[3-(l ,4,7,10-tetraaza-cyclododec-1 -ylmethyl)-pyrazol-l -
yl]-9-oxa-l-aza-anthracen-10-one 21 (0.026 g, 0.052 mmol), (/?)-/V-2-chloroethanoyl-2-
phenylethylamine (0.033 g, 0.165 mmol) and CS2CO3 (0.054 g, 0.167 mmol) in 
anhydrous CH3CN (5 ml). The procedure yielded the title compound as a free flowing 
pale yellow solid (0.037 g, 0.038 mmol, 74 % ) . Characterisation was identical to that 
reported for 2-{7-[l-(6-tert-hutyl-10-oxo-1 OH-9-oxa-l-aza-anthracen-2-yl)-1H-pyrazol-
3-ylmethylJ-4,10-hiS'[((S)-l-phenyl-ethylcarbamoyl)-methyl]-1,4, 7, lO-tetraaza-
cyclododec-1-yl}-N-((S)-I-phenyl-ethyl)-acetamide [L^J. 
( S S S ) - [ T b L ^ 
3 + 
N N 
3 CI 
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A stirred mixture of 2-{7-[l-(6-/£'/-/-butyl-10-oxo-10//-9-oxa-l-aza-anthracen-2-yl)-l//-
pyrazol-3-ylmethyl]-4,10-bis-[((S)-1 -phenyl-ethy]carbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododec-l-yl}-AA-((S)-l-phenyl-ethyl)-acetamide [L^| (0.044 g, 0.044 mmol) and 
Tb(OTf)3.6H20 (0.030 g, 0.049 mmol) in anhydrous CH3CN (1 ml) was heated at reflux, 
under argon, for 16 h. The resultant solution was allowed to cool to rt followed by the 
removal of solvent under reduced pressure to afford a glassy orange solid. CH2CI2 (5 ml) 
was added to the solid, and the mixture sonicated for 10 min. The solvent was then 
decanted and the solid material dissolved in a minimum volume of CH3CN (0.4 ml). The 
solution was added dropwise onto diethyl ether (15 ml) to induce precipitation. The solid 
material was isolated by centrifugation, and the process of induced precipitation repeated 
twice more to yield the complex as its triflate salt. The off white solid was made water 
soluble by the exchange of triflate anions for chloride anions using 'DOWEX 1 x 8 200-
400 mesh CF resin. The solid material was dissolved in a mixture of H2O - CH3OH (1:1 
v/v, 10 ml) and 0.5 g of prepared resin added to the solution, which was stirred at room 
temperature, for 3 h. The resin was removed by filtration, and the filtrate concentrated 
under reduced pressure to yield the title complex (SSS)-[ThV'] as a colourless solid 
(0.040 g, 0.030 mmol, 69 % ) ; K,^ (H2O) = 348 nm; x (H2O) = 2.00 ms; T (D2O) = 2.38 
ms; (f)Tb (H2O; pH 6.0; }iexc 355 nm) = 46 %; HPLC (Method A) /R = 11.0 min. 
( S S S ) - [ E u L ^ 
An analogous procedure to that described for (55'5)-|TbL^) was followed using 2-{7-[ l -
(6-tert-huty]-\0-oxo-10H-9-o\a-1 -aza-anthracen-2-yl)- l//-pyrazol-3-ylmethyl]-4,10-bis-
[((S)-1 -phenyl-ethy lcarbamoyl)-methyl]-1,4,7,10-tetraaza-cyclododec-1 -y 1} -A^-((S)-1 -
phenyl-ethyl)-acetamide [L^J (0.042 g, 0.042 mmol) and Eu(OTf)3.6H20 (0.033 g, 0.046 
mmol) in anhydrous CH3CN (1 ml). Following anion exchange, the procedure yielded the 
title complex (SSS)-\EuL^] as a colourless solid (0.027 g, 0.022 mmol, 54 % ) ; )tniax (H2O) 
= 348 nm. 
(RRR)-\TbL^ 
An analogous procedure to that described for (555)-[TbL"''] was followed using 2-{7-[ l -
(6-tert-hutyl-10-oxo-10//-9-oxa-1 -aza-anthracen-2-y 1)-1 //-pyrazol-3-y lmethyl]-4,10-bis-
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[((/?)-1 -pheny 1-ethy Icarbamoy l)-methyl]-1,4,7,10-tetraaza-cyclododec-1 -y 1} -7V-((/?)-1 -
phenyl-ethyl)-acetamide (0.021 g, 0.021 mmol) and Tb(OTf)3.6H20 (0.014 g, 0.023 
mmol) in anhydrous C H 3 C N (1 ml). Following anion exchange, the procedure yielded the 
title complex (RJiR)-[JhL^\ as a colourless solid (0.017 g, 0.013 mmol, 60 % ) . 
Photophysical characterisation was identical to that reported for {SSS)-\Th\J'\. 
An analogous procedure to that described for (555)-[TbL"''| was followed using 2-{7-[ l -
{6-tert-buty\-10-oxo-10//-9-oxa-1 -aza-anthracen-2-y 1)-1 //-py razol -3-ylmethy l]-4,10-bis-
[((/?)-1 -phenyl-ethylcarbamoyO-methyl]-1,4,7,10-tetraaza-cyciododec-1 -y\}-N-{{R)-1 -
phenyl-ethyl)-acetamide (0.011 g, 0.011 mmol) and Eu(OTf)3.6H20 (0.008 g, 0.012 
mmol) in anhydrous CH3CN (1 ml). Following anion exchange, the procedure yielded the 
title complex (RRR)-[E\iV\ as a colourless solid (0.008 g, 0.007 mmol, 66 % ) . 
Photophysical characterisation was identical to that reported for (555)-[EuL^]. 
(S)-2-Amino-3-phenyl-propionic ac id ethyl ester ^ 
O 
HCl(g), generated in situ by dropping cone. H2SO4 into a solution of cone. HCl / NaCl, 
was bubbled through a stirred mixture of (5)-phenylalanine (0.500 g, 3.03 mmol) in 
anhydrous ethanol (30 ml), under argon, for 1 h. The solution was then stirred and heated 
at reflux, under argon, for 24 h. The solution was allowed to cool to rt followed by the 
removal of solvent removed under reduced pressure to yield the hydrochloride salt of the 
title compound, as a colourless crystalline solid, in quantitative yield. ' H N M R ( C D 3 O D , 
500 MHz) 6 1.24 (3H, t, J = 7.0 Hz, CH3), 3.24 (2H, t, J = 7.0 Hz, CHCH2), 4.24 (2H, q, 
J = 7.0 Hz, OCH2), 4.30 ( IH , t, J = 7.0 Hz, CH), 7.15-7.24 (5H, m, Ph); '^ C NMR 
(CD3OD, 125 MHz, ' H decoupled 500 MHz) 5 13.1 (IC, CH3), 36.3 (IC, CH2), 54.1 (IC, 
183 
Chapter Seven; Experimental 
CH), 62.4 (IC, OCH2), 127.8 (IC, Ph(p)), 129.0 (2C, Ph(o/n,)), 129.3 (2C, Ph(o/n,)), 134.2 
(IC, Ph,q)), 168.9 (1C,C = 0) . 
(S)-2-(2-Bromo-acetylamino)-3-phenyl-propionic acid ethyl ester ^ 
\ ^ 0 ^ ^ ^ > k .Br 
o « 
A solution of (S)-2-amino-3-phenyl-propionic acid ethyl ester (0.500 g, 2.18 mmol), 
anhydrous NEta (0.305 ml, 2.18 mmol) and bromoacetyl bromide (0.482 g, 0.208 ml, 
2.40 mmol) in anhydrous THF, was stirred at - 5 "C, under argon, for 16 h. The solvent 
was removed under reduced pressure and the residue dissolved in CH2CI2 (15 ml). The 
organic phase was washed with H2O (20 ml), followed by 1 M HCl (aq) (20 ml). The 
organic phase was then concentrated under reduced pressure to yield the title compound 
as a colourless solid (0.505 g, 1.61 mmol, 74 % ) ; m.p. 32-33 °C; ' H N M R (CDCI3 , 500 
MHz) 5 1.26 (3H, J = 7.0 Hz, CH2CH3), 3.15 (2H, m, CH2Ph), 3.84 (2H, s, CHjBr), 4.18 
(2H, q, J = 7.0 Hz, C H 2 C H 3 ) , 4.83 ( I H , q,./ = 7.0 Hz, CH), 6.93 ( IH , br s, NH), 7.19-
7.28 (5H, m, Ph); '^C N M R (CDCI3 , 125 MHz, ' H decoupled 500 MHz) 5 14.3 (IC, 
CH3) , 28.9 (IC, CHzBr), 38.0 (IC, CHzPh), 54.0 (IC, CH), 62.1 (IC, C H 2 C H 3 ) , 127.5 
(IC, Ph(p)), 128.9 (2C, Ph(o/m)), 129.6 (2C, Ph<o/n.)), 135.6 (IC, Ph(q)), 165.5 (IC, C = O), 
171.1 (1C, ester C = O); M S (ES") 313.9 (100 %, [M + H]^). 
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{S)-2-(2-{4-[1 -(6-feit-Buty 1-10-oxo-10H-9-oxa-1 -aza-anthracen-2-y l)-1 H-
pyrazol-3-ylmethyl]-7,10-bis-[((S)-1-ethoxycarbonyl-2-phenyl-ethyl 
carbamoyl)-methyl]-1,4,7,10-tetraaza-cyclododec-1 -yl}-acetylamino)-3-
phenyl-propionic ac id ethyl ester ( [L^) 
I N - N 
o L J 
A stirred mixture of 6-/er/-butyl-2-[3-(l,4,7,10-tetraaza-cyclododec-l-ylmethyl)-pyrazol-
l-yl]-9-oxa-l-aza-anthracen-10-one 2 1 (0.033 g, 0.065 mmol), (5)-2-(2-bromo-
acetylamino)-3-phenyl-propionic acid ethyl ester (0.064 g, 0.206 mmol) and CS2CO3 
(0.073 g, 0.231 mmol) in anhydrous CH3CN (7 ml) was heated at reflux, under argon, for 
16 h. The resultant mixture was allowed to cool to room temperature, syringe filtered, and 
the filtrate concentrated under reduced pressure to afford an orange glassy solid. The 
crude material was sonicated in diethyl ether (15 ml) to yield a fine pale yellow 
precipitate which was isolated via centrifiigation. The material was sonicated in diethyl 
ether and centrifijged twice more to yield the title compound [L^ | as a free flowing pale 
yellow solid (0.028 g, 0.023 mmol, 36 % ) ; ' H NMR (CDCI3, 400 MHz) 5 1.13 (9H, t,J = 
6.0 Hz, OCH2CH3), 1.35 (9H, s, 'Bu CH3), 2.41-2.60 (12H, br m, cyclen CH2), 2.68-3.08 
(14H, br m, cyclen CH2; CH2CO; CHjPh), 4.02 (2H, s, CH2 pyrazole), 4.06 (6H, t, ./ = 
6.0 Hz, OCH2CH3), 4.76 (3H, q, CH), 6.38 ( IH , br s, H^'), 7.03-7.19 (15H, br m, Ph), 
7.50 ( I H , d,J= 8.0 Hz, H ' \ 7.77 ( I H , dd, J = 8.0 ; 2.0 Hz, H \ 7.94 ( IH , d,J= 8.0 Hz, 
U\ 8.24 ( IH, d, J = 2.5 Hz, H^), 8.52 ( I H , d, . / = 2.0 Hz, H '" ) , 8.92 ( IH , d, . / = 8.0 Hz, 
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H^); MS (ES^) m/z 1203.6 (100 %, [M + H]^); HRMS (ES*) m/z found 1203.6241 [M + 
H]^ C67H83N10O, , requires 1203.6237. 
U b L ^ 
3 + 
3 CI 
A stirred solution of (S)-2-(2-{4-[l-(6-/er^butyl-l 0-oxo-10//-9-oxa-l-aza-anthracen-2-
yl)-l//-pyrazol-3-ylmethyl]-7,10-bis-[((5)-l-ethoxycarbonyl-2-phenyl-ethylcarbamoyl)-
methyl]-1,4,7,10-tetraaza-cyclododec-1 -y 1} -acetylamino)-3-phenyl-propionic acid ethyl 
ester [L*"! (0.013 g, 0.011 mmol) and Tb(OTf)3.6H20 (0.007 g, 0.012 mmol) in 
anhydrous CH3CN (1 ml) was heated at reflux, under argon, for 16 h. The solution was 
allowed to cool to room temperature followed by the removal of solvent under reduced 
pressure to afford a glassy orange solid. CH2CI2 (5 ml) was added to the solid, and the 
mixture sonicated for 10 min. The solvent was then decanted and the solid material 
dissolved in a minimum volume of CH3CN (0.4 ml). The solution was added dropwise 
onto diethyl ether (15 ml) to induce precipitation. The solid material was isolated by 
centrifugation, and the process of induced precipitation repeated twice more to yield the 
complex as its triflate salt. The off white solid was made water soluble by the exchange 
of triflate anions for chloride anions using 'DOWEX 1 x 8 200-400 mesh CI ' resin. The 
solid material was dissolved in a mixture of H2O - CH3OH (1:1 v/v, 10 ml) and 0.5 g of 
prepared resin added to the solution, which was stirred at room temperature, for 3 h. The 
186 
Chapter Seven; Experimental 
resin was removed by filtration, and the filtrate concentrated under reduced pressure to 
yield the title complex [TbL**! as a colourless solid (0.008 g, 0.006 mmol, 56 % ) ; X.niax 
(H2O) = 348 nm, T (H2O) = 2.25 ms; <j),b (H2O; pH 6.0; l^^^ 355 nm) = 54 %; HPLC 
(Method A) /R = 11.2 min. 
[ E u L ^ 
An analogous procedure to that described for |TbL^| was followed using (5)-2-(2-{4-[l-
{6-tert-buty\-\0-oxo-1 OH-9-oxa-1 -aza-anthracen-2-yl)-1 //-pyrazol-3-y lmethyl]-7,10-bis-
[((S)-l-ethoxycarbonyl-2-phenyl-ethylcarbamoyl)-methyl]-l,4,7,10-tetraaza-cyclododec-
l-yl}-acetylamino)-3-phenyl-propionic acid ethyl ester [L^| (0.011 g, 0.009 mmol) and 
Eu(OTf)3.6H20 (0.008 g, 0.012 mmol) in anhydrous CH3CN (1 ml). Following anion 
exchange, the procedure yielded the title complex |EuL^] as colourless solid (0.008 g, 
0.007 mmol, 78 % ) . 
7.3.3 Tetraazatriphenylene Triamide Complexes 
10-(10,11,12,13-Tetrahydro-4,5,9,14-tetraaza-benzo[/)]trlphenylen-6-
ylmethyl)-1,4,7,10-tetraaza-cyclododecane-1,4,7-tr icarboxylic ac id tn-tert-
butyl ester * ( 2 2 ) 
A stirred mixture of l,4,7-tetraaza-cyclododecane-l,4,7-tricarboxylic acid tri-/eA-/-butyl 
ester 17 (0.400 g, 0.848 mmol), 3-chloromethyl-10,ll,12,13-tetrahydrodipyrido-
[3,2a:2',3'-c]-phenazine (0.300 g, 0.901 mmol) and K2CO3 (0.625 g, 4.56 mmol) in 
anhydrous C H 3 C N - CH2CI2 (1:1, 10 ml) was heated at reflux, under argon, for 16 h. The 
resultant mixture was allowed to cool to rt, syringe filtered and the filtrate concentrated 
under reduced pressure to afford a residual yellow oil. The crude material was purified by 
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column chromatography on silica gel (gradient elution: CH2CI2 to 2.5 % CH3OH : 
CH2CI2), utilising 0.1 % CH3OH increments) to yield the title compound as an orange 
crystalline solid (0.55 g, 0.65 mmol, 77 % ) ; Rf = 0.44 (Silica, CH2CI2 - CH3OH, 9 : 1 
v/v); m.p. 114-116 "C; ' H N M R (CDCI3 , 300 MHz) 5 0.71 (27H, br s, 'Boc CH3), 2.04 
(4H, m, H'*'; H ' \ 2.62 (4H, br s, cyclen CH2), 2.75 (8H, br s, cyclen CH2), 2.86 (4H, br 
s, cyclen CH2), 3.23 (4H, br s, H " ; H ' ^ ) , 4.24 (2H, s, CH2 dpqC), 7.67 ( I H , dd, J = 8.0; 
4.5 Hz, U\ 7.72 ( IH , br s, H^) , 9.71 ( IH , br s, H^) , 9.26 (2H, br m, H ' ; H ' ) ; MS (ES^) 
m/z 793.4 (100 %, [M + Na]^); HRMS (ES^) m/z found 793.4379 [M + Na]^ 
C42H5806N8Na requires 793.4377. 
6-(1,4,7,10-Tetraaza-cyclododec-1-ylmethyl)-10,11,12,13-tetrahydro-4,5,9,14-
tetraaza-benzo[b]triphenylene * (23) 
N 
N 
A solution of 10-(10,11,12,13-tetrahydro-4,5,9,14-tetraaza-benzo[6]triphenylen-6-
ylmethyl)-l,4,7,10-tetraaza-cyclododecane-l,4,7-tricarboxylic acid tn-tert-hutyl ester 22 
(0.090 g, 0.122 mmol) in CH2CI2 - TFA (2 : 1 v/v, 3 ml) was stirred at rt, in a sealed 
flask, for 24 h, to afford an orange solution. The solvent was removed under reduced 
pressure to yield a glassy orange solid. The crude material was repeatedly (x 3) dissolved 
in CH2CI2 (5 ml) and the solvent removed under reduced pressure to facilitate elimination 
of excess acid and tert-huty\ alcohol. The residue was finally taken into 1 M KOH ^q) (10 
ml) and extracted with CH2CI2 ( 3 x 1 5 ml). The organic extracts were combined, dried 
over K2CO3, filtered and the filtrate concentrated under reduced pressure to yield the title 
compound 23 as an orange coloured crystalline solid (0.053 g, 0.111 mmol, 96 % ) ; ' H 
NMR (CDCI3, 500 MHz) 5 2.08 (4H, br s, H ' ° ; H '^ ) , 2.62 (4H, br s, cyclen CH2), 2.75 
(8H, br s, cyclen CH2), 2.86 (4H, br s, cyclen CH2), 3.23 (4H, br s, H " ; H ' ^ ) , 4.24 (2H, s, 
CH2 dpqC), 7.73 ( I H , d, J = 8.0 Hz, H ' ) , 8.05 ( IH , d, J = 8.0 Hz, H\ 9.26 ( I H , d,J= 8.0 
Hz, H^), 9.45 (2H, d, . / = 8.0 Hz, H'/H**); '^C NMR (CDCI3 , 125 MHz, ' H decoupled 500 
MHz) 6 22.6 (IC, CH2), 32.6 (IC, CH2), 45.2 (2C, cyclen CH2), 46.3 (2C, cyclen CH2), 
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47.1 (2C, cyclen CH2) , 52.0 (2C, cyclen CH2) , 61.7 (IC, CH2 dpqC), 122.8 (IC, C^), 
123.2 (IC, C'), 125.9 (IC, Ar^q)), 127.0 (IC, Ar(q)), 132.7 (IC, C ^ 133.5 (IC, C'), 137.1 
(IC, Ar(q)), 146.0 (IC, Ar(q)), 146.8 (IC, Ar(q)), 151.3 (IC, C^), 153.3 (IC, Ar(q,), 153.6 
(IC, Ar(q)), 162.3 (lC,Ar(q)). 
2-[4,7-Bis-[((S)-1-phenyl-ethylcarbamoyl)-methyl]-10-(10,11,12,13-
tetrahydro-4,5,9,14-tetraaza-benzo[b]triphenylen-6-ylmethyl)-1,4,7,10-
tetraaza-cyclododec-1 -yl]-A/-((S)-1 -phenyl-ethyl)-acetamide * {[C]) 
N N 
N N 
A Stirred mixture of 6-(l,4,7,10-tetraaza-cyclododec-l-ylmethyl)-10,l l,12,13-tetrahydro-
4,5,9,14-tetraaza-benzo[6]triphenylene 23 (0.050 g, 0.104 mmol), (5)-7V-2-
chloroethanoyl-2-phenylethylamine (0.066 g, 0.332 mmol) and CS2CO3 (0.108 g, 0.332 
mmol) in anhydrous C H 3 C N (5 ml) was heated at reflux, under argon, for 16 h. The 
reaction mixture was allowed to cool to rt, syringe filtered and the filtrate concentrated 
under reduced pressure to afford a residual yellow oil. The crude material was purified by 
column chromatography on neutral alumina (gradient elution: CH2CI2 to 2 % C H 3 O H : 
CH2CI2, utilising 0.1 % C H 3 O H increments) to yield the title compound [L^\ as a pale 
yellow coloured solid (0.075 g, 0.079 mmol, 76 % ) ; = 0.57 (Alumina, CH2CI2 -
C H 3 O H , 99 : 1, v/v); ' H NMR ( C D C I 3 , 500 MHz) 6 1.44 (3H, d, J = 2.5 Hz, CH3), 1.46 
(6H, d, J = 2.5 Hz, CH3) , 2.10 (4H, br s, H ' ° : H ' ^ ) , 2.43-2.62 (16 H, br m, cyclen CH,), 
2.94 (6H, br s, CH2C(0)), 3.25 (4H, br s, H " : H ' ^ ) , 4.05 (2H, s, CH2 dpqC), 5.12 (3H, q, 
J =7.0 Hz, CH), 7.16-7.29 (15H, br s, Ph), 7.74 ( IH , dd,J= 8.0 Hz, H^), 7.82 ( IH , d, J = 
8.0 Hz, H^), 9.20 (1H, dd, J = 8.0; 2.0 Hz, H^), 9.33 (1H, d, J = 8.0 Hz, H ' ) , 9.48 (1H, dd. 
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J = 8.0; 2.0 Hz, H**); '^C NMR (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 22.2 (IC. 
CH3), 22.7 (2C, C"^, C'^), 22.8 (2C, CH3), 32.7 (2C, C " , C ' \ 49.5 (3C, CH), 49.8-52.4 
( l i e , cyclen CH2; CH2CO), 60.4 (CH2 dpqC), 123.4 (IC, C\ 125.1 (IC, C\ 126.3 (IC, 
Ar^q)), 126.4 (IC, Ar(q)), 126.8 ( IC, Ar(q)), 126.9 ( IC, Ar(qO, 127.4 (IC, Ar(q)), 128.1 ( IC. 
Ar(q)), 128.2 (IC, Ar(q)), 128.4 (IC, Ar(q)), 133.2 ( IC, C*), 134.1 (IC, C'), 137.0 (IC, 
Ar(q)), 137.5 (IC, Ar), 143.5 (IC, Ar), 144.2 (IC, Ar), 145.6 (IC, Ar), 146.2 (IC, Ar), 
153.6 (IC, Ar), 153.9 ( IC, Ar), 154.1 (IC, Ar), 159.9 (IC, Ar), 169.1 ( IC, C=0), 170.7 
(2C, C=0); MS (ES^) m/z 954.5 (100 %, [M + H]^); HRMS (ES^) m/z found 954.5505 
[M + HJ^CsyHfisN 1103 requires 954.5506. 
2-[4,7-Bis-[((/?)-1 -phenyl-€thylcarbamoyl)-methyl]-10-(10,11,12,13-
tetrahydro-4,5,9,14-tetraaza-benzo[l)]triphenylen-6-ylmethyl)-1,4,7,10-
tetraaza-cyclododec-1 -yl]-M-((R)-1 -phenyl-ethyl)-acetamide 
An analogous procedure to that described for 2-[4,7-bis-[((5)-l-phenyl-ethylcarbamoyl)-
methyl]-10-( 10,11,12,13-tetrahydro-4,5,9,14-tetraaza-benzo[6]triphenylen-6-ylmethyl)-
1,4,7,10-tetraaza-cyclododec-l-yl]-A'-((5)-l-phenyl-ethyl)-acetamide [L^] was followed 
using 6-(l ,4,7,10-tetraaza-cyclododec-1 -ylmethyl)-10,11,12,13-tetrahydro-4,5,9,14-
tetraaza-benzo[6]triphenylene 23 (0.085 g, 0.177 mmol), (/?)-A^-2-chloroethanoyl-2-
phenylethylamine (0.112 g, 0.564 mmol) and CS2CO3 (0.183 g, 0.564 mmol) in 
anhydrous CH3CN (5 ml). The procedure yielded the title compound as a free flowing 
pale yellow solid (0.117 g, 0.124 mmol, 70 %). Characterisation was identical to that 
reported for 2-[4.7-bis-[((S)-l-phenyl-ethylcarhamoyl)-methyl]-10-(10.11,12,13-
letrahydro-4,5,9,14-tetraaza-benzo[b]triphenylen-6-ylmethyl)-l,4,7,10-tetraaza-
cyclododec- 1 -yl]-N-((S)-1 -phenyl-ethylj-acetamide (L^). 
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(SSS) - [EuL^] ^ 
N N 
3 CI 
A solution of 2-[4,7-bis-[((5)-1-phenyl-ethy lcarbamoyl)-methyl]-10-( 10,11,12,13-
tetrahydro-4,5,9,14-tetraa2a-benzo[/)]triphenylen-6-ylmethy 1)-1,4,7,10-tetraaza-
cyclododec-l-yl]-^-((5)-l-phenyl-ethyl)-acetamide [L^l (0.070 g, 0.073 mmol) and 
Eu(OTf)3.6H20 (0.044 g, 0.073 mmol) in anhydrous CH3CN (1 ml) was heated at reflux, 
under argon, for 18 h. The solution was allowed to cool to rt followed by the removal of 
solvent under reduced pressure to afford a glassy orange solid. CH2CI2 (10 ml) was added 
to the solid, and the mixture sonicated for 10 min. The solvent was then decanted and the 
solid material dissolved in a minimum volume of CH3CN (0.5 ml). The solution was 
added dropwise onto diethyl ether (25 ml) to induce precipitation. The solid material was 
isolated by centrifugation, and the process of induced precipitation repeated twice more 
to yield the complex as its triflate salt. The yellow solid was made water soluble by the 
exchange of triflate anions for chloride anions using 'DOWEX 1 x 8 200-400 mesh CI' 
resin. The solid material was dissolved in a mixture of H2O - CH3OH (1:1 v/v, 20 ml) 
and 1.0 g of prepared resin added to the solution, which was stirred at room temperature, 
for 6 h. The resin was removed by filtration, and the filtrate concentrated under reduced 
pressure to yield the title complex (555)-[EUL'] as a pale yellow coloured solid (0.064 g, 
0.053 mmol, 72 % ) ; MS (ES^) ?n/z 368.1 (100 %, [M]^^); HRMS (ES^) m/z found 
368.1541 [M]^^C57H6703N,,Eu requires 368.1537; ?^ax(H20) = 348 nm; T (H2O) = 1.04 
ms; T (D2O) = 1.59 ms; (j)Eu (H2O; pH 7.4; ?iexc 348 nm) = 16 %; HPLC (Method A) /R = 
10.8 min. 
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(SSS)-\JbC] 
An analogous procedure to that described for (555)-|EuL^| was followed using 2-[4,7-
bis-[((S)-1 -phenyl-ethylcarbamoyl)-methyl]-10-( 10,11,12,13-tetrahydro-4,5,9,14-
tetraaza-benzo[6]triphenylen-6-yImethyl)-1,4,7,10-tetraaza-cyclododec-1 -yl]-A^-((5)-1 -
phenyl-ethyl)-acetamide | L ' | (0.075 g, 0.079 mmol) and Tb(OTf)3.6H20 (0.056 g, 0.081 
mmol) in anhydrous CH3CN (1 ml). Following anion exchange, the procedure yielded the 
title complex (SSS)-[Thh^\ as colourless solid (0.062 g, 0.051 mmol, 64 % ) ; MS (ES") 
m/z 370.0 (100 %, [M]^^); HRMS (ES^ )^ m/z found 370.8226 [M]^^ CsTHfivOsNnTb 
requires 370.8222; Imx, (H2O) = 348 nm; T (H2O) = 1.56 ms; T (D2O) = 1.72 ms; (|)Tb 
(H2O; pH 7.4; ?ie,,c 348 nm) - 40 % . 
(SSS)- [GdL^] 
An analogous procedure to that described for (555)-|EuL^] was followed using 2-[4,7-
bis-[((5)-l-phenyl-ethylcarbamoyl)-methyl]-10-(10,ll,12,13-tetrahydro-4,5,9,14-
tetraaza-benzo[6]triphenylen-6-ylmethyl)-l ,4,7,10-tetraaza-cyclododec-1 -yl]-jV-((5)-1 -
phenyl-ethyl)-acetamide | L ^ | (0.020 g, 0.021 mmol) and Gd(OAc)3 6H20 (0.008 g, 0.025 
mmol) in anhydrous CH3CN (1 ml). Following anion exchange, the procedure yielded the 
title complex {SSS)-\GdL'\ as colourless solid (0.013 g, 0.011 mmol, 54 % ) ; MS (ES^) 
m/z 1109.4 (100 %, [M - IH]^, HRMS (ES^) found 1109.4517 [M - 2H]^ 
C57H6503N , |Gd requires 1109.4513; ?iniax(H20) = 348 nm. 
{RRR)-[EuC] 
An analogous procedure to that described for (555)-1EUL'] was followed using 2-[4,7-
bis-[((.9)-1 -phenyl-ethylcarbamoyl)-methy 1]-10-(l 0,11,12,13-tetrahydro-4,5,9,14-
tetraaza-benzo[6]triphenylen-6-ylmethyl)-l ,4,7,10-tetraaza-cyclododec-1 -yl]-A'-((5)-l -
phenyl-ethyl)-acetamide [L'^I (0.016 g, 0.017 mmol) and Eu(OTf)3.6H20 (0.010 g, 0.017 
mmol) in anhydrous CH3CN (1 ml). Following anion exchange, the procedure yielded the 
title complex (RRR)-[EuL^] as colourless solid (0.015 g, 0.013 mmol, 73 % ) ; 
Photophysical characterisation was identical to that reported for (555)-|EuL^|. 
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(SSS)- ITbL^] 
An analogous procedure to that described for (5SS)-[EuL^J was followed using 2-[4,7-
bis-[((5)-1 -phenyl-ethylcarbamoyl)-methyl]-10-( 10,11,12,13-tetrahydro-4,5,9,14-
tetraaza-benzo[6]triphenylen-6-ylmethyl)-l ,4,7,10-tetraaza-cyclododec-1 -yl]-A^-((5)-1 -
phenyl-ethyl)-acetamide [L"'] (0.016 g, 0.017 mmol) and Eu(OTf)3 6H20 (0.010 g, 0.017 
mmol) in anhydrous CH3CN (1 ml). Following anion exchange, the procedure yielded the 
title complex {RRR)-[ThV] as colourless solid (0.014 g, 0.012 mmol, 66 % ) ; 
Photophysical characterisation M'as identical to that reported for {SSS)-\Th\J\. 
7.4 Amide Conjugate Complexes 
7.4.1 Conjugate Amide Pendant Arm 
(S)-^-Ethanoyl-1-(4-bromophenyl)ethylamine ^ (24) 
Acetyl chloride (2.40 ml, 30.0 mmol) was added dropwise to a sfirring solution of (5)-l-
(4-bromophenyl)ethylamine (5.00 g, 24.99 mmol) and anhydrous NEt3 (4.40 ml, 31.0 
mmol) in anhydrous diethyl ether (300 ml) at - 10 °C The solution was allowed to warm 
to rt then stir for a further 3 h. The reaction mixture was washed with H2O (150 ml) and 
then 0.1 M HCl(aq) (150 ml). The organic phase was separated, dried over Na2S04, 
filtered and the filtrate concentrated under reduced pressure to afford a colourless solid. 
Recrystallisation from warm diethyl ether yielded the title compound 24 as colourless 
needle-like crystals (4.56 g, 18.8 mmol, 76 % ) . m.p. 127-129 °C; ' H NMR(CDCl3, 500 
MHz) 6 1.47 (3H, d, J = 7.0 Hz, CH3), 2.00 (3H, s, C(0)CH3), 5.08 (1H, q, J = 7.0 Hz, 
CH), 5.71 (1H, br s, NH), 7.20 (2H, d, J = 8.5 Hz, H^), 7.46 (2H, d,./ = 8.5 Hz, H^); '^C 
NMR (CDCI3, 125 MHz, IH decoupled 500 MHz) 6 21.9 (IC, CH3), 23.7 (IC, 
C(0)CH3), 48.5 (IC, CH), 121.4 (IC, C'), 128.2 (2C, C^), 132.0 (2C, C"), 142.5 (IC, C^), 
169.3 (IC, C = O); MS (ES^) m/z 263.9 (100 %, [M + Na]""); HRMS (ES^) m/z found 
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263.9994 [M + Na]^ CoHuON^Br'^Na requires 263.9995; CoHuBrNO (%): calcd C 
49.61, H 5.00, N 5.79; found C 49.48, H 4.98, N 5.52. 
(S)-A/-Ethanoyl-1-(4-cyanophenyl)ethylamine ® (25) 
A stirred solution of (5)-A'-ethanoyl-l-(4-bromophenyl)ethylamine 24 (4.00 g, 16.5 
mmol) and CuCN (1.55 g, 17.3 mmol) in anhydrous, degassed DMF (40 ml) was heated 
at 180 °C, for 78 h. The resultant dark green solution was allowed to cool to rt followed 
by the removal of solvent under reduced pressure. The residue was taken up into 6 M 
HCl(aq) (50 ml) in a well ventilated fumehood and the resulting aqueous solution extracted 
with CH2CI2 (3 x 50 ml). The organic extracts were combined, washed with H2O (100 
ml), separated and the solvent removed under reduced pressure to yield the title 
compound 25 as a yellow crystalline solid (2.20 g, 11.7 mmol, 71 % ) ; m.p. 188-190 "C; 
' H N M R ( C D C I 3 , 500 MHz) 5 1.47 (3H, d, ./ = 7.0 Hz, CH3), 2.00 (3H, s, C(0)CH3), 
5.12 ( IH , q, J = 7.0 Hz, CH), 6.02 ( IH , d,J= 6.5 Hz, NH), 7.43 (2H, d, J = 8.0 Hz, H^), 
7.63 (2H, d, J = 8.0 Hz, H^); '^C N M R ( C D C I 3 , 125 MHz, ' H decoupled 500 MHz) 6 
22.0 (IC, CH3) , 23.5 (IC, C(0)CH3), 48.9 (IC, CH), 111.2 (IC, CN), 119.0 (IC, C \ 
127.1 (2C, CO, 132.7 (2C, C^), 149.2 (IC, C'), 169.7 (IC, C = O); MS (ES^ m/z 189.1 
(100 %, [M + H ] ^ ; HRMS (ES^ m/z found 189.1023 [M + H]^ C H n O N , requires 
189.1022; C,,H,2N20 (%): calcd C 70.19, H 6.43, N 14.88; found C 70.05, H 6.49, N 
15.00. 
A/-[(S)-1 -(4-Bromo-phenyl)-ethyl]-2,2,2-trifluoro-acetamide (27) 
= O 
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A solution of (5)-(-)-a-methylbenzylamine (7.81 g, 39.1 mmol) in anhydrous CH2CI2 (20 
ml) was added dropwise to a stirring solution of trifluoroacetic anhydride (14.0 g. 9.27 
ml, 66.7 mmol) in anhydrous CH2CI2 (35 ml), under argon, at 0 "C. The solution was 
allowed to warm to rt then stir for a further 3 h. The solution was cooled to -10 "C for the 
addition of 70 % methanesulfonic acid (16.3 g, 11.0 ml, 169 mmol) followed by 1,3-
dibromo-5,5-dimethylhydantoin (9.00 g, 31.6 mmol). The suspension was allowed to 
warm to rt then stir for 16 h. 1 M NaHS03(aq) (100 ml) was introduced into the reaction 
mixture and the organic phase washed with H2O (200 ml). The organic phase was 
separated, dried over MgS04, filtered and the filtrate concentrated under reduced pressure 
to afford a crude colourless solid. The crude material was recrystallised from diethyl 
ether to yield the title compound 27 as colourless needle-like crystals (5.80 g, 19.7 mmol, 
51 % ) ; m.p. 154-156 °C; ' H NMR ( C D C I 3 , 500 MHz) 5 1.57 (3H, d, J = 7.0 Hz, CH3) , 
5.10 ( IH , q, . /= 7.0 Hz, CH), 6.57 ( IH , br s, NH), 7.20 (2H, d, J = 8.0 Hz, U\ 7.51 (2H, 
d, J = 8.0 Hz, H^); '^ C NMR ( C D C I 3 , 125 MHz, ' H decoupled 500 MHz) 5 21.2 (IC, 
CH3) , 49.5 (IC, CH), 122.3 (IC, C'), 128.1 (2C, C^), 132.4 (2C, C\ 140.2 (IC, C^), 
156.7 (IC, C - O); '^ F NMR (CDCI3, 470 MHz, ' H decoupled 500 MHz) 6 -76.2 (3F, s, 
CF3) ; MS (ES"") m/z 318.1 (100 %, [M + N a f ) ; HRMS (ES^) m/z found 317.9713 [M + 
Na]"^  CioHgON^'^BrFj-^Na requires 317.9712; CoHgBrFsNO (%): calcd C 40.57, H 3.06, 
N 4.73; found C 40.47, H 3.03, N 4.67. 
/V-[(S)-1-(4-Cyano-phenyl)-ethyl]-2,2,2-trifluoro-acetamide ® (28) 
A stirring solution of A^-[(5)-l-(4-bromo-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 27 
(5.80 g, 19.7 mmol) and CuCN (2.12 g, 23.7 mmol) in anhydrous, degassed DMF (30 ml) 
was heated at 180 "C, under argon, for 48 h. The resultant dark green solution was 
allowed to cool to rt followed by the removal of the solvent under reduced pressure. The 
residue was taken up into 6 M HCl(aq) (50 ml) in a well ventilated fumehood and the 
resulting aqueous solution extracted with CH2CI2 (3 x 50 ml). The combined organic 
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extracts were combined and concentrated under reduced pressure to afford a brown solid. 
The crude material was purified by column chromatography on silica (using 100 % 
CH2CI2 elution) to yield the title compound 28 as a colourless solid (2 .86 g, 11.8 mmol, 
60 % ) ; Rf = 0 .34 (Silica, CH2CI2, 100 v); m.p. 98-99 ° C ; ' H NMR ( C D C I 3 , 500 MHz) 5 
I . 53 ( 3 H , d , = 7.5 Hz, CH3), 5 . 1 0 (1H, q,./ = 7.0 Hz, C H ) , 7.36 (1H, d,./ = 7.5 Hz, NH), 
7.41 ( 2 H , d,J= 8.0 Hz, H^), 7.60 ( 2 H , d, J = 8.0 Hz, H^); NMR ( C D C I 3 , 125 MHz, 
' H decoupled 500 MHz) 5 21.3 ( I C , CH3) , 49.9 ( I C , C H ) , 111.7 ( I C , C ' ) , 118.7 ( I C , 
C N ) , 127.1 ( 2 C , C\ 132.9 (2C , C") , 147.1 ( I C , C^), 156.9 ( I C , C = O ) ; '^F NMR 
(CDCI3, 4 7 0 MHz, ' H decoupled 500 MHz) 5 -75.7 (3F , s, CF3); MS (ES') m/z 241.2 
(100 %, [M - H]"); HRMS (ES) m/z found 241.0591 [M - H]" C|,H80N2F3 requires 
241.0594; C,,H9F3N20 (%): calcd C 54.55, H 3.75, N 11.57; found C 54.48, H 3.85, N 
I I . 65. 
(S)-4-(1-Aminoethyl)benzoic acid ^ (26) 
^NH2.HCI 
II I 
HO. 
O 
Procedure A: 
A solution of (S)-iV-ethanoyl-l-(4-cyanophenyl)ethylamine 25 (2.00 g, 10.6 mmol) in 6 
M HCl(aq) (35 ml) was heated at reflux, for 72 h. The solution was allowed to cool to rt 
followed by the removal of solvent under reduced pressure to yield the hydrochloride salt 
of the title compound 26, as a colourless crystalline solid, in quantitative yield. ' H NMR 
(D2O, 500 MHz) 5 1.52 (3H, d, J = 7.0 Hz, CH3) , 4.48 ( IH , q, J = 7.0 Hz, CH), 7.37 (2H, 
dd,J=6.5; 1.5 Hz, H\ 7.86 (2H, dd, .7-7.0; 2.0 Hz, H^); '^CNMR(D20, 125 MHz, ' H 
decoupled 500 MHz) 6 19.4 (IC, CH3) , 50.8 (IC, CH), 126.9 (2C, C^), 130.6 (2C, C^), 
132.3 (1C,C'), 143.1 (IC, C\ 170.2 (IC, C = O); MS (ES') m/z 164.4(100%, [M - H]"); 
HRMS (ES") m/z found 164.0715 [M - H]-C9H,o02N requires 164.0717. 
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Procedure B: 
An analogous procedure to that described in procedure A was followed using yV-[(S)-]-
(4-cyano-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 28 (2.67 g, 11.0 mmol) in 6 M HCl(aq) 
(50 ml) for 72 h. The procedure yielded the hydrochloride salt of (S)-4-(l-
aminoethyl)benzoic acid 26, as a colourless crystalline solid, in quantitative yield. 
Characterisation was identical to that reported in procedure A. 
(S)-Methyl-4-(1-aminoethyl)benzoate ® (29) 
Concentrated HCl(aq) (12 M, 2.00 ml) was added to a stirring solution of (5)-4-(l-
aminoethyl)benzoic acid 26 (2.60 g, 11.9 mmol) in anhydrous C H 3 O H (30 ml) and the 
solution heated at reflux, under argon, for 48 h. The solution was allowed to cool to rt 
followed by the removal of the solvent under reduced pressure to yield the hydrochloride 
salt of the title compound 29, as a bright yellow crystalline solid, in quantitative yield. ' H 
NMR (CH3OD, 500 MHz) 5 1.66 (3H, d, J = 7.0 Hz, CH3), 3.93 (3H, s, CO2CH3), 4.58 
( I H , q, J = 7.0 Hz, CH), 7.61 (2H, d, . / = 8.5 Hz, H^), 8.10 (2H, d, J = 8.5 Hz, H^); '^ C 
NMR (CH3OD, 125 MHz, ' H decoupled 500 MHz) 8 19.5 (IC, CH3), 50.8 (IC, CH), 
51.7 (IC, CO2CH3), 126.9 (2C, C^), 130.2 (2C, C"), 133.0 (IC, C'), 143.5 (IC, C \ 166.7 
(IC, C = O); MS (ES^) m/z 180.0 (100 %, [M + H]^); HRMS (ES^) m/z found 180.1019 
[M + H]^ C,oH,4N02 requires 180.1019. 
4-[(S)-1-(2-Chloro-acetylamino)-ethyl]-benzoic acid methyl ester (30) 
O 
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Chloroacetyl chloride (0.540 g, 0.380 ml, 4.78 mmol) was added dropwise to a stirring 
solution of (S)-methyl-4-(l-aminoethyl)benzoate 29 (0.791 g, 3.68 mmol) and anhydrous 
NEt3 (1.43 ml, 10.1 mmol) in anhydrous diethyl ether (100 ml) at - 10 °C. The solution 
was allowed to warm to rt then stir for a further 4 h. The reaction mixture was washed 
with H2O (150 ml) and then 0.1 M HCl (aq) (150 ml). The organic phase was separated, 
dried over K2CO3, filtered and the filtrate concentrated under reduced pressure to afford a 
crude solid. Recrystallisation from warm diethyl ether yielded the title compound 30 as 
colourless solid (0.704 g, 2.76 mmol, 75 % ) ; ' H NMR (CDCI3, 500 MHz) 5 1.55 (3H, d, J 
= 7.5 Hz, CH3), 3.92 (3H, s, CO2CH3), 4.08 (2H, dd, J = 15; 6.5 Hz, CH2), 5.18 (1H, q,./ 
= 7.0 Hz, CH), 6.85 ( IH , d, J = 6.0 Hz, NH), 7.39 (2H, d , . /= 8.5 Hz, H^), 8.03 (2H, d, J 
= 8.0 Hz, H-); '^ C NMR (CDCI3, 125 MHz, ' H decoupled 500 MHz) 6 22.0 (IC, CH3), 
42.8 (IC, CH2), 49.3 (IC, CH), 52.4 (IC, CO2CH3), 126.3 (2C, C^), 129.7 (IC, C^), 
130.4 (2C, C^), 147.7 (IC, C'), 165.4 (IC, C(0)CH2), 167.0 (IC, C(0)CH3); MS (ES^) 
m/z 256.0 (100 %, [M + H]""); HRMS (ES^) m/z found 256.0735 [M + H]* 
C|2H,503N|^'C1| requires 256.0735. 
1 -(2-Chloroacetyi)pyrrolidine-2,5-dione ^  
O 
A mixture of A^-hydroxysuccinimide (4.86 g, 42.3 mmol), chloroacetic acid (4.00 g, 42.6 
mmol) and A^-(3-dimethylaminopropyl)-A^-ethylcarbodiimide (8.10 g, 52.3 mmol) in 
anhydrous CH2CI2 (200 ml) was stirred at rt, for 16 h. The solvent was removed under 
reduced pressure to afford a residual orange oil. The crude material was purified by 
column chromatography on silica (using 100 % EtOAc elution) to yield the title 
compound as a colourless crystalline solid (3.30 g, 17.3 mmol, 41 % ) ; Rf = 0.51 (Silica, 
EtOAc, 100 v); m.p. 102-104 °C; ' H NMR(CDCl3, 500 MHz) 5 2.89 (4H, s, CH2), 4.38 
(2H, d, J = 4.0 Hz, CH2); '^ C NMR (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 25.8 
(2C, CH2), 38.1 (IC, CH2), 163.4 (IC, C(0)CH2C1), 168.7 (2C, C=0). 
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4-[(S)-1-(2-Chloro-acetylamino)-ethyl]benzoic acid (42) 
O 
A solution of (5)-4-(l-aminoethyl)benzoic acid 26 (0.152 g, 0.901 mmol), l-(2-
chloroacetyl)pyrrolidine-2,5-dione (0.302 g, 1.57 mmol) and anhydrous NEts (2 ml) in 
anhydrous THF (15 ml) was stirred at rt, for 16 h. The solvent was removed under 
reduced pressure and the residue partitioned between diethyl ether (15 ml) and H2O (10 
ml). The organic phase was separated, washed with 0.2 M HCl(aq) (10 ml) and then 
concentrated under reduced pressure to yield the litle compound 42 as a colourless solid 
(0.130 g, 0.541 mmol, 60 % ) ; ' H N M R ( C D 3 0 D , 200 MHz) 5 1.48 (3H, d, J =7.0 Hz, 
CH3), 4.06 (2H, s, CH2), 5.04 ( IH , q, J = 7.0 Hz, C H ) , 7.43 (2H, d , J = 8.0 Hz, H^), 7.96 
(2H, d, J = 8.0 Hz, U\ 8.79 ( I H , d, . /= 8.0 Hz, NH). 
(2-(4-[(S)-1 -(2-Chloro-acetylamino)-ethyl]-benzoylamino)-ethyl)-carbamic 
acid fe/t-butyl ester (43) 
A mixture of 4-[(5)-l-(2-chloro-acetylamino)-ethyl]benzoic acid 42 (0.080 g, 0.331 
mmol), A^-(3-dimethylaminopropyl)-A^-ethylcarbodiimide (0.060 g, 0.382 mmol) and A^ -
hydroxysuccinimide (0.044 g, 0.382 mmol) in anhydrous THF (10 ml) was stirred, under 
argon, at 0 °C. The mixture was stirred at 0 °C for 30 min, after which N-Boc-
ethylenediamine (0.060 ml, 0.382 mmol) was added to the solution. The reaction mixture 
was then stirred, at rt, for 4 h. The solvent was removed under reduced pressure and the 
residue partitioned between diethyl ether (15 ml) and H2O (15 ml). The organic layer was 
separated and the solvent removed under reduced pressure to yield the title compound 43 
as a colourless solid (0.067 g, 0.168 mmol, 53 % ) ; ' H N M R (CDCI3, 400 MHz) 5 1.42 
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(9H, s, 'Boc CH3), 1.54 (3H, d, J = 7.0 Hz, CH3), 3.40 (2H, m, N H C H 2 ) , 3.52 (2H, m, 
N H C H 2 ) , 4.05 (2H, s, CH2CI), 5.08 ( IH , br s, NH), 5.15 ( IH, q, CH), 6.84 ( IH , d, J = 7.0 
Hz, NH), 7.33 (2H, d,J=S.O Hz, H^), 7.78 (2H, d, J = 8.0 Hz, H^); MS (ES*) m/z 406.2 
(100%, [M + N a f ) . 
7,4.2 Cyclen Intermediates 
1,4,7,10-Tetraaza-cyclododecane-1,7-dicarboxylic acid dibenzyl ester (31) 
p 
:N N-
/ 
o 
Disodium hydrogen phosphate (14.0 g, 98.6 mmol) was added to a solution of cyclen 
(5.00 g, 29.0 mmol) in H2O - 1,4-dioxane (50 : 20 v/v, 70 ml) and the pH adjusted to pH 
2.5 by the addition of cone. HCl(aq)(12 M). Benzyl chloroformate (10.0 ml, 70.1 mmol) in 
dioxane (20 ml) was added dropwise to the stirred solution at rt, over 2 h, followed by 
stirring for a further 18 h to afford a colourless solution containing a white precipitate. 
The solvent was removed under reduced pressure and the residue dissolved in H2O (100 
ml). The pH of the aqueous phase was then raised to pH 7 by the addition of 1 M 
KOH(aq). The aqueous phase was then extracted with diethyl ether (2 x 100 ml), followed 
by CH2CI2 (2 x 100 ml). The CH2CI2 extracts were combined, dried over MgS04, filtered 
and the filtrate concentrated under reduced pressure to afford a colourless oil. The 
material was repeatedly washed with diethyl ether and concentrated under reduced 
pressure (3 x 50 ml) to yield the title compound 31 as a colourless crystalline solid (9.47 
g, 21.5 mmol, 74 % ) ; m.p. 113-116 "C; ' H N M R (CDCI3, 500 MHz) 5 2.05 (2H, br s, 
NH), 2.86-3.12 (8H, br m, cyclen CH2), 3.47-3.79 (8H, br m, cyclen CH2), 5.18 (4H, s, 
Cbz CH2), 7.33-7.40 (lOH, m, Ph); '^ C N M R (CDCI3, 125 MHz, ' H decoupled 500 
MHz) 5 49.2 ( IC, cyclen CH2), 49.4 ( IC, cyclen CH2), 49.9 ( IC, cyclen CH2), 50.1 (IC, 
cyclen CH2), 50.5 (IC, cyclen CH2), 50.7 ( IC, cyclen CH2), 50.9 (IC, cyclen CH2), 68.1 
(2C, Cbz CH2), 68.2 (IC, cyclen CH2), 128.3 (2C, Ph), 128.4 (2C, Ph), 128.7 (2C, Ph), 
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128.8 (2C, Ph), 129.0 (2C, Ph), 129.1 (2C, Ph), 136.1 (2C, Ph<q)), 136.2, 156.4 (IC, C = 
O), 156.5 (IC, C = O); MS (ES^) m/z 441.4 (100 %, [M + H f ) . 
4,10-bis-[((S)-1-Phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododecane-1,7-dicarboxylic acid dibenzyl ester (32) 
HN 
/ 
0 O 
Y ^ ) 
O 
NH 
A stirred mixture of l,4,7,10-tetraaza-cyclododecane-l,7-dicarboxylic acid dibenzyl ester 
31 (1.34 g, 3.05 mmol), (5)-jV-2-chloroethanoyl-2-phenylethylamine (1.31 g, 6.65 mmol), 
C S 2 C O 3 (1.97 g, 6.06 mmol) and KI (0.010 g) in anhydrous C H 3 C N (50 ml) was heated 
at reflux, under argon, for 24 h. The resulting orange solution was allowed to cool to 
room temperature, followed by the removal of the solvent under reduced pressure. The 
residual oil was dissolved in C H 2 C I 2 (20 ml) and washed with H 2 O (2 x 20 ml). The 
organic layer was concentrated under reduced pressure to afford a residual oil which was 
then sonicated in diethyl ether (2 x 50 ml). The solid precipitate was collected by 
centrifiigation, dissolved in C H 2 C I 2 and then dried under reduced pressure to yield the 
title compound 32 as a colourless crystalline solid (1.72 g, 2.26 mmol, 74 % ) ; m.p. 64-66 
°C; ' H NMR ( C D C I 3 , 500 MHz) 5 1.45 (6H, br s, C H 3 ) , 2.75 (8H, br s, cyclen C H 2 ) , 3.16 
(4H, br s, C H 2 C O ) , 3.43 (8H, br s, cyclen C H 2 ) , 4.96 (4H, br s, Cbz C H 2 ) , 5.11 (2H, m, 
CH), 7.22-7.39 (20H, m, Ph), 7.59 (2H, br s, NH); '^ C NMR ( C D C I 3 , 125 MHz, ' H 
decoupled 500 MHz) 5 22.0 (2C, C H 3 ) , 48.1 (IC, CH), 48.7 (IC, CH), 55.0 - 56.4 (4C, br 
s, cyclen C H 2 ) , 59.3 (2C, CHjCO), 67.6 (2C, Cbz C H 2 ) , 126.3 (2C, Ph), 126.6 (2C, Ph), 
127.4 (2C, Ph), 128.5 (2C, Ph), 128.6 (2C, Ph), 136.5 (2C, Cbz Ph(q)), 143.8 (2C, amide 
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arm Ph(q)), 157.1 (2C, C(O)OBn), 170.2 (2C, NHCO); MS (ES^) m/z 763.0 (100 %, [M + 
H]^); HRMS (ES"") m/z found 763.4187 [M + H]^ C44H55N6O0 requires 763.4178. 
N-((S)-^ -Phenyl-ethyl)-2-(7-[((S)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-
tetraaza-cyclododec-1 -yl)-acetamide (33) 
vO 
w o 
NH 
Procedure A: 
4,10-bis-[((S)-1 -Pheny l-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-cyclododecane-1,7-
dicarboxylic acid dibenzyl ester 32 (3.14 g, 4.12 mmol) in CH3OH - H2O (40 : 20 v/v, 60 
ml) was shaken in a Parr hydrogenation flask at 40 psi H2 over Pd(0H)2/C (0.35 g) for 48 
h. The resulting mixture was filtered through celite to afford a colourless solution which 
was concentrated under reduced pressure to yield the litle compound 33 as a colourless 
crystalline solid (1.77 g, 3.58 mmol, 87 % ) ; m.p. 140-143 °C; ' H NMR (CD3OD, 500 
MHz) 5 1.46 (6H, d, J = 7.0 Hz, CH3), 2.88-3.18 (16H, br m, cyclen CH2), 3.41 (2H, d, J 
= 16.5 Hz, CHCO), 3.54 (2H, d,J= 17.0 Hz, CHCO), 5.04 (2H, m, CH), 7.21-7.28 (lOH, 
m, Ph); '^ C NMR (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 23.5 (2C, CH3), 45.2 
(4C, cyclen CH2), 50.7 (2C, cyclen CH2), 51.1 (2C, cyclen CH2), 52.4 (2C, CH), 57.2 
(2C, C H 2 C O ) , 128.0 (4C, Ph(o/„,)), 129.0 (4C, Ph(o/m)), 130.5 (2C, Ph(p)), 145.8 (2C, Ph<q)), 
172.7 (2C, C = O); MS (ES^) m/z 495.3 (100 %, [M + H]""); HRMS (ES^) m/z found 
495.3447 [M + H]^ C28H43N6O2 requires 495.3442. 
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Procedure B: 
A solution of 4,10-bis-[((S)-l-phenyl-ethylcarbamoyl)-methyl]-l,4,7,10-tetraaza-
cyclododecane-l,7-dicarboxylic acid di-/er/-butyl ester 38 (0.150 g, 0.216 mmol) in 
CH2C12 - TFA (2 : I v/v, 3 ml) was stirred at rt, in a sealed flask, for 12 h, to afford a 
yellow solution. The solvent was removed under reduced pressure to yield a glassy solid. 
The crude material was repeatedly (x 3) dissolved in CH2CI2 (5 ml) and the solvent 
removed under reduced pressure to facilitate elimination of excess acid and /er/-butyl 
alcohol. The residue was finally taken into 1 M KOH(aq) (10 ml) and extracted with 
CH2CI2 (3x15 ml). The organic extracts were combined, dried over K2CO3, filtered and 
the filtrate concentrated under reduced pressure to yield the title compound 33 as a 
colourless crystalline solid (0.105 g, 0.211 mmol, 98 % ) ; Characterisation M>as indentical 
to that reported in procedure A. 
4,10-bis-[((S)-1 -Phenyl-ethylcarbannoyl)-methyl]-1,4,7,10-tetraaza-
cyclododecane-1-carboxylic acid te/t-butyl ester (37) 
HN 
J 
,H 
Kl N-
iX 
NH 
A solution of di-/er^butyl dicarbonate (0.205 g, 0.940 mmol) in anhydrous C H 3 O H (25 
ml) was added dropwise over 3 h, at rt, to a stirring solution of N-((5)-l-phenyl-ethyl)-2-
(7-[((S)- 1 -phenyl-ethylcarbamoy l)-methyl]-1,4,7,10-tetraaza-cyclododec -1 -yl)-
acetamide 33 (0.664 g, 1.34 mmol) in anhydrous C H 3 O H (200 ml). The reaction mixture 
was left to stir for 16 h, then concentrated under reduced pressure to afford a residual 
yellow viscous oil. The crude material was purified by column chromatography on 
neutral alumina (gradient elution; CH2CI2 to 2 % C H 3 O H : CH2CI2, utilising 0.1 % 
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CH3OH increments) to yield the title compound 37 as a glassy colourless solid (0.354 g, 
0.596 mmol, 63 % ) ; Rr = 0.46 (Alumina, CH2CI2 - C H 3 O H , 49 : 1 v/v); m.p. 98-101 °C; 
' H NMR (CDCI3, 500 MHz) 5 1.39 (9H, s, 'Boc CH3), 1.51 (6H, d,J= 7.0 Hz, CH3), 2.61 
(8H, br s, cyclen CH2), 2.86 (4H, br s, cyclen CH2), 2.94 (4H, br s, cyclen CH2), 3.09 
(4H, br s, CH2CO) , 4.95 (2H, q, CH), 7.17-7.23 (lOH, m, Ph), 8.34 ( I H , d, J = 5.5 Hz, 
NH); '^C NMR (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 22.0 (2C, CH3), 28.8 (3C, 
'Boc CH3), 48.7 (2C, CH), 49.0-53.8 (8C, br m, cyclen CH2) , 59.6 (2C, CH2CO) , 80.3 
( IC, C'Bu), 126.8 (4C, Ph(o/n,)), 127.5 (4C, Ph(o/„,)), 128.8 (2C, Ph<p)), 143.8 (2C, Ph(q)), 
156.7 (IC, 'Boc C=0), 170.5 (2C, amide C-0) ; MS (ES^) m/z 595.4 (100 %, [M + H]^); 
HRMS (ES^) m/z found 595.3972 [M + H]^ C33H51O4N6 requires 595.3966. 
4,10-bis-[((S)-1-Phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododecane-1,7-dicarboxyljc acid di-te/t-butyl ester (38) 
/ 
. 0 0 
NH 
4,10-bis-[((S)-l-Phenyl-ethylcarbamoyl)-methyl]-l,4,7,10-tetraaza-cyclododecane-l,7-
dicarboxylic acid di-/er/-butyl ester 3 8 was isolated using an identical procedure to that 
described for 4,10-bis-[((5)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododecane-l-carboxylic acid tert butyl ester 37. The procedure yielded the title 
compound 38 as a colourless solid (0.131 g, 0.188 mmol, 20 % ) ; /?F = 0.58 (Alumina, 
CH2CI2 - C H 3 O H , 49 : 1 v/v); m.p. 65-68 °C; ' H NMR (CDCI3 , 500 MHz) 5 1.39 (18H, 
s, 'Boc CH3), 1.51 (6H, d,J= 7.0 Hz, CH3), 2.61 (8H, br s, cyclen CH2), 2.86 (4H, br s, 
cyclen CH2), 2.94 (6H, br s, cyclen CH2; CH2CO), 3.09 (4H, br s, CH2CO), 4.95 (2H, q, 
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CH), 7.17-7.23 (lOH, m, Ph); MS (ES^) m/z 695.0 (100 %, [M + H f ) ; HRMS (ES^) m/z 
found 695.4488 [M + H]^ CsgHsgOeNe requires 695.4490. 
7.4.3 Pyridyl-azaxanthone Amide Conjugate Complex 
7-[6-(6-fert-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-pyridin-2ylmethyl] 
-4,10-bis-[((S)-1-phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-cyclo 
dodecane-1-carboxylic acid fe/t-butyl ester (39) 
N N 
N N 
A stirring mixture of 4,10-bis-[((S)-l-phenyl-ethylcarbamoyl)-methyl]-l,4,7,10-tetraaza-
cyclododecane-l-carboxylic acid /er/-butyl ester 3 3 (0.325 g, 0.547 mmol), 2-(6-
bromomethyl-pyridin-2-yl)-6-^er/-butyl-9-oxa-l-aza-anthracen-10-one 9 (0.254 g, 0.601 
mmol) and K2CO3 (0.113 g, 0.821 mmol) in anhydrous CH3CN (10 ml) was heated at 
reflux, under argon, for 16 h. The mixture was allowed to cool to rt, syringe filtered and 
the filtrate concentrated under reduced pressure to afford a residual yellow oil. The crude 
material was purified by column chromatography on neutral alumina (gradient elution; 
CH2CI2 to 0.5 % CH3OH : CH2CI2, utilising 0.1 % CH3OH increments) to yield the title 
compound 3 9 as an orange crystalline solid (0.379 g, 0.404 mmol, 74 % ) ; Rf = 0.74 
(Alumina, CH2CI2 - CH3OH, 49 : 1 v/v); m.p. 87-89 °C; ' H NMR (CDCI3, 500 MHz) 5 
1.38 (18H, br s, 'Bu CH3; 'Boc CH3), 1.46 (6H, d, ./ = 4.0 Hz, CH3), 2.61 (8H, br s, cyclen 
CH2), 2.82 (4H, br s, cyclen CH2), 3.07 (4H, br s, cyclen CH2), 3.33 (2H, br s, CH2CO), 
3.40 (2H, br s, CH2CO), 3.61 (2H, br s, CH2 pyridine), 5.12 (2H, br s, CH), 7.19 ( IH , d, J 
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= 8.0 Hz, H^'), 7.26 (lOH, br s, Ph), 7.46 ( IH , br s, NH), 7.58 ( IH , d, J = 8.5 Hz, H ' ° ) , 
7.64 ( I H , t, J = 8.0 Hz, H^*'), 7.74 ( I H , br s, NH), 7.82 ( I H , dd ,y= 9.0; 2.5 Hz, H\ 8.29 
( I H , d,J= 2.5 Hz, H \ 8.41 ( I H , d, 7 = 8.0 Hz, H^'), 8.46 ( I H , d, . / = 8.0 Hz, H \ 8.78 
( I H , d, J = 8.0 Hz, H^); '^C NMR (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 21.3 
(IC, CH3), 22.0 (IC, CH3), 28.7 (3C, 'Boc CH3), 31.5 (3C, C'^), 35.1 (IC, C ' \ 48.0 (IC, 
CH), 48.4 (IC, CH), 52.5 (2C, cyclen CH2), 53.2 (2C, cyclen CH2), 53.8 (2C, cyclen 
CH2), 54.6 (2C, cyclen CH2), 59.4 (IC, CH2 pyridine), 59.8 (IC, CH2CO), 60.6 (IC, 
CH2CO), 80.2 (IC, 'BoC(q)), 116.6 (IC, C \ 118.3 (IC, C ' \ 121.1 (IC, C^'), 121.3 (IC, 
C ^ 122.7 (IC, C ^ 124.8 (IC, C ' ) , 126.5 (IC, P(o/m)), 126.8 (IC, P(om), 127.3 (2C, 
P(o/ni)), 127.8 (2C, P(o/nn)), 128.7 (IC, P(om), 128.9 (IC, P(o/n,)), 133.8 (IC, C'), 137.6 (IC, 
C^'), 138.5 (IC, C^), 143.0 (IC, Ph(q)), 143.8 (IC, Ph<q)), 148.2 (IC, C\ 153.8 (IC, C' ), 
154.2 (IC, C"), 156.1 (IC, 'Boc C = O), 158.0 (IC, C^'), 160.1 (IC, C'), 160.3 (IC, C'^), 
170.1 (2C, amide C = O), 177.8 (IC, C^); MS (ES^ m/z 937.5 (100 %, [M + H f ) ; HRMS 
(ES^) m/z found 937.5331 [M + H]^ CssHegOeNg requires 937.5334. 
2-{4-[6-(6-fe/t-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-pyridin-
2ylmethyl]-7-[((S)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododec-1 -yl}-M-((S)-1 -phenyl-ethyl)-acetamide (40) 
HN 
/ 
A solution of 7-[6-(6-/erf-butyl-10-oxo-10H-9-oxa-l-aza-anthracen-2-yl)-pyridin-
2ylmethyl]-4,10-bis-[((S)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-cyclo 
dodecane-l-carboxylic acid tert-huty\ ester 39 (0.320 g, 0.341 nrniol) in CH2CI2 - TFA 
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(2 : 1 v/v, 6 ml) was stirred at rt, in a sealed flask, for 12 h, to afford a yellow solution. 
The solvent was removed under reduced pressure to yield a glassy solid. The crude 
material was repeatedly (x 3) dissolved in CH2CI2 (5 ml) and the solvent removed under 
reduced pressure to facilitate elimination of excess acid and /er/-butyl alcohol. The 
residue was finally taken into 0.2 M KOH (aq) (10 ml) and extracted with CH2CI2 (3x15 
ml). The organic layers were combined, dried over K2CO3, filtered and the filtrate 
concentrated under reduced pressure to yield the title compound 40 as an orange coloured 
crystalline solid (0.254 g, 0.304 mmol, 89 % ) ; m.p. 92-95 °C; ' H NMR (CDCI3 , 500 
MHz) 5 1.38 (9H, s, 'Bu CH3) , 1.47 (6H, d,./ = 7.0 Hz, CH3) , 2.58 (8H, br s, cyclen CH2) , 
2.64 (8H, br s, cyclen CH2) , 3.09 (4H, q, J = 17.0 Hz, C H 2 C O ) , 3.60 ( I H , d, J = 15.0 Hz, 
CH2 pyridine), 3.68 ( I H , d, J = 15.0 Hz, CH2 pyridine), 5.14 (2H, q, J = 7.5 Hz, CH), 
7.16 (3H, q, J = 8.0 Hz, H^": Ph(p)), 7.24 (4H, t, J = 7.5 Hz, Ph^^)), 7.30 (4H, d, J = 7.5 
Hz, Ph(„)), 7.56 ( I H , d, J = 9.0 Hz, H ' " ) , 7.62 ( IH, t, J = 7.5 Hz, H'* ), 7.82 ( IH , dd, J = 
8.5; 2.0 Hz, H\ 8.06 (2H, d, J = 8.5 Hz, NH), 8.28 (1H, d, J = 2.5 Hz, H^), 8.37(1 H, d, J 
= 7.5 Hz, H^ ), 8.44 ( I H , d,J= 8.5 Hz, H \ 8.77 ( I H , d, J = 8.5 Hz, H^); '^C ( C D C I 3 , 125 
MHz, ' H decoupled 500 MHz) 5 21.7 (2C, CH3) , 31.5 (3C, C'^), 35.0 (IC, C'^), 47.4 (2C, 
cyclen CH2), 48.6 (2C, CH), 52.5 (2C, cyclen CH2), 53.4 (2C, cyclen CH2), 53.7 (IC, 
cyclen CH,), 54.8 (IC, cyclen CH2), 58.7 (IC, CH2 pyridine), 60.2 (2C, CH2CO), 116.6 
(IC, C"), 118.3 (2C, C^ C ' \ 121.0 (IC, C^ ). 121.3 (IC, C^), 122.7 (IC, C^), 125.0 (IC, 
C'"), 126.7 (4C, Ph(o)), 127.5 (2C, Ph(p)), 128.8 (4C, Ph,„)), 133.8 (IC, C'), 137.6 (IC, 
C' ), 138.5 (IC, C^), 143.5 (2C, Ph<q)), 148.2 (IC, C ^ 153.6 (IC, C'"), 154.2 (IC, C"), 
158.0 (IC, C^"), 160.2 (IC, C'), 160.3 (IC, C'^), 170.8 (2C, amide C=0), 177.8 (IC, C=); 
MS (ES^) m/z 837.5 (100 %, [M + H f ) ; HRMS (ES^) m/z found 837.4817 [M + H]^ 
C50H61O4N8 requires 837.4810. 
207 
Chap fe r Seven: Exper imental 
[EuL«] 
N N 
N N 
3 CI 
A stirring solution of 2-{4-[6-(6-/er/-butyl-l0-oxo-10//-9-oxa-l-aza-anthracen-2-yl)-
pyridin-2ylmethyl]-7-[((5)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododec-l-yl}-A^-((5)-l-phenyl-ethyl)-acetamide 40 (0.020 g, 0.024 mmol) and 
Eu(OTf)3.6H20 (0.017 g, 0.024 mmol) in anhydrous C H 3 C N (1 ml) was heated at reflux, 
under argon, for 14 h. The solution was allowed to cool to rt followed by the removal of 
solvent under reduced pressure to afford a glassy orange solid. CH2CI2 (10 ml) was added 
to the solid, and the mixture sonicated for 10 min. The solvent was then decanted and the 
solid material dissolved in a minimum volume of C H 3 C N (0.5 ml). The solution was 
added dropwise onto diethyl ether (25 ml) to induce precipitation. The solid material was 
isolated by centrifugation, and the process of induced precipitation repeated twice more 
to yield the complex as its triflate salt. The pale yellow coloured solid was made water 
soluble by the exchange of triflate anions for chloride anions using 'DOWEX 1 x 8 200-
400 mesh CI' resin. The solid material was dissolved in a mixture of H2O - C H 3 O H (1:1 
v/v, 10 ml) and 0.5 g of prepared resin added to the solution, which was stirred at room 
temperature, for 3 h. The resin was removed by filtration, and the filtrate concentrated 
under reduced pressure to yield the title complex [EuL*] as a colourless solid (0.009 g, 
0.008 mmol, 34 % ) ; 1^^^ (H2O) = 355 nm; x (H2O) = 0.36 ms; HPLC (Method A) /r = 
l l .O min. 
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4-[(S)-1 -(2-{7-[6-(6-fert-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-
py ridin-2-ylmethyl]-4,10-bis-[((S)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-
tetraaza-cyclododec-1-yl}-acetylamino)-ethyl]-benzoic acid methyl ester 
([Li) 
A stirring mixture of 2-{4-[6-(6-/er/-butyl-10-oxo-10//-9-oxa-l-aza-anthracen-2-yl)-
pyridin-2ylmethy l]-7-[((5)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododec-l-yl}-A^-((5)-l-phenyl-ethyl)-acetamide 40 (0.131 g, 0.157 mmol), 4-[(5)-l-
(2-chloro-acetylamino)-ethyl]-benzoic acid methyl ester 30 (0.050 g, 0.196 mmol) and 
K2CO3 (0.043 g, 0.313 mmol) in anhydrous C H 3 C N (7 ml) was heated at reflux, under 
argon, for 18 h. The resultant mixture was allowed to cool to rt, syringe filtered and the 
filtrate concentrated under reduced pressure to afford a residual orange oil. The crude 
material was purified by column chromatography on neutral alumina (gradient elution; 
CH2CI2 to 1.0 % C H 3 O H : CH2CI2, ufilising 0.1 % C H 3 O H increments) to yield the title 
compound as an orange crystalline solid (0.105 g, 0.102 mmol, 64 % ) ; /?p = 0.27 
(Alumina, CH2CI2 - C H 3 O H , 49 : 1 v/v); m.p. 87-89 °C; ' H NMR ( C D C I 3 , 500 MHz) 5 
1.40 (9H, s, 'Bu CH3) , 1.44 (9H, d, J = 7.0 Hz, CH3) , 2.71 (16 H, br s, cyclen CH2) , 3.25 
(6H, br s, C H 2 C O ) , 3.75 (2H, s, CH2 pyridine), 3.84 (3H, s, C(0)0CH3), 5.05 (3H, q, 
CH), 7.16 (2H, d, J = 8.0 Hz, H^"; Ph<p)), 7.28 (lOH, m, Ph), 7.33 (2H, d, J = 8.0 Hz, 
Ph(o/ni)), 7.60 ( I H , d, . / = 8.5 Hz, H ' ^ ) , 7.73 ( I H , t, J = 8.0 Hz, H^'), 7.85 ( I H , dd, J = 8.5; 
2.5 Hz, H \ 7.89 (2H, d,J= 8.0 Hz, Ph,o/m)), 8.30 ( I H , d, J = 2.5 Hz, H^), 8.43 (2H, d, J 
= 8.0 Hz, H^; H^), 8.77 ( I H , d, J = 8.0 Hz, H^); '^C (CDCI3, 125 MHz, ' H decoupled 500 
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MHz) 5 21.9 (3C, CH3) , 31.5 (3C, C"*), 35.0 (IC, C ' \ 48.9 (3C, CH), 51.5 (2C, cyclen 
CH2), 52.3 (IC, C(0)0CH3), 52.5 (2C, cyclen CH2) , 53.0 (2C, cyclen CH2) , 53.7 (2C, 
cyclen CH2) , 58.5 (3C, C H 2 C O ) , 60.2 (IC, CH2 pyridine), 116.6 (IC, C^), 118.3 (2C, C^; 
C ' \ 121.3 (IC, C^). 121.4 (IC, C^), 122.7 (IC, C\ 125.4 (2C, Ph), 126.2 (2C, Ph), 
126.5 (4C, Ph), 127.5 (IC, C^), 128.8 (4C, Ph), 129.2 (IC, Ph), 130.1 (2C, Ph), 133.8 
(IC, C^), 137.8 (IC, C^ ), 138.6 (IC, C\ 143.5 (2C, Ph(q)), 148.2 (IC, C^), 153.6 (IC, 
C' ), 154.2 (IC, C"), 159.9 (IC, C^), 160.2 (IC, C'), 160.3 (IC, C'^), 166.9 (IC, 
C(0)0CH3), 170.8 (3C, amide C = O), 177.8 (IC, C'); MS (ES^) m/z 1056.6 (100 %, [M 
+ H]^); HRMS (ES^) m/z found 1056.5733 [M + H]^ C62H74O7N9 requires 1056.5706. 
[EuL^ 
3 + 
N N 
3 CI 
A stirred solution of 4-[(5)-l-(2-{7-[6-(6-/er/-butyl-10-oxo-10//-9-oxa-]-aza-anthracen-
2-yl)-pyridin-2-y lmethyl]-4,10-bis-[((S)-l -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-
tetraaza-cyclododec-l-yI}-acetyIamino)-ethyl]-benzoic acid methyl ester [L^] (0.061 g, 
0.057 mmol) and Eu(OTf)3.6H20 (0.045 g, 0.063 mmol) in anhydrous C H 3 C N (2ml) was 
heated at reflux, under argon, for 17 h. The resultant solution was allowed to cool to rt 
followed by the removal of solvent under reduced pressure to afford a glassy orange 
solid. CH2CI2 (10 ml) was added to the solid, and the mixture sonicated for 10 min. The 
solvent was then decanted and the solid material dissolved in a minimum volume of 
C H 3 C N (1.0 ml). The solution was added dropwise onto diethyl ether (50 ml) to induce 
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precipitation. The solid material was isolated by centrifugation, and the process of 
induced precipitation repeated twice more to yield the complex as its triflate salt. The 
yellow solid was made water soluble by the exchange of triflate anions for chloride 
anions using 'DOWEX 1 x 8 200-400 mesh CI' resin. The solid material was dissolved in 
a mixture of H2O - CH3OH (1:1 v/v, 20 ml) and 0.8 g of prepared resin added to the 
solution, which was stirred at rt, for 6 h. The resin was removed by filtration, and the 
filtrate concentrated under reduced pressure to yield the title complex | E U L ' | as a pale 
yellow coloured solid (0.044 g, 0.036 mmol, 64 % ) ; ^„,ax (H2O) = 348 nm; T (H2O) = 1.02 
ms; T (D2O) = 1.34 ms; HPLC (Method A) /R = 10.9 min. 
7.4.4 Pyrazoyl-azaxanthone Amide Conjugate Complex 
244-[1 -(6-feff-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-1 H-py razol-3-y I 
methyl]-7-[((S)-1-phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododec-1 -yl}-W-((S)-1 -phenyt-ethyl)-acetamide (34) 
™ =0 
] N—N, 
NH 
A stirring mixture of /V-((5)-l-phenyl-ethyl)-2-(7-[((S)-l-phenyl-ethylcarbamoyl)-
methyl]-l,4,7,10-tetraaza-cyclododec-l-yl)-acetamide 33 (0.104 g, 0.211 mmol), 2-(3-
bromomethyl-pyrazol-l-yl)-6-/er/-butyl-9-oxa-l-aza-anthracen-10-one 12 (0.087 g, 0.211 
mmol) and NaHC03 (0.020 g, 0.231 mmol) in anhydrous CH3CN (5 ml) was heated at 60 
°C, under argon, for 18 h. The resultant mixture was allowed to cool to rt, syringe filtered 
and the filtrate concentrated under reduced pressure to afford a yellow residue. The crude 
material was purified by column chromatography on neutral alumina (gradient elution: 
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CH2CI2 to 0.5 % CH3OH : CH2CI2, utilising 0.1 % CH3OH increments) to yield the title 
compound 34 as a pale yellow coloured solid (0.124 g, 0.150 mmol, 71 % ) ; m.p. 152-154 
°C; ' H NMR (CDCI3, 500 MHz) 5 1.40 (9H, s, 'Bu CH3), 1.47 (6H, d, J = 7.0 Hz, CH3), 
2.58 (4H, br s, cyclen CH2), 2.79 (4H, br s, cyclen CH2), 2.91 (8H, br s, cyclen CH2), 
3.36 (4H, s, CH2C(0)), 3.71 (2H, s, CH2 pyrazole), 5.07 (2H, q, J = 14.0; 7.5 Hz, CH), 
6.31 ( I H , d, J = 2.5 Hz, H^'), 7.13 (2H, t, J = 7.5 Hz, Ph), 7.21 (4H, t, J = 7.5 Hz, Ph), 
7.35 (4H, d,J= 7.5 Hz, Ph), 7.54 ( IH , d, J = 9.0 Hz, H ' \ 7.84 ( IH , dd, J - 8.5; 2.5 Hz, 
H^), 7.91 (2H, br s, NH), 7.98 ( I H , d, J = 8.5 Hz, H ' ) , 8.29 ( I H , d,J= 2.5 Hz, }i\ 8.55 
( I H , d, J = 2.5 Hz, H'"), 8.76 ( I H , d, J = 8.5 Hz, ); MS (ES^) m/z 826.0 (100 %, [M + 
H]*); HRMS (ES^) m/z found 826.4769 [ M + H]* C48H60N9O4 requires 826.4763. 
4-[(S)-1 -(2-{7-[1 -(6-ferf-Butyl-10-oxo-10H-9-oxa-1 -aza-anthracen-2-yl)-1 H-
pyrazol-3-ylmethyl]-4,10-bis-[((S)-1-phenyl-ethylcarbamoyl)-methyl]-
1,4,7,10-tetraaza-cyclododec-1-yl}-acetylamino)-ethyl]-benzoic acid methyl 
ester ([L^°]) 
N N--. \v / 
A stirring mixture of 2-{4-[l-(6-rer/-butyl-10-oxo-10//-9-oxa-l-aza-anthracen-2-yl)-l//-
pyrazol-3-ylmethyl]-7-[((5)-1 -phenyl-ethylcarbamoyl)-methyl]-1,4,7,10-tetraaza-
cyclododec-l-yl}-//-((5)-l-phenyl-ethyl)-acetamide 34 (0.060 g, 0.073 mmol), 4-[(S)-l-
(2-chloro-acetylamino)-ethyl]-benzoic acid methyl ester 30 (0.021 g, 0.084 mmol) and 
CS2CO3 (0.031 g, 0.095 mmol) in anhydrous CH3CN (5 ml) was heated at reflux, under 
argon, for 16 h. The resultant mixture was allowed to cool to rt, syringe filtered and the 
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filtrate concentrated under reduced pressure to afford a yellow residue. The crude 
material was purified by column chromatography on neutral alumina (gradient elution: 
CH2CI2 to 0.5 % CH3OH : CH2CI2, utilising 0.1 % CH3OH increments) to yield the title 
compound | L ' " | as a pale yellow coloured solid (0.060 g, 0.058 mmol, 79 % ) ; Rr = 0.68 
(Alumina, CH2CI2 - CH3OH, 49 : 1 v/v); m.p. 187-189 °C; ' H N M R (CDCI3, 400 MHz) 5 
1.41 (12H. br s, 'Bu CH3; CH3), 1.45 (6H, d, J = 7.0 Hz, CH3), 2.57 (16H, br, cyclen 
CH2), 2.86 (2H, br s, CH2CO), 2.99 (4H, br s, CH2CO), 3.62-3.84 (5H, br, CH2 pyrazole; 
CO2CH3) , 5.14 (3H, q, J = 7.0 Hz, C H ) , 6.30 ( I H , d, J = 2.5 Hz, H^"), 6.21-7.32 (12H, br, 
Ph), 7.47 (2H, d, . /= 8.0 Hz, Ph), 7.55 ( IH , d, . /= 9.0 Hz, H ' " ) , 7.82 ( IH, dd,./= 8.0; 2.5 
Hz, H^), 7.98 ( I H , d , J = 8.0 Hz, H"), 8.31 ( I H , d, J=2 .5 Hz, H^), 8.78 ( I H , d, J = 8.0 
Hz, H^); MS (ES^) m/z 1067.7 (100 %, [M + Na]^); HRMS (ES*) m/z found 1045.5706 
[M + H]^ C6oH73N,o07 requires 1045.5698. 
[TbU°] 
3 + 
HN 
NH Q 
3 CI 
A solution of 4-[(S)-l-(2-(7-[l-(6-rer/-butyl-10-oxo-10H-9-oxa-l-aza-anthracen-2-yl)-
l//-pyrazol-3-ylmethyl]-4,10-bis-[((5)-l-phenyl-ethylcarbamoyl)-methyl]-l,4,7,10-
tetraaza-cyclododec-l-yl}-acetylamino)-ethyl]-benzoic acid methyl ester [ L ' " ] (0.054 g, 
0.051 mmol) and Tb(OTf)3.6H20 (0.033 g, 0.054 mmol) in anhydrous C H 3 C N (1 ml) 
was heated at reflux, under argon, for 16 h. The resultant solution was allowed to cool to 
rt followed by the removal of solvent under reduced pressure to afford a glassy orange 
solid. CH2CI2 (10 ml) was added to the solid, and the mixture sonicated for 10 min. The 
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solvent was then decanted and the solid material dissolved in a minimum volume of 
C H 3 C N (0.5 ml). The solution was added dropwise onto diethyl ether (25 ml) to induce 
precipitation. The solid material was isolated by centrifugation, and the process of 
induced precipitation repeated twice more to yield the complex as its triflate salt. The 
yellow solid was made water soluble by the exchange of triflate anions for chloride 
anions using 'DOWEX 1 x 8 200-400 mesh CI' resin. The solid material was dissolved in 
a mixture of H2O - CH3OH (1:1 v/v, 14 ml) and 0.6 g of prepared resin added to the 
solution, which was stirred at rt, for 6 h. The resin was removed by filtration, and the 
filtrate concentrated under reduced pressure to yield the title complex [TbL'"] as a pale 
yellow coloured solid (0.037 g, 0.028 mmol, 55 % ) ; ?in,a.x (H2O) = 348 nm, i (H2O) = 2.27 
ms; (t)Tb (H2O; pH 6.0; X.exc 355 nm) = 63 %; HPLC (Method A) = 10.9 min. 
7.4.5 Tetraazatriphenylene Amide Conjugate Complex 
4,10-bis-[((S)-1 -Phenyl-ethylcarbamoyl)-methyl]-7-(10,11,12,13-tetrahydro-
4,5,9,14-tetraaza-benzo[b]triphenylen-6-ylmethyl)-1,4,7,10-tetraaza-
cyclododecane-1-carboxylic acid terf-butyl ester (41) 
N N 
N N 
A Stirring mixture of 4,10-bis-[((5)-l-phenyl-ethylcarbamoyl)-methyl]-l,4,7,10-tetraaza-
cyclododecane-l-carboxylic acid tert-buty] ester 3 7 (0.131 g, 0.218 mmol), 3-
chloromethyl-10,ll,12,13-tetrahydrodipyrido-[3,2a:2',3'-c]-phenazine (0.080 g, 0.240 
mmol) and K2CO3 (0.045 g, 0.327 mmol) in anhydrous C H 3 C N (5 ml) was heated at 
reflux, under argon, for 16 h. The resultant mixture was allowed to cool to rt, syringe 
filtered and the filtrate concentrated under reduced pressure to afford a residual yellow 
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oil. The crude material was purified by column chromatography on neutral alumina 
(gradient elution; CH2CI2 to 2 % CH3OH : CH2CI2, utilising 0.1 % CH3OH increments) to 
yield the title compound 41 as a yellow coloured crystalline solid (0.171 g, 0.190 mmol, 
87 % ) ; Rv = 0.61 (Alumina, CH2CI2 - CH3OH, 1 9 : 1 v/v); m.p. 149-150 "C; ' H N M R 
(CDCI3, 500 MHz) 5 1.35 (6H, d, J = 2.5 Hz CH3), 1.39 (9H, s, 'Boc CH3), 2.08 (4H, br s, 
H ' ° ; H ' ^ ) , 2.43 (4H, br s, cyclen CH2), 2.78 (6H, br s, CH2CO), 3.05 (4H, br s, cyclen 
CH2), 3.24 (8H, br s, cyclen CH2), 3.54 (2H, s, CH2 dpqC), 5.00 (2H, q, 7 = 8.0 Hz, CH), 
7.07-7.15 (1 OH, m, Ph), 7.60 (1H, d, J = 8.0 Hz, H^), 7.84 (1H, dd, J = 8.0; 4.5 Hz, H^), 
8.07 (2H, br s, NH), 8.97 (1H, dd, J = 4.5; 1.5 Hz, H% 9.44 (1H, d,./ = 8.0 Hz, H ' ) , 9.56 
( IH , d, J = 8.0 Hz, H^); '^C NMR ( C D C I 3 , 125 MHz, ' H decoupled 500 MHz) 5 22.3 
(2C, C'°, C'^), 22.9 (2C, CH3), 28.8 (3C, 'Boc CH3), 33.1 (2C, C", C'^), 47.3 (IC, CH), 
48.9 (IC, CH), 50.4 (2C, cyclen CH2), 51.5 (2C, cyclen CH2), 52.9 (2C, cyclen CH2), 
53.7 (2C, cyclen CH2), 55.9 (2C, CH2CO), 61.1 (IC, CH2 dpqC), 80.3 (IC, C'Bu), 124.8 
(IC, C'), 125.5 (IC, C'), 126.4 (2C, Ph(o/m)), 126.7 (2C, Ph(o/^)), 126.9 (2C, Ph(o/m)), 
127.1 (2C, Ph(o/n,)), 128.5 (2C, Ph(p)), 134.7 (IC, C ^ 135.0 (IC, C"), 137.1 (IC, Ar(q)), 
137.4 (IC, Ar(q)), 144.5 (2C, Ph(q)), 146.1 (IC, Ar(q)), 146.3 (IC, Ar(q)), 150.6 (IC, Ar(q)), 
155.1 (IC, Ar(q)), 155.3 (IC, Ar(q)), 160.2 (IC, Ar(q)), 170.3 (2C, amide C = O); MS (ES^) 
m/z 915.5 (100 %, [M + Na]^); HRMS (ES^) m/z found 915.5011 [M + Na]^ 
C52H6404Nio^^Nai requires 915.5004. 
W-({S)-1-Phenyl-ethyl)-2-[7-[((S)-1-phenyl-ethylcarbamoyl)-methyl]-4-
(10,11,12,13-tetrahydro-4,5,9,14-tetraaza-benzo[/)]triphenylen-6-ylmethyl)-
1,4,7,10-tetraaza-cyclododec-1-yl]-acetamide (36) 
N N 
N 
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Procedure A: 
A stirring mixture of jV-((5)-l-phenyl-ethyl)-2-(7-[((5)-l-piienyl-ethylcarbamoyl)-methyl] 
-l,4,7,10-tetraaza-cyclododec-l-yl)-acetamide 3 3 (0.370 g, 0.748 mmol), 3-
chloromethyl-10,ll,12,13-tetrahydrodipyrido-[3,2a:2',3'-c]-phenazine (0.250 g, 0.748 
mmol) and NaHC03 (0.069 g, 0.823 mmol) in anhydrous C H 3 C N (8 ml) was heated at 55 
°C, under argon, for 7 h. The reaction mixture was allowed to cool to rt, syringe filtered 
and the filtrate concentrated under reduced pressure to afford an orange solid. The crude 
material was purified by column chromatography on neutral alumina (gradient elution: 
CH2CI2 to 0.5 % CH3OH : CH2CI2) to yield the title compound 3 6 as a pale cream 
coloured solid (0.330 g, 0.416 mmol, 56 % ) ; ' H N M R (CDCI3 , 500 MHz) 6 1.35 (6H, d, J 
= 2.5 Hz CH3), 2.08 (4H, br s, H ' ° ; H ' ^ ) , 2.43 (4H, br s, cyclen CH2), 2.78 (6H, br s, 
CH2CO), 3.05 (4H, br s, cyclen CH2), 3.24 (8H, br s, cyclen CH2), 3.58 (2H, s, CH2 
dpqC), 5.00 (2H, q, J = 8.0 Hz, CH), 7.07-7.15 (lOH, m, Ph), 7.60 ( IH , d, J = 8.0 Hz, 
H^), 7.84 ( IH , dd, J = 8.0; 4.5 Hz, H \ 8.07 (2H, br s, NH), 8.97 ( IH , dd, . /= 4.5; 1.5 Hz, 
H^), 9.44 ( IH , d, . / = 8.0 Hz, H ' ) , 9.56 ( I H , d, J = 8.0 Hz, H^), 10.61 ( I H , br s, cyclen 
NH); '^ C N M R (CDCI3 , 125 MHz, ' H decoupled 500 MHz) 5 22.3 (2C, C'^ C'^), 22.9 
(2C, CH3), 33.1 (2C, C", 47.3 (IC, CH), 48.9 (IC, CH), 50.4 (2C, cyclen CH2), 
51.5 (2C, cyclen CH2), 52.9 (2C, cyclen CH2), 53.7 (2C, cyclen CH2), 55.9 (2C, CH2CO), 
61.1 (IC, CH2 dpqC), 124.8 (IC, C\ 125.5 (IC, C\ 126.4 (2C, Ph(o/m)), 126.7 (2C, 
Ph(o/n.)), 126.9 (2C, Ph,o/,r,)), 127.1 (2C, Ph(o/n,)), 128.5 (2C, Ph(p)), 134.7 (IC, C'), 135.0 
(IC, C'), 137.1 (IC, Ar(q)), 137.4 (IC, Ar(q)), 144.5 (2C, Ph(q)), 146.1 (IC, Ar(q,), 146.3 
(IC, Ar(q)), 150.6 (IC, Ar(q)), 155.1 (IC, Ar(q)), 155.3 (IC, Ar(q)), 160.2 (IC, Ar(q)), 170.3 
(2C, amide C = O); MS (ES^) m/z 793.6 (100 %, [M + H]^); HRMS (ES^) m/z found 
793.4660 [M + H]^ C47H57N10O2 requires 793.4660. 
Procedure B: 
A solution of 4,10-bis-[((S)-l-phenyl-ethylcarbamoyl)-methyl]-7-(10,l l,12,13-
tet^ahydro-4,5,9, 14-tetraaza-benzo[6]triphenylen-6-ylmethyl)-1,4,7,10-tetraaza-
cyclododecane-l-carboxylic acid tert-huty\ ester 41 (0.159 g, 0.177 mmol) in CH2CI2 -
TFA (2 : 1 v/v, 6 ml) was stirred at rt, in a sealed flask, for 5 h, to afford an orange 
solution. The solvent was removed under reduced pressure to yield a glassy solid. The 
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crude material was repeatedly (x 3) dissolved in CH2CI2 (10 ml) and the solvent removed 
under reduced pressure to facilitate elimination of excess acid and tert-hutyl alcohol. The 
residue was finally taken into 1 M KOH(aq) (10 ml) and extracted with CH2CI2 (2 x 20 
ml). The organic extracts were combined, dried over K2CO3, filtered and the filtrate 
concentrated under reduced pressure to yield the title compound 3 6 as an orange coloured 
crystalline solid (0.129 g, 0.162 mmol, 92 % ) . Characterisation was identical to that 
reported in procedure A. 
4-((S)-1-{2-[4,10-bls-[((S)-1-Phenyl-€thylcarbamoyl)-methyl]-7-(10,11,12,13-
tetrahydro-4,5,9,14-tetraaza-benzo[b]triphenylen-6-ylmethyl)-1,4,7,10-
tetraaza-cyclododec-1-yl]-acetylamino}-ethyl)-benzoic acid methyl ester 
A stirring mixture of A^-((5)-l-phenyl-ethyl)-2-[7-[((5)-l-phenyl-ethylcarbamoyl)-
methyl]-4-( 10,11,12,13-tetrahydro-4,5,9,14-tetraaza-benzo[6]triphenylen-6-ylmethy 1)-
l,4,7,10-tetraaza-cyclododec-l-yl]-acetamide 3 6 (0.100 g, 0.126 mmol), 4-[(5)-l-(2-
chloro-acetylamino)-ethyl]-benzoic acid methyl ester 3 0 (0.037 g, 0.145 mmol) and 
CS2CO3 (0.049 g, 0.151 mmol) in anhydrous C H 3 C N (5 ml) was heated at reflux, under 
argon, for 18 h. The resultant mixture was allowed to cool to rt, syringe filtered and the 
filtrate concentrated under reduced pressure to afford an orange solid. The crude material 
was purified by column chromatography on neutral alumina (gradient elution: CH2CI2 to 
0.5 % CH3OH : CH2CI2) to yield the title compound [ L " ] as a fi-ee flowing cream 
coloured solid (0.117 g, 0.115 mmol, 92 % ) ; ' H N M R ( C D C I 3 , 500 MHz) 5 1.43 (3H, d, J 
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= 2.0 Hz, CH3), 1.45 (6H, d, J = 2.0 Hz, CH3), 2.09 (4H, br s, H"^; H ' ^ ) , 2.29-2.63 (16H, 
br s, cyclen CH2), 3.23 (4H, br s, H " ; H ' ^ ) , 3.86 (3H, s, CO2CH3), 4.10 (2H, s, CH2 
dpqC), 5.14 (3H, q, . / = 7.5 Hz, CH), 7.15-7.23 (lOH, m, Ph), 7.30 (2H, d, J = 8.0 Hz, 
Ph), 7.38 (2H, d, J = 8.0 Hz, H^), 7.72 (2H, dd, . / = 8.5; 4.5 Hz, Ph), 7.90 (2H, d, J = 8.0 
Hz, H\ 9.19 ( I H , dd, J = 4.5;1.5 Hz, H^), 9.33 ( I H , d, . /= 8.5 Hz, H ' ) , 9.48 ( IH , dd, J = 
8.5 ; 2.0 Hz, H**); 5c (CDCI3, 125 MHz) 21.6 (3C, CHCH3), 23.0 (C"^, C ' \ 33.1 (C", 
C''), 48.3 (2C, CH), 48.4 (IC, CH), 52.3 (IC, CO2CH3), 53.6 (2C, cyclen CH2), 53.7 
(2C, cyclen CH2), 53.8 (2C, cyclen CH2), 53.9 (2C, cyclen CH2), 59.8 (3C, CH2CO), 62.6 
(IC, CH2 dpqC), 123.3 (IC, C'), 123.9 (IC, C'), 126.3 (2C, Ph(o/n.)), 126.4 (2C, Ph(o/n,)), 
126.5 (2C, Ph(o/ni)), 127.7 (2C, Ph(o/n,)), 127.8 (2C, Ph(o/n,)), 128.8 (2C, Ph(p)), 128.9 (2C, 
Ph(o/m)), 133.6 (IC, C\ 137.7 (IC, C'), 137.8, 143.3 (IC, Ar(q)), 146.8 (IC, Ar(q))„ 147.0 
(IC, Ar(q)), 148.7 (IC, Ar(q)), 151.8 (IC, Ar(q)), 154.0 (IC, Ar(c,)), 154.2 (IC, Ar(q)), 161.3 
(IC, Ar(q)), 166.9 (IC, ester C = O), 170.14 (IC, amide C = O), 170.2 (2C, amide C = O). 
MS (ES^) m/z 1034.7 (100 %, [M + Na]^); HRMS (ES^) m/z found 1012.55580 [M + H]^ 
C59H7oN,,05 requires 1012.55559. 
[TbU^l 
3 + 
\ n HN^ ^ 
r ^ T b - P f - N - ^ ^ -\ \ 3 C I 
NH 
A solution of 4-((S)-l-{2-[4,10-bis-[((S)-l-phenyl-ethylcarbamoyl)-methyl]-7-
(10,11,12,13-tetrahydro-4,5,9,14-tetraaza-benzo[6]triphenylen-6-ylmethyl)-l ,4,7,10-
tetraaza-cyclododec-l-yl]-acetylamino}-ethyl)-benzoic acid methyl ester [ L " ] (0.035 g, 
0.035 mmol) and Tb(OTf)3.6H20 (0.023 g, 0.038 mmol) in anhydrous CH3CN (1 ml) 
was heated at reflux, under argon, for 18 h. The solution was allowed to cool to rt. 
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followed by the removal of solvent under reduced pressure to afford a glassy orange 
solid. CH2CI2 (10 ml) was added to the solid, and the mixture sonicated for 10 min. The 
solvent was then decanted and the solid material dissolved in a minimum volume of 
C H 3 C N (1.0 ml). The solution was added dropwise onto diethyl ether (50 ml) to induce 
precipitation. The solid material was isolated by centrifligation, and the process of 
induced precipitation repeated twice more to yield the complex as its triflate salt. The 
yellow solid was made water soluble by the exchange of triflate anions for chloride 
anions using 'DOWEX 1 x 8 200-400 mesh CI' resin. The solid material was dissolved in 
a mixture of H2O - C H 3 O H (1:1 v/v, 20 ml) and 0.8 g of prepared resin added to the 
solution, which was stirred at rt, for 4 h. The resin was removed by filtration, and the 
filtrate concentrated under reduced pressure to yield the title complex [TbL"| as a 
colourless solid (0.033 g, 0.026 mmol, 74 % ) ; K,^ (H2O) = 348 nm; x (H2O) = 1.57 ms; 
HPLC (Method A) / r = 10.9 min. 
[ E u L " ] 
An analogous procedure to that described for [TbL"| was followed using 4-((5)-l-{2-
[4,10-bis-[((S)-1 -phenyl-ethylcarbamoyl)-methyl]-7-( 10,11,12,13-tetrahydro-4,5,9,14-
tetraaza-benzo[6]triphenylen-6-ylmethyl)-1,4,7,10-tetraaza-cyclododec-1 -yl ] -
acetylamino}-ethyl)-benzoic acid methyl ester ( L " ] (0.031 g, 0.031 mmol) and 
Eu(OTf)3.6H20 (0.019 g, 0.034 mmol) in anhydrous C H 3 C N (1 ml). The procedure 
yielded the title complex [ E U L " ] , as a colourless solid (0.025 g, 0.021 mmol, 69 % ) ; A a^x 
(H2O) = 348 nm; t (H2O) = 1.04 ms. 
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7.5 Activation and Conjugation of Conjugate Complexes 
7.5.1 Pyridyl-azaxanthone, [EuL^] 
[EuL^.COzH] 
3 + 
/ 
HN. 
3 CI 
A solution of | E U L ' ] (1.5 i^mol) in C H 3 O H - 0.02 M KOH(aq) (1:1 v/v, 2 ml) was stirred 
at rt. The progress of hydrolysis was monitored by reverse phase HPLC using a 
Chromolith performance RP18e 100 x 4.6 mm column. (Method D; //? (ester) = 6.40 
mins, tR(acid) = 6.24 mins). 
The reaction ran to completion in approximately 2 h and was neutralised using a dilute 
HCl(aq) solution. The solvent was removed under reduced pressure and the crude residue 
used directly in the next step without further purification. 
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[EuL^_CONHBG] 
3 + 
/ 
HN. 
To a stirred solution of | E u L _C02H1 in anhydrous DMF (2 ml) was added incremential 
equivalents of TSTU and DIPEA (50 | i l of a 100 mM solution in DMF in each case, 5 
|imol). The progress of the reaction was monitored by reverse phase HPLC using a 
Chromolith performance RP18e 100 x 4.6 mm column. 
BG-NH2 was added to the stirred solution of in situ [TbL'*'_NHS] (1 jimol) in anhydrous 
DMF (400 111). The mixture was stirred at rt and the progress of the reaction was 
monitored by reverse phase HPLC using a Chromolith performance RP18e 100 x 4.6 mm 
column. (Method D; IR (NHS) = 6.28 mins, tR (BG) = 5.97 mins). 
The reaction ran to completion in approximately 1 h. The product was purified by reverse 
phase semi-preparative HPLC using a Chromolith performance RP18e 100 x 10 mm 
column. (Method E; t^ (BG) = 6.67 mins). The product was obtained as a colourless solid 
(320 nmol, 34 % ) . 
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7.5.2 Pyrazoyl-azaxanthone, [TbL^°] 
[TbL^°_C02H] 
3 + 
3 CI 
A solution of [TbL'"] (1.3 ^mol) in C H 3 O H - 0.02 M KOH^aq) (1:1 v/v, 2 ml) was stirred 
at rt. The progress of hydrolysis was monitored by reverse phase HPLC using a 
Chromolith performance RP18e 100 x 4.6 mm column. (Method C; tR (ester) = 6.07 
mins, ta (acid) = 5.78 mins). 
The reaction ran to completion in approximately 2 h and was neutralised using a dilute 
HCl(aq) solution. The solvent was removed under reduced pressure and the crude residue 
used directly in the next step without further purification; MS (ES"^ ) m/z 594 [M - H]'^; 
1187 [ M - 2 H f . 
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[TbU"_CONHBG] 
H2N 
N N 
3 + 
To a stirred solution of |TbL"*_C02H] in anhydrous DMF (2 ml) was added 
incremential equivalents of TSTU and DIPEA (50 |al of a 100 mM solution in DMF in 
each case, 5 j^mol). The progress of the reaction was monitored by reverse phase HPLC 
using a Chromolith performance RP18e 100 x 4.6 mm column. (Method C; (acid) = 
6.07 mins, IR (NHS) = 6.28 mins). 
BG-NH2 was added to the stirred solution of in situ |TbL"'_NHS) (1 )imol) in anhydrous 
DMF (400 1^ 1). The mixture was stirred at rt and the progress of the reaction was 
monitored by reverse phase HPLC using a Chromolith performance RP18e 100 x 4.6 mm 
column. (Method C; tR (NHS) = 6.28 mins, (BG) = 5.97 mins). 
The reaction ran to completion in approximately 15 min. The product was purified by 
reverse phase semi-preparative HPLC using a Chromolith performance RP18e 100 x 10 
mm column. (Method E; tR (BG) = 5.23 mins). 
The product was obtained as a colourless solid (380 nmol, 38 % ) ; MS (ES^) m/z 721 [ M -
H f ^ ; 1440 [ M - 2 H ] ' . 
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7.5.3 Tetraazatriphenylene, [EuL^^] 
[EuL^'.COzH] 
3 + 
/ 
3 CI 
n HN 
' ° ^ N H 
A solution of | E U L " 1 (5 ^mol) inCH3OH-0 .02 M KOH(aq) (1:1 v/v, 4 ml) was stirred at 
rt. The progress of hydrolysis was monitored by reverse phase HPLC using a Chromolith 
performance RPl 8e 100 x 4.6 mm column. (Method B; tR (Ester) =5.17 mins, IR (acid) = 
4.93 mins). 
The reaction ran to completion in approximately 2 h and was neutralised using a dilute 
HCl(aq) solution. The solvent was removed under reduced pressure and the crude residue 
used directly in the next step without further purification; MS (ES*) m/z 1154 [M - 2 H ] ^ . 
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[EuL^2_CONHBG] 
N N 
3 + 
To a sfirred solution of [ E U L ' ^ _ C 0 2 H ] in anhydrous DMF (2 ml) was added incremential 
equivalents of TSTU and DIPEA (50 ^1 of a 100 mM solution in DMF in each case, 5 
fxmol). The progress of the reaction was monitored by reverse phase HPLC using a 
Chromolith performance RP18e 100 x 4.6 mm column. (Method C; tR (acid) = 4.90 mins, 
iR(NHS) =5.18 mins). 
After the reaction had ran to completion, the material was used directly in the next step, 
without further purification. 
BG-NH2 was added to a stirred solution of [ E U L ' ^ _ N H S 1 (1 |amol) in anhydrous DMF 
(400 The mixture was stirred at rt and the progress of the reaction was monitored by 
reverse phase HPLC using a Chromolith performance RP18e 100 x 4.6 mm column. 
(Method C; tR (NHS) = 5.12 mins, tR (BG) = 4.93 mins). 
The reaction ran to completion in less than 30 mins. The product was purified by reverse 
semi-preparative HPLC using a Chromolith performance RP18e 100 x 10 mm column. 
(Method F; tR (BG) = 11.49 mins). 
The product was obtained as a colourless solid (380 nmol, 38 % ) ; MS (ES^) m/z 1406 [M 
- 2H]^ 
[TbL^2] 
Analogous procedures to that described for [EUL '^1 were followed using (TbL'^J to yield 
[TbL'^_BGl. 
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7.6 Carboxylate Conjugate Complexes 
7.6,1 Carboxylate Conjugate Arm 
12 
(S)-2-Bromo-pentanedioic acid 5-benzyl ester (44) 
o o 
A solution of NaN02 (5 .50 g, 80.1 mmol) in H2O ( 50 ml) was added dropwise over 30 
min to a stirred solution of (5)-glutamic acid 5-benzyl ester (10.0 g, 42.1 mmol) and 
NaBr (16.0 g, 1 1 6 mmol) in 1 M HBr (250 ml), cooled at - 5 °C. After 1 0 h, cone. 
H2S04(aq) (5 ml) was slowly added to the reaction mixture, which was then extracted with 
diethyl ether (3 x 300 ml). The combined organic extracts were washed with brine ( 2 0 0 
ml), dried over Na2S04, filtered and the filtrate concentrated under reduced pressure. The 
crude material was purified by column chromatography on silica (gradient elution: 
Hexane - 2 0 % EtOAc : Hexane, utilising 1 % EtOAc increments) to yield the title 
compound 44 as a yellow oil (7 .40 g, 24.6 mmol, 58 % ) ; Rp = 0.25 (Silica, Hexane -
EtOAc 1 7 : 3 v/v); ' H NMR (CDCI3, 700 MHz) 5 2 .30 ( I H , m, CHjCHBr), 2 .42 ( I H , m, 
CHiCHBr), 2.60 ( 2 H , m, CH2CH2CHBr), 4 .41 ( I H , dd, J = 9.0; 6.0 Hz, CH), 5 .14 ( 2 H , 
s, CH2Ph), 7.33-7.39 ( 5 H , m, Ph); '^ C NMR (CDCI3, 176 MHz, ' H decoupled 700 MHz) 
5 29.7 (IC, CH2CH2CHBr), 31.6 (IC, CHjCHBr), 44.2 (IC, CH), 66.9 (IC, CH2Ph), 
128.4 (IC, Ph(o/n,)), 128.5 (IC, Ph(o/m)), 128.6 (IC, Ph(o/m)), 128.7 (IC, Ph^ o/m)), 128.8 (IC, 
Ph(p)), 135.8 (IC, Ph(q)), 172.1 (IC, Cbz C = O), 173.4 (IC, Acid C = O); MS (ES^) m/z 
323.2 ( 1 0 0 % , [M + H f ) . 
(S)-2-Bromo-pentanedioic acid 5-benzyl ester 1-tert-butyl ester (45) 
o o 
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A solution of (5)-2-bromo-pentanedioic acid 5-benzyl ester 44 (2.00 g, 6.85 mmo!) in 
tert-buty\ acetate (25 ml) and HCIO4 in H2O (70 %, 0.34 mmol) was stirred, at rt, for 16 
h. H2O (35 ml) was added to the reaction mixture, and the organic phase separated. The 
organic phase was washed with H2O (25 ml), followed by 5 % Na2C03 ^q) (25 ml). The 
solvent was removed under reduced pressure to yield the title compound 45 as a yellow 
coloured oil (2.15 g, 6.03 mmol, 88 % ) ; ' H NMR ( C D C I 3 , 700 MHz) 5 1.46 (9H, s, 'Boc 
CH3) , 2.25 ( IH , m, CH.CHBr), 2.35 ( IH , m, CH .CHBr), 2.55 (2H, m, CH2 ,CH2 ,CHBr), 
4.23 ( IH , q,J= 5.5; 2.0 Hz, CH), 5.12 (2H, s, CH2Ph), 7.31-7.36 (5H, m, Ph); '^ C NMR 
( C D C I 3 , 176 MHz, ' H decoupled 700 MHz) 5 27.9 (3C, 'Boc CH3) , 29.9 (IC, CHjCH), 
31.8 (IC, C H 2 C H 2 ) , 46.9 (IC, CH), 66.7 (IC, CH2Ph) , 82.8 (IC, 'BoC(q)), 128.4 (IC, 
Ph(oM), 128.5 (IC, Ph(o/m)), 128.6 (IC, Ph<o/m)), 128.7 (IC, Ph(o/m)), 128.8 (IC, Ph<p)), 
136.0 (IC, Ph(q)), 168.5 (IC, 'Boc C = O), 172.2 (IC, Cbz C = O); MS (ES*) m/z 379.0 
(100%, [M + N a f ) . 
7.6.2 Cyclen Intermediates 
4,10-bis-fe/t-Butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododecane-1,7-
dicarboxylic acid dibenzyl ester (46) 
A stirred mixture of 1,4,7,10-tetraaza-cyclododecane-l,7-dicarboxylic acid dibenzyl ester 
31 (2.65 g, 6.02 mmol), tert-buty\ bromoacetate (2.64 g, 2.00 ml, 13.5 mmol) and CS2CO3 
(5.88 g, 18.1 mmol) was heated at reflux in anhydrous C H 3 C N (25 ml), under argon, for 
18 h. The reaction mixture was allowed to cool to rt, syringe filtered and the filtrate 
concentrated under reduced pressure to yield a residual yellow oil. The crude material 
was purified by column chromatography on silica (gradient elution: CH2CI2 to 1.5 % 
C H 3 O H : CH2CI2, utilising 0.1 % C H 3 O H increments) to yield the title compound 46 as a 
yellow coloured oil (2.46 g, 3.68 mmol, 61 % ) ; R,: = 0.53 (Silica, CH2CI2 - C H 3 O H , 39 : 
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1 v/v); ' H NMR (CDCI3, 700 MHz) 6 1.46 (18H, s, 'Boc CH3), 2.86 (8H, br s, cyclen 
CH2), 3.31 (4H, br s, CH2CO), 3.42 (8H, br s, cyclen CH2), 5.12 (4H, s, CH2Ph), 7.25-
7.33 (lOH, br s, Ph); '^C NMR (CDCI3, 176 MHz, ' H decoupled 700 MHz) 5 28.0 (6C, 
'Boc CH3), 46.7 (2C, cyclen CH2), 46.8 (2C, cyclen CH2), 54.2 (2C, cyclen CH2), 54.5 
(2C, cyclen CH2), 55.9 (2C, CH2CO), 66.8 (2C, CHjPh), 80.7 (2C, 'BoC(q)), 127.7 (2C, 
Ph), 127.8 (2C. Ph), 128.3 (2C, Ph), 128.5 (2C, Ph), 136.8 (2C, Ph), 156.3 (2C, Cbz C = 
O), 170.4 (2C, 'Boc C = O), MS (ES^) m/z 669.4 (100 %, [M + H]^); HRMS (ES^) m/z 
found 669.3860 [M + H]^ C36H53O8N4 requires 669.3858. 
(7-te/t-Butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid 
fert-butyl ester (47) 
0 C ^ 
^ N 
4,10-Bis-/er/-butoxycarbonylmethyl-l,4,7,10-tetraaza-cyclododecane-l,7-dicarboxylic 
acid dibenzyl ester 46 (2.46 g, 3.68 mmol) in CH3OH - H2O (3:1 v/v, 20 ml) was shaken 
in a Parr hydrogenation flask at 40 psi H2 over Pd(OH)2/C (0.25 g) for 48 h. The resulting 
mixture was filtered through Celite to afford a colourless solution which was 
concentrated under reduced pressure to yield the title compound 47 as a colourless 
crystalline solid (1.46 g, 0.365 mmol, 99 % ) ; ' H NMR ( C D C I 3 , 500 MHz) 6 1.46 (18H, s, 
'Boc CH3), 2.65 (8H, br s, cyclen CH2), 2.84 (8H, br s, cyclen CH2), 3.33 (4H, s, 
CH2CO); '^ C (CDCI3, 125 MHz, ' H decoupled 500 MHz) 5 27.3 (6C, 'Boc CH3), 51.8-
53.4 (8C, cyclen CH2), 82.7 (2C, 'BoC(q)), 171.9 (2C, C = O); MS (ES^) m/z 401.4 (100 
%, [M + H]^); HRMS (ES^) m/z found 401.3121 [M + H]^ C20H41O4N4 requires 
401.3122. 
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2-(4,10-bis-te/t-Butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1 -yl)-
pentanedioic acid 5-benzyl ester 1-te/t-butyl ester (49) 
N N 
N N 
A Stirred mixture of (7-/er/-butoxycarbonyImethy 1-1,4,7,10-tetraaza-cyclododec-l-yl)-
acetic acid tert-huty\ ester 47 (0.369 g, 0.925 mmol), (5)-2-bromo-pentanedioic acid 5-
benzyl ester l-tert-huiy\ ester 45 (0.325 g, 0.923 mmol) and NaHCOs (0.074 g, 0.925 
mmol) was heated at 55 °C in anhydrous CH3CN (15 ml), under argon, for 18 h. The 
reaction mixture was allowed to cool to rt, syringe filtered and the filtrate concentrated 
under reduced pressure to afford an orange residual oil. The crude material was purified 
by column chromatography on neutral alumina (gradient elution: C H 2 C I 2 - 1.0 % C H 3 O H 
: C H 2 C I 2 , utilising 0.1 % C H 3 O H increments) to yield the title compound 49 as a yellow 
coloured solid (0.373 g, 0.552 mmol, 60 % ) ; /?F = 0.28 (Alumina, C H 2 C I 2 - C H 3 O H , 49 : 
1 v/v); ' H N M R ( C D C I 3 , 700 MHz) 6 1.34 (27H, s, 'Boc CH3), 1.80 (2H, m, arm CH2), 
2.41 (4H, m, cyclen CH2; arm CH2), 2.70 (6H, m, cyclen CH2), 3.05 (8H, m, cyclen 
CH2), 3.24 (4H, q, C H 2 C O ) , 3.31 ( I H , t, J = 7.5 Hz, C H ) , 5.03 (2H, q,J= 12.5; 5.5 Hz, 
Cbz CH2), 7.19-7.27 (5H, m, Ph); '^C N M R ( C D C I 3 , 176 MHz, ' H decoupled 700 MHz) 
5 25.0 (IC, CH2), 28.3 (9C, 'Boc CH3), 30.9 ( IC, CH2), 46.6 (2C, cyclen CH2), 49.8 (2C, 
cyclen CH2), 50.8 (2C, cyclen CH2), 51.4 (2C, cyclen CH2), 56.5 (2C, CH2CO), 60.8 (IC, 
CH), 66.6 (IC, Cbz CH2), 81.7 (2C, 'BoC(q)), 82.2 (IC, 'BoC(q)), 128.4 (2C, Ph(o/m)), 128.5 
(IC, Ph(p)), 128.7(2C, Ph(o/m)), 136.0 (IC, Ph(q)), 170.4 (2C, 'Boc C = O), 171.4 (IC, 'Boc 
C = O), 172.9 (IC, Cbz C = O); MS (ES^ m/z 677.4 (100 %, [M + H]^); HRMS (ES^ 
m/z found 677.4484 [M + H]^ C36H61O8N4 requires 677.4484. 
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7.6.3 Pyridyl-azaxanthone Carboxylate Conjugate Complex 
2-{4,10-bis-ferf-Butoxycarbonylmethy l-7-[6-(6-ferf-butyl-10-oxo-10H-9-oxa-1 -
aza-anthracen-2-yl)-pyridin-2-ylmethyl]-1,4,7,10-tetraaza-cyclododec-1-yl}-
pentanedioic acid 5-benzyl ester 1-fe/t-butyl ester ([L^^]) 
N N 
N 
A Stirred mixture of 2-(6-bromomethyl-pyridin-2-yl)-6-/er/-butyl-9-oxa-l-aza-anthracen-
lO-one 9 (0.110 g, 0.318 mmol), 2-(4,10-bis-/err-butoxycarbonylmethyl-l,4,7,10-
tetraaza-cyclododec-l-yl)-pentanedioic acid 5-benzyl ester \-tert-hutyl ester 49 (0.195 g, 
0.289 mmol) and K2CO3 (0.086 g, 0.636 mmoi) in anhydrous CH3CN (10 ml) was heated 
at reflux, under argon, for 40 h. The reaction mixture was allowed to cool to rt, filtered 
and the filtrate concentrated under reduced pressure to afford an orange residual oil. The 
crude material was purified by column chromatography on neutral alumina (gradient 
elution: C H 2 C I 2 - 1.0 % C H 3 O H : C H 2 C I 2 , utilising 0.1 % C H 3 O H increments) to yield 
the title compound | L ' ^ ] as a yellow oil (0.188 g, 0.116 mmol, 40 % ) ; Rp = 0.37 
(Alumina, C H 2 C I 2 - C H 3 O H , 1 9 : 1 v/v); ' H N M R ( C D C I 3 , 700 MHz) 5 1.34 (27H, s, 
'Boc C H 3 ) , 1.38 ( 9 H , s 'Bu C H 3 ) , 2.37 (4H, m, cyclen C H 2 ; arm C H 2 ) , 2.73 (6H, m, 
cyclen C H 2 ) , 3.07 (8H, m, cyclen C H 2 ) , 3.26 (4H, q, C H 2 C O ) , 3.31 ( I H , t, J = 7.5 Hz, 
CH), 5.04 (2H, q,J= 12.5; 5.5 Hz, Cbz C H 2 ) , 7.19-7.27 (6H, m, Ph; H^ ), 7.54 ( I H , d, J 
= 8.5 Hz, H ' \ 1.12-1.n (2H, br s, 8.24 ( I H , d , . /= 3.0 Hz, W\ 8.32 ( IH , d, J 
= 8.0 Hz, H^ X 8.40 ( I H , br s, cyclen NH), 8.48 ( I H , d, J = 7.0 Hz, H^), 8.75 ( IH , d, J = 
8.0 Hz, H^); '^ C N M R ( C D C I 3 , 176 MHz, ' H decoupled 700 MHz) 5 25.0 (IC, C H 2 ) , 
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28.3 (9C, 'Boc C H 3 ) , 30.9 (IC, C H 2 ) , 31.5 (3C, C"), 34.9 (IC, C ' ^ 46.6 (2C, cyclen 
C H 2 ) , 49.8 (2C, cyclen C H 2 ) , 50.8 (2C, cyclen C H 2 ) , 51.4 (2C, cyclen C H 2 ) , 56.5 (2C, 
C H 2 C O ) , 63.3 (IC, CH), 66.6 (IC, Cbz C H 2 ) , 81.7 (2C, 'Boq^,,), 82.2 (IC, 'BoC(q)), 116.4 
(IC, C\ 118.3(1C,C' \ 118.5 (IC, C^), 119.7 (IC, C^ ), 121.3 (IC, C^), 122.7 (IC, C\ 
123.8 (IC, C' ), 128.4 (2C, PH^OM), 128.5 (IC, Ph^p)), 128.7(2C, Ph(o/n,)), 133.6 (IC, C^), 
136.1 (IC, Ph<q)), 137.9 (IC, C'"), 138.4 (IC, C ^ 148.1 (IC, C ^ 153.6 (IC, C'"), 154.2 
(IC, C"), 158.6 (IC, C^'), 160.2 (IC, C'), 160.6 (IC, C'^), 170.4 (2C, 'Boc C = O), 171.4 
(IC, 'Boc C = O), 172.9 (IC, Cbz C = O), 177.8 (IC, C^); MS (ES^) /n/z 1019.6 (100 %, 
[M + H]^); HRMS (ES^) m/z found 1019.5866 [M + H]^ CsgHTgOioNe requires 
1019.5852; HPLC (Method A) /R = 12.0 min. 
[ E u L " ] 
A stirred mixture of 2-{4,10-bis-^er/-butoxycarbonylmethyl-7-[6-(6-/er/-butyl-10-oxo-
10//-9-oxa-l-aza-anthracen-2-yl)-pyridin-2-ylmethy]]-l ,4,7,10-tetraaza-cyclododec-l -
yl}-pentanedioic acid 5-benzyl ester l-/er/-butyl ester [L'^J (0.021 g, 0.021 mmol) in 
hydrobromic acid (5 ml) was heated at 40 "C, for 4 h. The solvent was removed under 
reduced pressure to yield a glassy solid. The crude material was analysed by 1H NMR to 
ensure complete deprotection, with the material used immediately for complexation. 
HPLC (Method A) /R = 10.83 min. 
The deprotected ligand was dissolved in C H 3 O H - H 2 O (2 : 2 v/v, 4 ml) and 
Eu(OAc)3 .6H20 (0.008 g, 0.023 mmol) added to the solution. The pH of the solution was 
raised to 5.4 by the addition of 1 M KOH (aq), then stirred and heated at 90 °C, for 14 h. 
The reaction mixture was allowed to cool to rt before raising the pH of the solution to 
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10.0 using dilute KOH (aq). The reaction mixture was stirred for 1 h to allow precipitation 
of excess Eu metal as its hydroxide salt, Eu(0H)3. The solid precipitate was removed by 
syringe filtration and the pH of the colourless aqueous filtrate reduced to pH 5.5 using a 
solution of 1 M HCl (aq>. The solvent was removed under reduced pressure using a freeze-
drier to yield the title complex [ E U L ' ^ ] as a colourless solid (0.008 g, 0.009 mmol, 45 % ) ; 
>^max(H20) = 355 nm. 
7.6.4 Tetraazatriphenylene Carboxylate Conjugate Complex 
[7-ferf-Butoxycarbonylmethyl-4-(10,11,12,13-tetrahydro-4,5,9,14-tetraaza-
benzo[b]triphenylen-6-ylmethyl)-1,4,7,10-tetraaza-cyclododec-1 -yl]-acetic 
acid fert-butyl ester (48) 
N N 
A stirred mixture of (7-/e/-/-butoxycarbonylmethyl-l,4,7,10-tetraaza-cyclododec-l-yl)-
acetic acid tert-huty\ ester (0.195 g, 0.488 mmol), 3-chloromethyl-10,11,12,13-
tetrahydrodipyrido-[3,2a:2\3'-c]-phenazine (0.125 g, 0.374 mmol) and NaHCOa (0.063 
g, 0.750 mmol) was heated at 60 "C in anhydrous CH3CN (15 ml), under argon, for 18 h. 
The reaction mixture was allowed to cool to rt, syringe filtered and the filtrate 
concentrated under reduced pressure to afford a yellow solid. The crude material was 
purified by column chromatography on neutral alumina (gradient elution: C H 2 C I 2 - 0.8 % 
C H 3 O H : C H 2 C I 2 , utilising 0.1 % C H 3 O H increments) to yield the title compound 48 as a 
pale yellow coloured solid (0.220 g, 0.315 mmol, 84 % ) ; Rp = 0.21 (Alumina, C H 2 C I 2 -
C H 3 O H 19 : 1 v/v); m.p. 175-177 "C; ' H N M R ( C D C I 3 , 500 MHz) 5 1.29 (18H, s, 'Boc 
C H 3 ) , 2.06 (4H, s, cyclen C H 2 ) 2.67 (4H, s, cyclen C H 2 ) , 2.80 (4H, s, cyclen C H 2 ) , 2.99 
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(4H, s, cyclen C H 2 ) , 3.21 (4H, cyclen C H 2 ) , 3.57 (4H, s, C H 2 C O ) , 4.02 (2H, s, C H 2 
dpqC), 7.65 ( IH , m, H^), 7.75 ( I H , m, H^), 8.76 ( IH , dd, J = 5.0; 1.5 Hz, H^), 9.42 ( I H , 
m, H ' ) , 9.48 ( I H , m, H^); '^ C NMR ( C D C I 3 , 126 MHz, ' H decoupled 500 MHz) 5 28.2 
(6C, 'Boc CH3), 44.5 (2C, cyclen C H 2 ) , 49.6 (2C, cyclen C H 2 ) , 49.8 (2C, cyclen C H 2 ) , 
53.7 (2C, C H 2 C O ) , 55.7 (2C, cyclen C H 2 ) , 81.6 (2C, 'BoC(q)), 123.6 (IC, C\ 123.9 (IC, 
Ar), 126.2 (IC, C Ar), 127.7 (IC, Ar), 133.5 (IC, Ar), 133.9 (IC, Ar), 137.2 (IC, C^), 
137.5 (IC, C'), 145.8 (IC, C Ar), 146.4 (IC, Ar), 152.2 (IC, C"), 154.5 (IC, Ar), 154.6 
(IC, Ar), 159.6 (IC, Ar), 170.4 (2C, C = O); MS (ES^) m/z 699A (100 %, [M + H]^); 
HRMS (ES^) m/z found 699.4335 [M + H ] ' C39H55N8O4 requires 699.4340. 
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A p p e n d i c e s 
Append ix 1 - Substituted Pyrazoyl-azaxanthone Ctiaracterlsation 
Phosphorescence 
/ ^N N 
Absorption 
in 0 ,2 
2 5 0 3 0 0 350 4 0 0 4 5 0 
Wavelength (nm) 
500 550 6 0 0 
Figure 7A: Absorption (left) and Phosphorescence (right) spectrum of Ph-pyrazoyl-
azaxanthone (Absorption 298 K, MeOH; Phosphorescence 77 K, EPA) 
Phosphorescence (77 K) 
ft 
HO,C 
2 5 0 300 350 4 0 0 4 5 0 
Wavelength (nm) 
500 550 6 0 0 
Figure 7.2: Absorption (left) and Phosphorescence (right) spectrum of C02H-pyrazoyl-
azaxanthone (Absorption 298 K, MeOH; Phosphorescence 77 K EPA) 
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Phosphorescence (77 K) 
— 0,8 
O 0,2 
250 300 3 5 0 4 0 0 450 500 550 6 0 0 
Wavelength (nm) 
Figure 7.3: Absorption (left) and Phosphorescence (right) spectrum of CF^-pyrazoyl-
azaxanthone (Absorption 298 K, MeOH; Phosphorescence 77 K, EPA) 
Append ix 2 - Analyt ical Reverse Phase HPLC Analysis / Characterisation 
\.R= 10.9 min 
1 2 3 4 5 6 7 8 fl 10 11 12 13 M 15 « 17 18 19 » 21 
Figure 7.4: HPLC analysis o/'[EuL''] (Chromolith RP18e Column, Method A) 
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Figure 7.5: HPLC analysis of[TbL^] (Chromolith RP!8e Column, Method A) 
3 + 
HN 
t R = 11.2 min 
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Figure 7.6: HPLC analysis q/[TbL^] (Chromolith RP18e Column, Method A) 
t R = 10.8 min 
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Figure 7.7: HPLC analysis q/fEuL^] (Chromolith RPI8e Column, Method A) 
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Chapfer Seven: Experimental 
tR = 11.0 min 
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Figure 7.8: HPLC analysis of[EuL^] (Chromolith RP18e Column, Method A) 
t R = 10.9 min 
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Figure 7.9: HPLC analysis of[EuL^] (Chromolith RP18e Column, Method A) 
tR= 10.9 min 
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Figure 7.10: HPLC analysis q/ [TbL'°] (Chromolith RP18e Column, Method A) 
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Chapter Seven: Experimental 
t R = 10.9 mm 
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Figure 7.11: HPLC analysis O/1EUL"1 (Chromolith RPI8e Column, Method A) 
Appendix 3 - Crystal Data and Structure Refinement Parameters 
Methylpyridyl-azaxanthone 8 Bromopyrazoyl-azaxanthone 12 
Empirical Formula C22H20N2O2 C2oH,gBrN302 
Molecular Weight 344.40 412.28 
Crystal System Monoclinic Monoclinic 
Space Group P2\lc P2\lc 
Crystal Size / nm 0.54x0.36x0.13 0.50 X 0.05 X 0.05 
Temperature / K 120 120 
a/A 13.4718 (3) 17.044 (3) 
b/A 6.7227 (7) 13.303 (2) 
elk 19.4491 (19) 8.0788(12) 
Volume / A 1760.7 (3) 1817.6 (3) 
Z 4 4 
Density / g cm"^  1.299 1.507 
^ / mm"' 0.08 2.28 
0.028 0.104 
Data [/>2a(7)] 4671 3201 
/?i/w/?2 [/>2o(/)] 0.042/0.118 0.073 /0.125 
Goodness of fit (5) 1.03 1.14 
N° of variables 315 228 
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